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GeneraL introduction
Staphylococcus aureus was first described in 1881 by Scottish surgeon Alex Ogston, who 
observed round bacterial cells (Greek: kókkos) in grape-like clusters (Greek: staphyle) 
within pus from abscesses [1]. Four years later, German surgeon Friederich Rosenbach 
was the first to isolate and culture these bacteria, describing colonies with a yellow/
golden colour (Latin: aureus). At that time, a causal link between S. aureus and skin in-
fections, abscess formation and blood poisoning (bacteraemia) was readily established. 
These infections were widespread in the pre-antibiotic era; for instance, it is estimated 
that about half of all casualties in the trenches during World War I (1914-1918) were due 
to septic wound infections with S. aureus [2].
At present, S. aureus is still a leading cause of a wide range of community-acquired 
infections, including those of the skin and soft tissue [3], heart valves (endocarditis) [4], 
bone (osteomyelitis) [5, 6] and lungs (pneumonia) [7]. These infections are often associ-
ated with significant morbidity and, in the case of a serious infection such as bacteremia, 
mortality (20 to 30% mortality rate) [8, 9]. In addition, S. aureus is the most common 
cause of health-care associated surgical site infections [10, 11]. These infections lead 
to increased length of stay within the hospital and increased hospital costs, adding an 
estimated $5-$10 billion yearly to U.S. health costs, for example [12].
Between 12 to 30% of individuals within the general population is persistently 
colonized by S. aureus, predominantly within the mucosa of the nose [13]. Another 30% 
(range 16-70%) is intermittent carrier. Although colonization by S. aureus is asymptom-
atic in healthy individuals and does not warrant treatment, persistent carriers have a 
three to six time higher risk for experiencing health-care-associated S. aureus infections 
[14, 15], mostly caused by the endogenous, colonizing strain [16, 17]. Furthermore, 
within certain patient groups affected by chronic disease, such as young cystic fibrosis 
patients, S. aureus colonization is associated with unfavourable clinical outcomes [18].
S. aureus virulence factors
S. aureus are gram-positive cocci that can produce many surface-associated and ex-
creted virulence factors which enable the potential of this species to cause the above 
mentioned infections. These proteins can generally be divided into several groups based 
on their function. For instance, S. aureus expresses multiple surface-anchored proteins, 
such as Fibronectin binding proteins A and B (FnBPA and B), which can bind to specific 
host molecules and thereby facilitate interaction with host cells and the extracellular 
matrix [19-21]. This allows effective colonization of host tissue and indwelling foreign 
materials coated with host molecules, such as catheters and prosthetic joints [22].
Another group of virulence factors comprises the many toxins secreted by S. aureus.   
Some of these can efficiently lyse host cells, such as the pore-forming alpha-toxin [23] 
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and the bi-component leukocidins and gamma-hemolysin [24, 25]. These toxins defend 
S. aureus against neutrophils [26] and disrupt host tissue, clinically manifesting itself as 
necrosis, scalding or abscess formation of the skin or soft tissues [27, 28]. Many toxins, 
including alpha toxin [29], the enterotoxins [30] and toxic shock syndrome toxin [31], 
also interfere with the host innate and adaptive immune response. These latter toxins 
act as superantigens, directly activating T-helper cells which leads to massive cytokine 
release, ultimately causing clinical syndromes such as food poisoning and toxic shock 
syndrome.
In addition to toxins, several factors secreted by S. aureus interfere with specific parts 
of the host immune response. For example, the recruitment and phagocytic activity of 
neutrophils is inhibited by a range of secreted proteins, including the Staphylococcal 
Superprotein Like proteins (SSLs) [32], the formyl-peptide receptor-like 1 inhibitor (FLIPr) 
[33] and the Chemotaxis Inhibitory protein of S. aureus (CHIPS) [34].
Many of the surface-associated and secreted virulence factors mentioned above are 
also involved in biofilm formation of S. aureus [35-38], a phenotypic trait which impor-
tance for S. aureus virulence is increasingly recognized. Biofilms are complex communi-
ties of bacteria enclosed in a polymer matrix [39], believed to provide shelter for the 
bacteria residing within against antibiotics and the host immune system [40-42]. Forma-
tion of biofilms are specifically associated with chronic infections such as osteomyelitis 
and prosthetic joint infections [40, 43].
treatment of S. aureus infections
Apart from local treatment with topical antibiotics (mupirocin, fusidic acid) and surgical 
interventions, including the drainage of abscesses and removal of infected prostheses, 
intravenous beta-lactam antibiotics are the first-choice agents for treating systemic 
S. aureus infections. During World War II penicillin was introduced on a large scale to 
treat septic wound infections among allied soldiers, an intervention which had such an 
impact on military campaigns that the production process was designated as a military 
secret. Soon afterwards though, penicillinase-producing S. aureus became ubiquitous 
and nowadays the penicillinase-resistant flucloxacillin is the treatment of first choice 
within the Netherlands. Unfortunately, additional resistance towards all beta-lactam 
antibiotics, including the penicillin-related indicator agent methicillin, is now endemic 
in most countries worldwide [44]. Vancomycin, the alternative therapeutic agent used 
for treating Methicillin-resistant S. aureus (MRSA), is clinically inferior compared to beta-
lactam antibiotics and, although still rare, the emergence of vancomycin-resistance 
among MRSA has become a concern [45].
Apart from antimicrobial resistance, serious S. aureus infections can be difficult to 
treat due to their notorious propensity to cause secondary infections, to relapse or to 
establish chronic infection. This can have devastating consequences, as illustrated by 
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1osteomyelitis, requiring surgery and prolonged antibiotic treatment with often still 
uncertain outcome [46].
In this context alternative treatment strategies to treat or prevent infections with S. 
aureus are receiving great scientific and clinical interest. Some of these alternatives, such 
as antimicrobial peptides and si-RNA interfering with bacterial gene expression, appear 
promising yet are still far away from clinical use [47, 48]. Other treatment strategies 
which rely on preventive use of current (local) antibiotics to decolonize carriers of S. 
aureus have been shown to significantly reduce health-care associated infections [49], 
although decolonization might fail and concerns about practicalities and induction of 
antibiotic resistance remain [50]. In this light, the development of an anti-S. aureus vac-
cine remains an attractive treatment strategy.
the human immune response against S. aureus
The host immune response towards a pathogen generally consist of an innate (non-spe-
cific) and adaptive (specific) part, the latter including the antibody-mediated (humoral) 
immune response. In the case of S. aureus infections it is now increasingly recognized 
that cellular immunity, including the actions of neutrophils and T-helper cells, plays a 
central part in both innate and adaptive immunity of the host [51, 52]. This is supported 
by the increased incidence of infections with S. aureus observed in patients with defects 
in cellular immunity, such as neutropenia [53, 54]. Based on in vitro and in vivo animal 
models, it appears that especially the actions of T-helper 17 cells are important for the 
host defence against S. aureus (reviewed in [51, 52]). These cells recruit and activate neu-
trophils at the site of infection and promote the production of antimicrobial peptides 
within skin surfaces. 
In addition to cellular immunity, specific antibodies against virulence factors of S. au-
reus aid in the host defence. Ever since the first observation of anti-hemolysin properties 
of human serum in 1901 [55], these antibodies have received great scientific interest. 
Neutralizing antibodies can interfere with the actions of e.g. bacterial toxins and surface-
anchored proteins. Furthermore, binding of antibodies to the bacterial cell surface can 
trigger complement activation and opsonophagocytosis of the bacteria [56]. Currently, 
the presence of antibodies against many virulence factors of S. aureus, ranging from al-
pha toxin to the fibronectin-binding proteins, has been quantified in humans. In general, 
specific anti-staphylococcal antibodies are detectable at an early phase of life, firstly be-
ing of maternal origin and then being replaced by the infants own antibody production 
around the first half year [57]. Antibodies against S. aureus are ubiquitously detectable in 
human blood, ranging from blood obtained from healthy non-carriers to patients at the 
start of a clinically apparent infection [58-60]. This suggests that everyone is frequently 
exposed to S. aureus and that these (often brief but repetitive) exposures induce the pro-
duction of specific antibodies. Furthermore, persistent carriers of S. aureus develop an 
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antibody repertoire that is specifically directed against their colonizing strain [58]. From 
this immunological baseline, each person will develop a highly individualized antibody 
response against the infecting strain of S. aureus after the onset of infection [59-61]. 
In light of the increasingly complicated treatment of S. aureus infections, extensive 
attempts have been made to exploit the humoral immune response for vaccination. 
Monovalent vaccines targeting a wide range of virulence factors have repeatedly been 
shown to protect or reduce severity of infections in various animal models [62, 63] and 
the levels of specific antibodies in human patients are associated with clinical outcome 
[59, 60, 64, 65]. Subsequently, multiple clinical studies have evaluated the efficacy of 
vaccines to prevent or treat infections in patients (Table 1). However, despite that all 
these vaccines induced the production of opsonophagocytic antibodies in patients, so 
far none was shown to have any clinical benefit [for recent reviews see [52, 63, 66-68]. 
Currently, data from several clinical studies, evaluating the efficacy of multivalent vac-
cines targeting different S. aureus virulence factors, are still pending (Table 1).
The reason why so far all attempts to develop a clinically effective vaccine in humans 
failed, despite the plethora of promising data from animal models, remains a matter of 
debate. The active manipulation of the host immune response by S. aureus, the masking 
of immunogenic epitopes within virulence factors for the host immune system or the 
lack of expression of a virulence factor, targeted by a vaccine, might all contribute to this. 
In light of the latter possibility, it is currently unclear whether specific virulence factors, 
previously evaluated as vaccine targets, are actually expressed by S. aureus and present 
during (specific stages of ) infection in patients. This is a prerequisite for an effective vac-
cine. Furthermore, if present, the immunogenic potential of many virulence factors to 
ubiquitously induce a protective antibody response in humans remains to be confirmed, 
both in terms of quantity (does the amount of antibodies increase after the onset of 
infection?) and quality (are they neutralizing?). Finally, currently little is known about the 
capacity of human antibodies to interfere with the function of most S. aureus virulence 
factors. To fill in these gaps in our knowledge, at least in part, the studies presented in 
this thesis were started. In line with the current awareness that multivalent vaccines 
targeting different virulence factors are likely to have a higher chance of success than 
monovalent vaccines, these studies were performed using a wide range of functionally 
diverse, well-characterized virulence factors of S. aureus.
aim of this thesis
The general aim of this thesis is twofold. Firstly, this thesis aims to provide further insights 
into the presence of a wide range of well-characterized virulence factors of S. aureus 
during growth of clinically isolated strains in in vitro and ex vivo models, mimicking the 
in vivo situation during infection in humans.
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table 1. Overview of the most important anti- S. aureus vaccines developed by pharmaceutical companies.
Vaccine 
name1
Company Targeted virulence 
factors
Study 
phase
Major results Remarks
Veronate® Inhibitex ClfA and SdrG III No reduction in late-onset 
sepsis vs placebo
Pooled human IgG; 
passive immunization
Aurexis® Inhibitex ClfA II No reduction in relapse of 
bacteraemia or death
Humanized 
monoclonal antibody; 
passive immunization
StaphVAX® GSK Capsular 
polysaccharide (CP) 
5 and 8
III No reduction in sepsis Active immunization
PentaStaph® GSK CP 5, 8, 
polysaccharide type 
336, alpha toxin and 
Pantom-Valentine 
leukocidin
II No longer listed in 2015 
pipeline report
Active immunization
AltaStaph® GSK Capsular 
polysaccharide (CP) 
5 and 8
II No reduction in sepsis or 
death
IgG pooled from 
volunteers immunized 
with StaphVAX®
Aurograb® Novartis ABC transporter with 
unknown function
II No difference in treatment 
outcome for deep-seated 
infections when combined 
with vancomycin
Vaccine combined 
with vancomycin 
treatment
Pagibaximab® Biosynexus Lipoteichoic acid III No reduction in sepsis Chimeric monoclonal 
antibody; passive 
immunization
V710® Merck IsdB III No reduction in post-
operative wound infections
Active immunization
           
PF 6290510 Pfizer ClfA, MntC, CP 5 
and 8
II Results pending (study 
involving post-operative 
infections)
Active immunization
NDV3 Novadigm Candida albicans 
agglutinin-like 
sequence 3 (Als3)
II Results pending (study 
involving safety and 
immunogenicity)
Recombinant protein 
of Candida albicans 
surface protein 
with cross-reactivity 
against S. aureus
4C-Staph Novartis FhiD2, EsxA and B, 
alpha toxin, Sur-2
Pre-
clinical
_ Active immunization
MEDI4893 Medimmune Alpha toxin II Results pending (study 
involving ventilation-
associated pneumonia)
Human monoclonal 
IgG; passive 
immunization
AR 301 Aridis Alpha toxin II Results pending (study 
involving ventilation-
associated pneumonia)
Human monoclonal 
IgG; passive 
immunization
1 Both previously (upper half ) and currently (lower half ) evaluated vaccines are shown (partially based on 
[52, 69, 70] ).
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Secondly, this thesis aims to further characterize the human antibody response in-
duced by the same S. aureus virulence factors during different infections in patients.
Ultimately, these aims help in identifying the virulence factors of S. aureus that are 
important for bacterial pathogenesis in humans and could be potential vaccine targets.
methods: detecting proteins, antibodies and antibody functionality using the 
Luminex assay
The Luminex assay, which is a flow cytometry technique based on polystyrene beads 
(xMAP®, Luminex corporation), is used in all studies in this thesis for different measure-
ments. In brief, Luminex beads can be covalently coupled to recombinant proteins 
(such as the virulence factors of interest). The beads are color-coded with a mixture 
of 2 fluorescent dyes (red and infra-red), allowing the inclusion of up to 100 different 
proteins in one single measurement. Coupling of proteins is performed by activating 
carboxylated beads with N-hydroxysulfosuccinimide (sulfo-NHS) and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) according to a previously optimized protocol 
[71]. Protein-coupled beads can then be incubated with human serum, washed, and 
bound antibodies can be quantified using a fluorescently labeled, secondary anti-human 
antibody as previously described [61, 71]. This method is used in chapters 2, 3 and 5.
In chapters 3 and 4 the alternative Competitive Luminex Assay (CLA) is described. In 
this assay, which was recently validated [72], serum is first incubated with living bacteria 
instead of protein-coupled beads. In this way, specific antibodies will bind proteins 
that are expressed by the bacteria and as such will be absorbed from the serum. After 
removal, the amount of specific antibody remaining in the serum is measured using the 
standard protocol as mentioned above, and compared to the original antibody levels in 
control serum that was not incubated with bacteria. Antibody absorption is expressed as 
a percentage decrease in antibody levels, which in a semi-quantitative manner reflects 
the presence of bacterial proteins.
In chapter 6, a novel functional Luminex-based assay is described wherein specific 
binding between FnBPA, coupled to beads, and fluorescently labelled fibrinogen is dem-
onstrated.
outline of this thesis
In chapter 2, we expand on previous studies by characterizing the human antibody 
response against 56 virulence factors of S. aureus in 21 patients suffering from bacterae-
mia. IgG and IgA levels are prospectively measured following infection and patient IgG 
levels are compared with those of age-matched, healthy controls. In addition, all infect-
ing strains are genetically characterized and the expression of 3,626 genes is examined 
more closely for two strains during  growth in human blood, using a micro-array setup.
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1In contrast to bacteraemia, less is known about the human antibody response against 
S. aureus during a chronic, biofilm-associated infection such as osteomyelitis. Therefore, 
in chapter 3 IgG levels against 50 virulence factors of S. aureus are prospectively mea-
sured in serum of 10 patients suffering from osteomyelitis. Furthermore, the presence 
of the same 50 virulence factors is established in biofilms of the infecting strains grown 
in vitro on polystyrene (PS) and human bone using CLA. In vivo and in vitro data are 
compared and the relationship between protein presence and antibody responses are 
discussed.
The presence of 52 S. aureus virulence factors during biofilm formation by 5 (methicil-
lin resistant) strains is further established in chapter 4 using the CLA and in vitro biofilm 
models on PS and on a previously described human skin model (Leiden Epidermal 
Models) [73]. The presence of virulence factors are compared between different strains 
and biofilm models, respectively. Presence of virulence factors is additionally confirmed 
by RT-PCR and mass-spectrometry and, in the case of the ubiquitously expressed alpha 
toxin with GFP-reporter technology.
in chapter 5, in vivo serologic data are further expanded and associated with clinical 
outcome in Cystic Fibrosis (CF) patients, another patient group suffering from chronic 
S. aureus infection. As part of this observational prospective longitudinal study, the as-
sociation between IgG levels against 44 S. aureus virulence factors and diverse clinical 
parameters, including lung function, is assessed. In addition, these IgG levels are com-
pared between 182 patients and 53 healthy nasal carriers of S. aureus.
Finally, in chapter 6 the human antibody response against one specific virulence fac-
tor, FnBPA, is studied in more detail. Amongst the 21 infecting strains from the same 
bacteremia patients who are described in chapter 2, amino acid sequence diversity in 
the FnBPA protein is established. Subsequently, the influence of this diversity on the 
human antibody response is characterized. Finally, the capacity of antibodies, obtained 
from both patients and non-infected controls, to interfere with binding between FnBPA 
and its substrate fibrinogen is determined using a novel Luminex-based assay.
18
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abstract
Attempts to develop an efficient anti-staphylococcal vaccine in humans have so far 
been unsuccessful. Therefore, more knowledge of the proteins that are expressed by 
Staphylococcus aureus in human blood and induce an immune response in S. aureus-
infected patients is required. In this study we further characterize the serial levels of 
IgG and IgA antibodies against 56 staphylococcal proteins in multiple serum samples 
of 21 patients with a S. aureus bacteremia (median of 10 serum smaples per patient), 
compare peak IgG levels between patients and 30 non-infected controls, and analyze 
the expression of 3626 genes by two genetically distinct isolates in human blood. The 
serum antibody levels were measured using a bead-based flow cytometry technique 
(xMAP®, Luminex corporation). Gene expression levels were analyzed using a microarray 
(BµG@s microarray).
The initial levels and time taken to reach peak IgG and IgA antibody levels were het-
erogeneous in bacteremia patients. Proteins SA0688 and PrsA were associated with the 
highest median initial-to-peak antibody fold-increase for both IgG (5.05 and 2.92-fold) 
and IgA (2.07 and 2.72-fold for SA0688 and PrsA, respectively). Peak IgG levels against 
27 proteins, including the protein SA0688, were significantly elevated in bacteremia 
patients versus controls (P≤0.05). Expression of diverse genes, including SA0688 and 
PrsA, was ubiquitously high in both isolates at all time points during incubation in blood. 
However, only a limited number of genes were specifically up- or downregulated in both 
isolates when cultured in blood, compared to the start of incubation in blood or during 
incubation in BHI broth.
In conclusion, most staphylococcal proteins tested in this study, including many 
known virulence factors, do not induce uniform increases in the antibody levels in 
bacteremia patients. In addition, the expression of these proteins by S. aureus is not 
significantly altered by incubation in human blood over time or compared to standard 
growth medium. One immunogenic and ubiquitously expressed protein is the putative 
iron-regulated ABC transporter SA0688.
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introduction
Staphylococcus aureus is one of the most common causes of bloodstream infections [1, 
2] and S. aureus bloodstream infections are associated with serious complications such 
as infective endocarditis and prosthetic device infection [3-5]. The mortality rate of S. 
aureus bacteremia is approximately 20-30% [6-8]. Unfortunately, due to the increasing 
antibiotic resistance of clinical S. aureus isolates [9, 10] and the simultaneous decrease 
in the number of newly approved antimicrobial agents [11, 12], the treatment of S. 
aureus bacteremia is becoming increasingly difficult. Therefore, alternative strategies to 
prevent or treat S. aureus bacteremia are much needed.
One potential strategy is the development of a vaccine. However, despite the 
promising results of anti-staphylococcal vaccines in animal models, efforts to develop 
an efficient vaccine against S. aureus in humans have so far failed [13-15]. Classically, 
vaccine development has focused on stimulating the humoral immune response during 
S. aureus infection, as this response is considered to play an important role in clearing in-
fections [16]. Although recent work questions the effectiveness of the humoral immune 
response in clearing infections [15] and suggests a more important role for the Th17 
cell-mediated immune response [14, 17], knowledge of which proteins are expressed 
by bacteria and are immunogenic in infected patients remains essential for new im-
munotherapies. However, to date the number of reports exploring the immunogenic-
ity of S. aureus proteins, especially in humans, is limited and all of these studies have 
investigated relatively small numbers of bacterial proteins (reviewed in [16]. In short, 
two of the most recent studies found detectable yet heterogeneous antibody levels in 
single serum samples of both infected patients and healthy controls against 19 [18] or 
8 [19] recombinant S. aureus proteins. Another study analyzed the immunogenicity of 
whole-cell wall protein preparations using 2-dimensional gel electrophoresis (2-DE) 
immunoblotting of pooled sera from both infected patients and controls [20]. Fifteen 
immunogenic surface proteins were identified, including SdrE and SA0688, for which 
significantly increased IgG levels had previously been demonstrated in infected patients, 
compared to non-infected controls [18]. In the most comprehensive study to date, the 
antibody levels against 19 staphylococcal proteins were serially measured in multiple 
serum samples from bacteremia patients [21], and heterogeneity in the antibody levels 
between different patients was again observed. IsdA was associated with increased 
antibody levels in the majority of patients and was therefore suggested as a potential 
vaccine component. However, several proteins analyzed in earlier studies including wall 
teichoic acid, peptidoglycan, SA0688, alpha toxin and other proteins which are hypoth-
esized to be important virulence factors were not analyzed in this study.
To further characterize the humoral immune response during S. aureus bacteremia, 
we analyzed the levels of IgG and IgA antibodies against 56 staphylococcal proteins 
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in serial serum samples from 22 bacteremia patients. This is the largest collection of 
known staphylococcal proteins analyzed to date, including the non-protein proteins 
wall-teichoic acid and peptidoglycan. In addition, we compared the IgG levels against 
all 56 proteins in bacteremia patients and non-infected controls. Finally, to gain further 
insight into the bacterial proteins which are expressed in human blood and could be 
involved in the pathogenesis of bacteremia, we studied the expression changes of 3626 
S. aureus genes during the incubation of two genetically distinct strains in human blood 
using microarray analyses. Based on these investigations and previous data, we discuss 
the potential of specific staphylococcal proteins as components of human vaccines.
materiaLs and methods
ethics statement
All patient serum samples used in this study were obtained from coded left-over mate-
rial from routine diagnostic blood samples. In concordance with the guidelines of the 
Erasmus University Medical Hospital and the Dutch federation of Biomedical Scientific 
Societies (Federatie van Medische Wetenschappelijke Verenigingen), all patients were 
informed of the possibility that left-over material from diagnostic samples could be used 
for scientific research and all patients were offered the opportunity to give written re-
fusal to this. Serum samples used in this study were only obtained from patients who did 
not object to the use of left-over material for scientific research and gave verbal consent 
for this. This procedure was approved and the acquisition of additional written consent 
was waived specifically for this retrospective study by the Medical Ethics Committee 
of the Erasmus University Medical Center Rotterdam (MEC-2007-106, addendum 2). All 
collected serum samples were coded and only qualified physicians of the department 
of Medical Microbiology and Infectious Diseases had access to the original patient data.
Patients, controls and definitions
Twenty-one adult patients, admitted to the Erasmus Medical Center between March 
2007 and March 2011 were followed from the time of diagnosis of S. aureus bacteremia 
until discharge from the hospital or, if applicable, during outpatient appointments 
after discharge. Bacteremia was defined as the isolation of S. aureus from at least one 
blood culture set. A median number of 10 (interquartile range, 12) serum samples were 
collected per patient over a median period of 34.5 (interquartile range, 35.8) days. The 
median age of the bacteremia patients included in the study was 65.5 years (interquar-
tile range, 14 years), of whom 73% were male.
All patients were treated with antibiotics according to hospital guidelines under the 
supervision of a consultant of the Department of Medical Microbiology and Infectious 
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Diseases. During admission to the hospital, 4 of the 22 patients died; however, none of 
these deaths could be directly attributed to staphylococcal bacteremia.
Single serum samples were collected from 30 non-infected patients, admitted to the 
Erasmus Medical Center between July 2011 and February 2012 for reasons other than 
any infectious disease. In addition, control patients did not suffer from any clinically 
apparent infection in at least the past 6 months. The median age of the non-infected 
control patients was 62 years (interquartile range, 11.5 years), of whom 80% were male. 
S. aureus nasal carrier status was not tested for either the bacteremia patients or the 
control group. However, previous results [22] and additional data (not shown) suggest 
that there is no overall significant difference in the IgG levels of persistent carriers and 
non-carriers for all of the proteins tested in this study, except for TSST-1 and SasG.
S aureus strains, detection of virulence genes and genotyping
S. aureus isolates from bacteremia patients were identified on the basis of colony and 
cellular morphology and Slidex Staph Plus agglutination testing (bioMérieux, Marcy 
l’Etoile, France). The identification of all staphylococcal isolates was confirmed by Staph-
ylococcus protein A (spa)-PCR [23]. The obtained PCR fragments were sequenced; these 
sequences formed the basis of spa-typing. All of the isolates were methicillin-sensitive, 
as determined by the cefoxitin disk diffusion test according to the Clinical and Labora-
tory Standards Institute (CLSI) criteria [24]. Antimicrobial susceptibility to additional 
antibiotics was determined using the VITEK® 2 system with card AST-P549 (bioMérieux).
For each of the 22 bacteremia patients, the first S. aureus isolate obtained from a 
blood culture was screened using PCR for the presence of the 54 genes encoding the 
proteins to which the antibody responses were measured. PCR was not performed for 
peptidoglycan and wall teichoic acid biosynthesis genes, as these were assumed to 
be obligatorily present in all isolates. Primers were both newly designed (Table 1) or 
described previously [21, 25]. In addition, pulsed-field gel electrophoresis (PFGE) was 
performed on Sma1-digested chromosomal DNA from all 22 isolates, as described 
previously [26]. Relatedness among the PFGE profiles was evaluated using Bionumerics 
software (version 3.0; Applied Maths, Ghent, Belgium).
bacterial proteins
All S. aureus proteins used for Luminex experiments were 6x His-tagged proteins with 
the exception of the synthetic phenol-soluble modulin α 1-4 peptides and the sugars 
petidoglycan and wall-teichoic acid. The following proteins were coupled to xMAP® 
beads (Luminex Corporation, Austin, TX, USA): protein secretion system ESX-1-associated 
factors EsxA and B; Nuclease (Nuc); peptidoglycan hydrolase LytM; immunodominant 
protein A (IsaA); glucosaminidase; lipase; peptidoglycan (PG); wall teichoic acid (WTA); 
foldase-protein PrsA; clumping factor A and B (ClfA and ClfB); SD-repeat containing pro-
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teins D and E (SdrD and SdrE); iron-responsive surface determinants A and H (IsdA and 
IsdH); fibronectin-binding proteins A and B (FnbpA and FnbpB); extracellular fibrinogen-
binding protein (Efb); S. aureus surface protein G (SasG); staphylococcal complement 
inhibitor (SCIN); chemotaxis inhibitory protein of Staphylococcus aureus (CHIPS); formyl 
peptide receptor-like inhibitory protein (FLIPr); phenol-soluble modulin α 1-4 peptides 
(PSM alpha 1-4), alpha toxin; gamma-hemolysin B (HlgB); leukocidins D, E, F and S (LukD, 
LukE, LukF and LukS); staphylococcal enterotoxins A-E, G-J, M-O, Q, R (SEA–SEE, SEG-SEJ, 
SEM-SEO, SEQ, SER); exfoliative toxins A and B (ETA and ETB); toxic shock syndrome toxin 
1 (TSST-1); staphylococcal superprotein-like proteins 1, 3, 5, 9, 10 and 11 (SSL1, SSL3, 
SSL5, SSL9, SSL10 and SSL11) and hypothetical proteins SA0104, SA0486 and SA0688. 
table 1. Newly designed primers used in this study.
Gene Forward primer Reverse primer
Hla CGGGATCCGCAGATTCTGATATTAATATT AACTGCAGTTAATTTGTCATTTCTTCTT
EsxA CTTACGGGCAAGGTTCAGAC CTTGTTCTTGAACGGCATCA
EsxB GGGTGGATATAAAGGTATTAAAGCA ATGGGTTCACCCTATCAAGC
ETA ACTGTAGGAGCTAGTGCATTTGT TGGATACTTTTGTCTATCTTTTTCATCAAC
ETB ACAAGCAAAAGAATACAGCG GTTTTTGGCTGCTTCTCTTG
FlipR TCGCTGCAGGTCTTTTAACTC GCTTTCTTCACATCACCTTGG
HlgB GTCAGAGAGTCCATAATGCATTTAA CACCAAATGTATAGCCTAAAGTG
IsaA ACCTGAAGCACCTGATGGGT TACGCAGCAGGTACAGGACA
Lipase CAATAGGCGTGGTGTCAGTG AATCGCCAACTTGTGGTTTC
LukDE TGAAAAAGGTTCAAAGTTGATACGAG TGTATTCGATAGCAAAAGCAGTGCA
LukF ATCATTAGGTAAAATGTCTGGACATGATCCA GCATCAA(GC)TGTATTGGATAGCAAAAGC
LukS GCAGACGCGTCAACACAA TTTTACATTTTCCCTATCTTTTT
LytM CATGCGAAAGACGCAAGCTG AGGCGCTGTTGAATTACCCG
Nuc TTATTAAGTGCTGGCATATGTATG TTTTCTAATATTAAATACACTTAC
PrsA AAGCAATACGGCGGTAAAGA GTGCGCCACCTTGTTTAAGT
SSL1 TTCAATTTTTGCATTTTGAGGTT TTCTTCATCTGAAGCGAAAGC
SSL3 TCGAGTATGACTTCAATTTGTGC GAACCACATCAACACAACTTCC
SSL5 GATGACAGCAATTGCGAAAG ATAGCCGCCATCTTTCATTG
SSL9 ATCGGCCAATGCAGAAGTAG CCACCGACCGAGTATTTGTC
SSL10 CAGCATTAGCAAAAGCGACA GCTTTCTATGACTTCCCCCATA
SSL11 GCACTAGGGATTTTAACAACAGG CCATGCGATGAGGCTGTAAT
SEC CTTGTATGTATGGAGGAATAACAA TGCAGGCATCATATCATACCA
SED GTGGTGAAATAGATAGGACTGC ATATGAAGGTGCTCTGTGG
SEE TACCAATTAACTTGTGGATAGAC CTCTTTGCACCTTACCGC
SEG CGTCTCCACCTGTTGAAGG CCAAGTGATTGTCTATTGTCG
SEH CAACTGCTGATTTAGCTCAG GTCGAATGAGTAATCTCTAGG
SEN CGTGGCAATTAGACGAGTC GATTGATTTGATGATTATAG
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The following purified non-staphylococcal proteins were also coupled to xMAP beads as 
negative controls: Moraxella catarrhalis ubiquitous surface protein 1 (UspA1); Streptococ-
cus pneumoniae pneumococcal surface adhesin A (PsaA) and human metapneumovirus 
surface protein (hMPV).
SasG, SdrD, SdrE, ClfB, IsdA, IsdH, FnbpA and FnbpB were expressed and purified as de-
scribed previously [27]. The constructs were kindly provided by T. Foster (Trinity College, 
Dublin, Ireland). Alpha toxin, HlgB, LukD, LukE, LukF, LukS, SEA and SEC were prepared 
as described previously [28]. All other proteins were kindly provided by other research 
groups, as indicated in the acknowledgments.
The purity of all proteins was confirmed using SDS-page. The proteins were coupled to 
xMAP® beads as described previously [29, 30] with some modifications for PG, WTA and 
PSM alpha 1-4. For PG and WTA, the beads were incubated with the cross-linkers adipic 
acid dihydrazide (ADH; 35 mg/ml) and EDC (200 mg/ml) before incubation with the 
proteins according to the standard protocol. For PSM alpha 1-4 peptides, the activated 
beads were firstly coupled to 25 μg streptavidin per reaction according to the standard 
protocol, and then subsequently coupled to biotin-labeled PSM alpha 1-4 peptides for 
one hour.
measurement of anti-staphylococcal antibodies
The levels of IgG and IgA antibodies against 56 staphylococcal proteins in the serum 
samples of bacteremia patients were measured using a bead-based flow cytometry 
technique (xMAP®; Luminex Corporation), as previously described [21, 29, 30]. In addi-
tion to staphylococcal proteins, the IgG levels against the non-staphylococcal proteins 
UspA1 (Moraxella cattharalis), PsaA (Streptococcus pneumoniae) and hMPV (human 
metapneumovirus) were also determined. Serum samples were diluted 1:100 in PBS and 
secondary phycoerythrin (PE)-labeled goat anti-human antibodies against either total 
IgG or IgA were diluted 1:200. All measurements were performed in duplicate and the 
median fluorescence intensities (MFIs), a semi-quantitative measure of antibody levels, 
were averaged. Duplicate measurements for which the coefficient of variation was larger 
than 25% were excluded from further analysis. All measurements were corrected for 
non-specific background signal by subtracting the MFIs of control beads not coupled 
to any protein.
For the determination of immunological cross-reactivity, 1:200 diluted serum from 
one bacteremia patient with high MFIs for all leukocidins was pre-incubated with re-
combinant proteins serially diluted in PBS for 35 minutes on a thermomixer plate shaker. 
After incubation the serum was spun down twice for 10 minutes at 3400 RPM and non-
bound specific antibodies remaining in the supernatant were measured following the 
standard protocol.
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microarray experiments
Two S. aureus isolates from different bacteremia patients were used for the microarray 
experiments. Overnight cultures were diluted 100 times in fresh prewarmed brain-heart 
infusion (BHI) broth and grown at 37oC in 5% CO2 until an OD590 of 0.5 was reached. A 
volume of 30 ml of the culture was pelleted, and then resuspended in 5 ml of freshly 
isolated heparinized human blood or BHI broth, and incubated with gentle rotation at 
37°C in 5% CO2. All experiments were independently repeated twice with blood from 
two healthy volunteers (both nasal S. aureus carriers). At time point 0 minutes for BHI 
and time point 0, 30, 60 and 90 minutes for blood, 10 ml RNA protect (Qiagen, German-
town, MD, USA) was added to the samples and incubated for 5 minutes at roomtem-
perature. The cultures were then pelleted, cold water was added and subsequently 10 
x concentrated PBS was added. After centrifugation the pellets were lysed using 1 ml 
RLT buffer (Qiagen) and 10 µl β-mercaptoethanol, and finally the bacterial pellets were 
resuspended in 1 ml RNA Pro solution (Qbiogene Inc., City, CA, USA).
S. aureus RNA was isolated using the FastRNA® Pro Blue Kit according to the manufac-
turer’s instructions (Qbiogene Inc.) using the Fastprep FP120 instrument (Qbiogene; two 
cycles of 45 seconds at a speed setting of 6.0). After isolation, the RNA was treated with 6 
U TURBO DNase (Ambion, Austin, TX, USA) according to the manufacturer’s instructions, 
and then the RNA was further purified using the RNAeasy kit (Qiagen) following the 
manufacturer’s protocol.
Chromosomal DNA was isolated from overnight cultures grown in BHI broth. Bacteria 
were lysed using FastProtein™ Blue Matrix and the FastPrep® instrument (Qbiogene; two 
cycles of 45 seconds at a speed setting of 6.0). DNA was then purified using the QIAamp 
DNA Mini Kit (Qiagen) and treated with 10 μl RNase (Promega, Madison, WI, USA).
Hybridization probes were generated from 5 μg total RNA or 1 μg DNA according to 
the protocol of the Bacterial Microarray Group (BµG@s; St. George’s Hospital Medical 
School, London, UK). RNA or DNA was mixed with 3 μg random primers (Invitrogen, 
Breda, The Netherlands), heat denatured and snap cooled on ice. The RNA was reverse 
transcribed to cDNA to incorporate the Cy5 dCTP (GE Healthcare, Diegem, Belgium) 
fluorescent analog, and DNA was labeled with Cy3 dCTP (GE Healthcare). Labeled RNA 
and DNA samples were pooled, and hybridized overnight to an S. aureus microarray 
with PCR amplicons printed on Ultragaps (Corning, NY, USA) glass slides (BµG@S) [31]. 
The array design is available in BµG@Sbase (Accession No. A-BUGS-17; http://bugs.sgul.
ac.uk/A-BUGS-17) and also ArrayExpress (Accession No. A-BUGS-17).
The microarray slides were scanned using the ScanArray Express HT scanner (Perkin 
Elmer, Groningen, The Netherlands) following the manufacturer’s instructions. The spots 
were quantified using Imagene 6.0 software (BioDiscovery, Marina Del Ray, CA, USA). 
The fully annotated microarray data have been deposited in BμG@Sbase (accession 
number E-BUGS-137; http://bugs.sgul.ac.uk/E-BUGS-137) (http://bugs.sgul.ac.uk/E-
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BUGS-137%29) and also ArrayExpress (accession number E-BUGS-137). GeneSpring GX 
version 7.3 Software (Agilent Technologies, Santa Clara, CA, USA) was used for normal-
ization and further data analysis. Expression levels were quantified as the log ratio of 
the signal derived from RNA isolated from blood divided by the signal derived from 
DNA isolated from broth. Expression levels were averaged for the duplicate experiments 
from each blood donor, and then the average expression levels from both donors were 
averaged.
statistical analysis
Fold-increases in antibody levels were calculated as the ratio of the peak antibody 
level divided by the initial antibody level (as measured in the first serum sample). If the 
antibody level only declined after the initial measurement, than the ratio of the lowest 
antibody level divided by the initial antibody level was calculated. Both fold-increases 
and decreases were pooled to determine the median fold-change in antibody levels per 
protein.
Evaluation of histogram plots and the Kolmogorov-Smirnov test revealed a non-nor-
mal distribution of the IgG levels for most proteins. The non-parametric Mann-Whitney 
U test was used to compare the antibody levels of bacteremia patients and controls. 
Spearman’s correlation coefficient was used for correlation analysis of the microarray 
data. P-values ≤ 0.05 were considered statistically significant. All statistical analyses were 
performed using SPSS version 15.0 (SPSS, Chicago, IL, USA) or Graphpad Prism version 5 
(Graphpad Inc. La Jolla, CA, USA).
resuLts
Genetic typing and presence of virulence genes in clinical S. aureus isolates
PFGE analysis was performed on the first available S. aureus isolates from all 22 bacteremia 
patients. The dendogram in Figure 1 illustrates the overall lack of relatedness between 
the isolates from different patients, with the exception of the isolates from patients 4, 
5 and 14. However, there was no epidemiological relationship between these or any of 
the patients included in this study. To further characterize the genetic background of the 
clinical isolates, all strains were spa-typed. A broad range of spa-types linked to different 
clonal clusters were observed, including two unknown new spa-types. All of the isolates 
were methicillin-sensitive.
For 54 of the 56 proteins analyzed in this study, the presence of the corresponding 
genes was determined in all clinical isolates using PCR. In addition to the biosynthesis 
genes for peptidoglycan and wall teichoic acid which are obligatorily present in each 
isolate, 11 genes were found to be ubiquitously present in all isolates: alpha toxin, 
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clumping factor A and B, glucosaminidase, IsaA, IsdA, lipase, LytM, nuclease, PrsA and 
SA0688. Five genes were present in only one isolate: exfoliative toxin A, leukocidins F 
and S, and staphylococcal enterotoxins C and Q. Exfoliative toxin B and enterotoxins 
E and H were not present in any of the isolates. A summary of the number of isolates 
containing each gene is presented in Table 2.
anti-staphylococcal antibodies in bacteremia patients
To study the humoral immune response against a wide array of staphylococcal proteins 
in bacteremia patients, the total IgG and IgA levels against 56 proteins were measured in 
serial serum samples from 22 bacteremia patients. The IgG and IgA levels against EsxA, 
PSM alpha 1-4 peptides, SA0104, SEI and SEJ, and additionally IgA levels against EsxB 
and SEO were excluded from further analysis, due to the very low signal intensities with 
coefficients of variation larger than 25% between duplicate experiments.
In general, IgG levels directed against all proteins were already detectable at the time 
of diagnosis and showed a transient increase in the majority of bacteremia patients. 
The increases in IgA levels were generally many-fold lower than the increases in IgG 
levels. The levels of protein-specific IgG, and to a lesser extent IgA, varied extensively 
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figure 1. Dendogram of clinical isolates.
Pulsed-field gel electrophoresis data and spa-types of S. aureus isolates obtained from blood cultures of 22 
bacteremia patients are shown.
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in the first serum sample obtained from each patient (median of 1 day after diagnosis; 
range, 0-21 days) (Figure 2). The time taken to reach the peak antibody levels varied 
widely between patients and proteins, and ranged from 7 to 86 days after diagnosis. The 
course of antibody levels after reaching the peak height was generally characterized by 
a decrease back towards the initial level and remaining at this level for up to 97 days 
after diagnosis (Figure 2).
table 2. Overview of gene presence and associated IgG responses for bacterial proteins
Protein No. of patients 
with gene pos 
isolates (%)
No. of patients 
with increase in 
IgG level (%)
Median fold 
increase from 
initial to peak 
level (range)
Significant 
difference1
p value2
Alpha toxin 22/22 (100%) 20/22 (91%) 1.3 (0.9-3.47) ND ND
CHIPS 14/22 (64%) 16/18 (89%) 1.2 (0.4-2.95) no 0.389
ClfA 22/22 (100%) 18/20 (90%) 1.6 (0.02-6.09) yes 0.011
ClfB 22/22 (100%) 14/20 (70%) 1.1 (0.01-5.42) yes 0.036
Efb 21/22 (96%) 11/15 (73%) 1.5 (0.51-7.96) no 0.430
EsxA 22/22 (100%) CV>25% CV>25% ND ND
EsxB 14/22 (64%) 15/17 (88%) 1.4 (0.22-2.91) yes 0.022
ETA 1/22 (5%) 15/22 (68%) 1.3 (0.29-23.78) no 0.337
ETB 0/22 (0%) 15/21 (71%) 1.31 (0.29-23.78) no 0.624
FlipR 16/22 (73%) 18/21 (86%) 1.31 (0.43-8.02) yes 0.003
FnbpA 20/22 (91%) 14/15 (93%) 1.41 (0.04-5.15) no 0.274
FnbpB 7/22 (32%) 9/10 (90%) 1.31 (0.75-3.68) yes 0.040
Glucosaminidase 22/22 (100%) 21/21 (100%) 1.38 (1.02-25.75) yes <0.0001
HlgB 17/22 (77%) 22/22 (100%) 1.26 (1.02-5.14) yes 0.001
IsaA 22/22 (100%) 20/21 (95%) 1.09 (0.9-13.2) yes 0.001
IsdA 22/22 (100%) 22/22 (100%) 1.68 (1.07-40.45) yes 0.005
IsdH 21/22 (95%) 16/18 (89%) 1.94 (0.62-6.6) yes 0.024
Lipase 22/22 (100%) 21/22 (95%) 1.35 (0.85-20.99) yes 0.002
LukD 16/22 (72%) 22/22 (100%) 1.3 (0.64-4.63) yes 0.004
LukE 16/22 (72%) 21/22 (95%) 1.3 (0.64-4.63) yes 0.002
LukF 1/22 (5%) 21/22 (95%) 1.52 (0.95-3.92) yes <0.0001
LukS 1/22 (5%) 22/22 (100%) 1.34 (1.02-4.99) yes 0.002
LytM 22/22 (100%) 19/22 (86%) 1.35 (0.25-32.08) no 0.641
Nuc 22/22 (100%) 21/21 (100%) 1.57 (1.0-9.48) yes 0.020
Peptidoglycan ND 19/21 (90%) 1.26 (0.3-4.53) yes 0.005
PrsA 22/22 (100%) 13/13 (100%) 2.92 (1.32-34.21) no 0.096
PSMa peptides 1-4 22/22 (100%) CV>25% CV>25% ND ND
SA0104 16/22 (73%) CV>25% CV>25% ND ND
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table 2. Overview of gene presence and associated IgG responses for bacterial proteins (continued)
Protein No. of patients 
with gene pos 
isolates (%)
No. of patients 
with increase in 
IgG level (%)
Median fold 
increase from 
initial to peak 
level (range)
Significant 
difference1
p value2
SA0486 17/22 (77%) 7/9 (78%) 1.37 (0.46-3.43) yes 0.030
SA0688 22/22 (100%) 19/20 (95%) 5.05 (0.74-56.96) yes <0.0001
SasG 12/22 (55%) 7/10 (70%) 1.17 (0.35-21.64) no 0.331
SCIN 21/22 (95%) 20/21 (95%) 1.37 (0.92-16.58) yes 0.0004
SdrD 18/22 (82%) 12/13 (92%) 1.32 (0.01-5.17) yes 0.047
SdrE 15/22 (68%) 16/18 (89%) 1.69 (0.7-14.59) no 0.572
SEA 3/22 (14%) 17/22 (77%) 1.21 (0.3-52.14) no 0.343
SEB 5/22 (23%) 6/8 (75%) 1.13 (0.28-5.21) no 0.218
SEC 1/22 (5%) 19/22 (86%) 1.14 (0.68-19.37) no 0.430
SED 2/22 (9%) 19/22 (86%) 1.49 (0.56-8.54) no 0.089
SEE 0/22 (0%) 16/21 (76%) 1.45 (0.51-7.29) no 0.222
SEG 11/22 (50%) 16/22 (72%) 1.13 (0.11-5.07) no 0.157
SEH 0/22 (0%) 14/22 (63%) 1.14 (0.08-3.8) no 0.240
SEI 11/22 (50%) CV>25% CV>25% ND ND
SEJ 2/22 (9%) CV>25% CV>25% ND ND
SEM 8/22 (36%) 9/13 (69%) 1.34 (0.12-7.79) no 0.075
SEN 10/22 (45%) 18/22 (82%) 1.41 (0.62-4.72) no 0.060
SEO 11/22 (50%) 11/15 (73%) 1.08 (0.098-2.03) no 0.084
SEQ 1/22 (5%) 6/11 (55%) 1.06 (0.03-1.42) no 0.287
SER 2/22 (10%) 15/21 (71%) 1.48 (0.46-10.09) no 0.309
SSL1 19/22 (86%) 18/22 (82%) 1.46 (0.7-11.21) yes 0.001
SSL3 20/22 (91%) 21/22 (95%) 1.29 (0.9-3.87) yes 0.003
SSL5 21/22 (95%) 20/22 (91%) 1.83 (0.65-8.43) yes <0.0001
SSL9 6/22 (27%) 18/22 (82%) 1.35 (0.77-10.15) yes 0.003
SSL10 14/22 (64%) 19/20 (95%) 1.37 (0.84-4.83) yes 0.030
SSL11 8/22 (36%) 20/22 (91%) 1.58 (0.67-8.67) yes 0.01
TSST1 3/22 (14%) 17/22 (77%) 1.26 (0.27-10.69) no 0.279
Wall teichoic acid ND 18/20 (90%) 1.16 (0.29-6.26) no 0.420
UspA1 ND 11/14 (79%) 1.21 (0.72-2.07) ND ND
PsaA ND 10/12 (83%) 1.32 (0.7-2.07) ND ND
hMPV ND 12/13 (92%) 1.11 (0.89-1.79) ND ND
1Comparison of mean IgG levels between 22 patients and 30 healthy controls, where significant differences 
are indicated by ‘yes’.
2Comparison P-values ≤ 0.05 were considered statistically significant
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figure 2. Antibody courses against the protein SA0688 in bacteremia patients.
a: Courses of anti-SA0688 IgG levels in 22 bacteremia patients. Each data point represents the average of 
duplicate Luminex measurements. Each patient is represented by a serial set of the same symbols and a 
polynomial trend lines is drawn through this set.
b: Course of anti-SA0688 IgA levels in the same 22 patients. Note that the MFI values on the Y-axis are a 
factor of 10 lower than in Figure 2A.
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For 15 proteins, an increase in IgG levels was observed at some time point after the 
onset of bacteremia in 95 to 100% of all patients: glucosaminidase, HlgB, IsaA, IsdA, 
lipase, leukocidins D, E, S and F, nuclease, PrsA, SA0688, SCIN and SSL3 and 10 (Table 2). 
In contrast to these 15 proteins, only PrsA and Efb were associated with increased IgA 
levels in 95 to 100% of all patients (Table S1). However, due to the lower signal intensities 
and coefficients of variation larger than 25% between duplicate experiments, PrsA and 
Efb-associated IgA levels in the majority of patients were excluded from further analysis. 
No other proteins were associated with increased IgA and/or IgG levels in at least 95% 
of all patients.
When the increases in the IgG levels against each bacterial protein in individual pa-
tients were combined, the highest median fold increase from the initial serum sample 
to the peak IgG level was observed for SA0688 (5.05-fold increase; range, 0.74-56.96) 
followed by PrsA (2.92-fold increase; range, 1.32-34.21; Figure 3, Table 2). PrsA was 
also associated with the highest median fold increase in IgA levels (2.72-fold increase, 
range, 1.02-20.83), followed by SasG (2.51-fold increase; range, 0.63-13.02) and SA0688 
(2.07-fold increase; range, 0.67-11.31) (Table S2). All other proteins showed median fold 
increases close to the overall median increase of 1.33 for IgG and 1.42 for IgA.
SA
06
88
Pr
sA
Isd
A
Cl
fA
alp
ha
 to
xin Isa
A
10
100
1
5
50
Fo
ld
-in
cr
ea
se
 in
 Ig
G
 le
ve
ls
figure 3. Initial-to-peak fold-increases in IgG levels for 6 bacterial proteins in bacteremia patients.
Each data point represents a single patient; the median fold-increase in IgG levels and interquartile range 
are indicated by lines. Patients for whom the duplicate Luminex measurements had a CV > 25% were ex-
cluded from the analysis. Note the log10 scale of the y-axis.
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The median fold increases in the IgG levels for the non-staphylococcal control proteins 
UspA1, PsaA and hMPV were 1.21 (range 0.72-2.07), 1.32 (range 0.7-2.07) and 1.11 (range 
0.89-1.79), respectively.
For 306 (35%) of the 882 observed increases in IgG levels, the corresponding gene 
was not present in the S. aureus isolate from the same patient as determined by PCR. 
Of these 306 ‘false-positive’ increases, 270 (88%) were observed for known excreted 
proteins, mainly exfoliative toxins, enterotoxins and hemolysins. When all of the initial-
to-peak fold-increases were classified as occurring in either the presence or absence of 
the corresponding genes in corresponding isolates, an overall median fold increase of 
1.37 (range, 0.85-18.07) was observed in the presence of corresponding genes and 1.32 
(range, 0.83-2.44) in the absence of corresponding genes.
comparison of anti-staphylococcal antibodies in patients and controls
To investigate the significance of the increased IgG levels observed in bacteremia pa-
tients, the peak IgG levels of all 22 bacteremia patients were compared to the IgG levels 
of 30 non-infected, age-matched control patients. The IgG levels directed against 27 
proteins were significantly higher in bacteremia patients than the non-infected controls 
(Table 2). The proteins associated with the most significant elevations in IgG levels in 
bacteremia patients compared to controls were SA0688 (Figure 4) and glucosaminidase 
(P < 0.0001), the immune modulators SSL5 (P < 0.0001), SSL1 (P = 0.0007) and SCIN (P = 
0.0004), and the toxins gamma-hemolysin B (P = 0.0007) and leukocidin F (P < 0.0001).
In vitro expression of bacterial proteins in human blood
To gain further insight into which bacterial proteins are expressed in human blood 
and could be involved in the pathogenesis of bacteremia, microarray experiments 
were performed using the genetically distinct isolates from patients 1 and 4 (Figure 1) 
to measure the global changes in S. aureus mRNA expression during culture in human 
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figure 4. Comparison of anti-SA0688 IgG lev-
els in bacteremia patients and non-infected 
controls.
Peak IgG levels of 22 bacteremia patients were 
compared to IgG levels of 30 non-infected con-
trols. The median value and interquartile range 
are indicated by lines. Note the log10 scale of 
the y-axis.
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blood. The mRNA expression levels of 3626 S. aureus genes were measured during log-
phase growth in BHI broth and also after 0, 30, 60 and 90 minutes culture in human 
blood. Compared to the transcriptomes at the start of incubation in blood (0 minutes), 
only 86 out of the 3626 tested genes showed a two-fold or higher increase in mRNA 
expression in both isolates at all time points (30, 60 and 90 minutes) when incubated 
in blood (Table S2). A majority of these upregulated genes have an unknown/unclas-
sified function, are involved in carbon metabolism or are excreted lipoproteins (Figure 
5). The only known virulence factors for which mRNA expression was upregulated after 
culture in blood were the IgG-binding protein sbi and the gamma-hemolysin A and 
B precursors. Thirty genes showed a two-fold or more reduction in mRNA expression 
in both isolates at all time points, compared to the transcriptomes of both isolates at 
the start of incubation in blood (Table S2). These downregulated genes are also mainly 
involved in cellular metabolism or have an unknown function (Figure 5). Comparison 
of the transcriptomes at each individual time point (30, 60 and 90 minutes) with the 
transcriptomes of both isolates at the start of incubation in blood (0 minutes), revealed 
that a total of 360, 420 and 641 genes, respectively, were up- or downregulated two-fold 
or more. The functional distribution of the differentially expressed genes at each time 
point was similar to the functional distribution of the differentially expressed genes at all 
time points combined. In addition to the earlier mentioned upregulation of hemolysin 
precursors, a more than two-fold upregulation of IsdA, -B, -C and –F, FnbpA and B and ClfA 
was noted after 90 minutes incubation in blood; whereas only IsdA, -B, -C, -D and FnbpA 
were upregulated two-fold or higher after 60 minutes and only IsdC was upregulated at 
least two-fold after 30 minutes, compared to the transcriptomes of both isolates at the 
start of incubation in blood.
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 Laterally acquired elements
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Degradation of small molecules
 Biosynthesis of amino acids  
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figure 5. Functional distribution of genes with altered mRNA expression in human blood.
The functional classes are shown for which the largest number of genes showed an at least twofold in-
creased or decreased mRNA expression at all time points in blood (30, 60 and 90 minutes) in both strains 
compared to trancriptomes at the start of incubation in blood (0 minutes).
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Compared to log-phase growth in BHI broth, only 7 of the 3626 analyzed genes showed 
a two-fold or higher increase in mRNA expression in both strains at all time points (30, 
60 and 90 minutes) when cultured in blood: dihydrolipoamide succinyltransferase, the 
sugar phospate antiporter uhpT, the murein hydrolase regulatory gene IrgA and the 
transcripts encoding the putative proteins SA0806, 0211, 0622 and 0761.
Of the 56 bacterial proteins for which the antibody responses were characterized in 
bacteremia patients, microarray data for 35 genes was available for at least two time 
points per isolate. In general, the mRNA expression levels of these 35 proteins, quanti-
fied as the RNA:DNA log ratios, correlated significantly between both isolates at all time 
points (P ≤ 0.001), indicating similar expression levels for these specific 35 genes in both 
strains. The mRNA expression levels of four genes were consistently high in both isolates 
during log-phase growth in BHI broth and during all measured time points (0, 30, 60 and 
90 minutes) of culture in blood: SA0688, IsaA, EsxA and SCIN (Table S3). In addition, the 
mRNA expression level of PrsA was high at all time points, except for the 90 minutes time 
point in one isolate. Compared to the expression level during log-phase growth in BHI 
broth, none of these 35 genes displayed a two-fold or higher mRNA expression level at 
any time point when cultured in blood.
discussion
In this study we investigated the humoral immune response against 56 staphylococcal 
proteins in bacteremia patients. Firstly, we further demonstrate considerable variation 
in the IgA and IgG levels of all patients at the time of diagnosis; the time taken to reach 
peak antibody levels for each protein in each patient was also heterogeneous. Even 
after extensive visual comparison of specific antibody responses to diverse proteins we 
could not observe any distinct patterns or profiles between patients. Both patients and 
proteins were rather all associated with unique combinations of extensively varying an-
tibody responses. These heterogeneous, highly individual antibody responses are in line 
with previous data [18, 19, 21, 32] and will likely be the result of an individually unique 
interplay between patients and genetically diverse S. aureus strains. Indeed, parallel to 
the diversity of patient antibody responses we further confirmed the presence of a large 
genetic diversity amongst infecting strains (figure 1).
The increases observed in the IgG levels of bacteremia patients were generally 
many-fold higher than the increases in the IgA levels. This may be explained either by 
hypothesizing that IgA production is not induced by hematogenic bacterial challenge 
to the same extent as IgG production, or that IgA levels may not alter considerably in 
blood but may increase more locally on mucosal surfaces. In any case, the relatively low 
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IgA responses prompted us to focus attention on the more dynamic IgG responses in 
bacteremia patients.
The IgG levels against fifteen bacterial proteins, including well-described virulence 
factors such as IsdA and gamma-hemolysin B, were found to increase in at least 95% 
of the bacteremia patients. Additionally, the peak IgG levels against these 15 proteins 
were significantly higher in bacteremia patients than age-matched, non-infected pa-
tients. The putative ABC transporter SA0688 and the membrane-associated foldase PrsA 
were associated with the highest median fold increase in IgG levels (5.05 and 2.92-fold, 
respectively). Although other proteins were also associated with significantly increased 
IgG levels in individual patients, these data indicate that SA0688 and PrsA appear to 
be among the most broadly expressed and immunologically recognized proteins. This 
observation is in line with previous studies which demonstrated the immunogenicity 
of SA0688 in human serum [18, 20]. In addition, the protein SA0688 showed promis-
ing results as part of a multivalent vaccine in an animal model of osteomyelitis [25]. 
Unfortunately, at current nothing is known about the exact function of SA0688 and how 
antibodies could interfere in staphylococcal infection through this protein. Moreover, in 
general other proteins than SA0688 or PrsA which were not associated with significantly 
increased antibody levels in this study may also provide interesting targets for a vaccine, 
although we can only speculate about these proteins based on our data and previous 
studies.
In addition to the question which proteins should ideally be selected for a vaccine 
component, we can only speculate about whether or not the associated antibody 
responses will be protective against infection. We observed clearly detectable, pre-
existent IgG levels against all proteins in patients at the time of diagnosis, which is in line 
with previous observations of stable, pre-existent IgG levels in both bacteremia patients 
and healthy controls [21, 27, 32]. These observations suggest that all individuals have an 
immunological memory specifically against S. aureus, possibly due to earlier, subclinical 
infections. It remains a question whether a further increase in these pre-existent IgG lev-
els will have an additional protective effect against infection, even though this increase 
is significant for diverse proteins such as SA0688 and PrsA compared to non-infected 
controls. In any case, the significant increases in IgG levels for diverse proteins suggests 
that the corresponding proteins are being expressed in vivo in patients, which will be a 
pre-requisite for any potential vaccine target.
To gain further insight into which bacterial proteins are expressed in human blood, 
the global changes in the mRNA expression levels of two genetically distinct S. aureus 
isolates during incubation in human blood were investigated. In general, of the 3626 
genes investigated, we could only associate limited numbers of genes with significantly 
altered mRNA expression levels specifically during incubation in blood, compared to the 
transcriptomes of each isolate at the start of incubation in blood or BHI broth. As noted 
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for 35 of the 56 proteins investigated in this study, most of the corresponding genes had 
a relatively constant RNA:DNA log ratio at all time points during culture in blood (Table 
S3). Most notably, the proteins SA0688, IsaA, EsxA, SCIN and, with the exception of one 
measurement, PrsA were highly expressed in both isolates in BHI broth and blood over 
time. This stable expression of genes by genetically distinct isolates in human blood or 
tissue would be a first prerequisite for any protein to be a potential vaccine component.
Most of the genes which were up- or downregulated in S. aureus specifically during 
incubation in blood belong to functional classes involved in cellular metabolism or have 
an unknown function. Exceptions to this were the IgG-binding protein sbi and gamma-
hemolysin component A precursor, which were upregulated in both isolates at all time 
points (30, 60 and 90 minutes) in blood compared to the start (0 minutes). In addition, 
other genes were upregulated at specific time points, mainly surface proteins such as 
FnbpA, ClfA and the diverse iron-regulated surface determinant (Isd) proteins. These 
findings are in agreement with a previous study which reported that a limited number 
of S. aureus genes encoding known virulence factors were specifically upregulated in 
blood [33]. In this study, mRNA expression of the gamma-hemolysin subunits were 
found to be most significantly upregulated during incubation in blood.
Although our study demonstrates the in vitro expression and in vivo immunogenicity 
of several proteins, there are several limitations in regard to the used techniques. Firstly, 
in regard to the bead-based flow cytometry assay, we observed significant increases in 
the antibody levels against leukocidins S and F, for which corresponding genes were 
present in only one isolate. The increases in specific IgG for these two leukocidin com-
ponents may be the result of immunological cross-reactivity, where antibodies specific 
to one toxin component may cross-react with structurally similar components [34-36]. 
We confirmed the presence of immunological cross-reactivity between the leukocidins F 
and D and gamma-hemolysin B in our assay (Figure S1). No cross-reactivity was observed 
between the enterotoxins in our assay (data not shown). Secondly, we used recombi-
nant staphylococcal proteins in our assay, which may lack certain naturally-occurring 
antibody-binding epitopes or may not have been optimally coupled to our assay beads, 
thereby possibly missing increases in the levels of specific antibodies. This could provide 
an alternative explanation for the low signal intensities observed for EsxA, PSM alpha 1-4 
peptides, SA0104, SEI and SEJ.
In regard to the analysis of the serially measured IgG levels, we observed a median 
fold-increase of 1.32 in IgG levels while the corresponding genes were not present in 
the isolate of the same patient. This median ‘false-positive’ increase of 1.32 was com-
parable to that of all PCR confirmed positive increases (1.37) and the overall median 
fold-increase of 1.33. Furthermore, these increases were also comparable to those of the 
non-Staphylococcal control proteins UspA1, PsaA and hMPV (1.21, 1.32 and 1.11 fold-
increase, respectively). This apparent background signal could on one hand be explained 
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by a broad, non-specific rise in antibody levels during infection or, alternatively, by the 
phenomenon that maximum values always tend to be higher than single measurements 
over an extended time period. Indeed, although IgG levels tend to remain constant over 
time in both healthy persons [27] and up to three years after infection (unpublished 
data), small variations in measured IgG levels are consequently observed. This could 
explain the observed non-specific rise in antibody levels.
In regard to the micro array data, one limitation is that we only investigated protein 
expression in two out of 21 strains. Investigating protein expression in more genetically 
diverse strains would allow for more robust conclusions about the expression of specific 
proteins, however due to practical reasons we were unable to do this. Secondly, as with 
other in vitro models the question remains how well our blood infection model reflects 
the in vivo situation during a bacteremia. Especially the high dose of infecting bacteria 
is likely to not reflect the real in vivo situation and this could influence bacterial mRNA 
expression, however the adaptation to blood should still be associated with global 
changes in mRNA expression. Finally, considering the expression of the proteins for 
which we characterized antibody responses, it should be noted that any direct correla-
tion of in vitro bacterial gene expression with the in vivo immune response in patients 
should be interpreted with caution. The mode and phase of bacterial growth in vivo may 
be different and more diverse than the pattern of growth in vitro. In addition, the expres-
sion of a bacterial protein does not necessarily induce an antibody response in vivo, 
either due to immune modulation by the bacterium or the complex regulatory immune 
processes within the host. Nonetheless, data on both bacterial gene expression in vitro 
and the in vivo immune response can yield valuable insight into the pathogenesis of 
infection and complement each other for the identification of potential vaccine targets.  
To summarize, our study suggests that most of the staphylococcal proteins tested, 
including many known virulence factors, do not lead to uniform increases in the anti-
body levels in bacteremia patients. In addition, the expression of these proteins by S. 
aureus is not significantly altered by incubation in human blood over time or compared 
to standard growth medium. One immunogenic protein is the putative iron-regulated 
ABC transporter SA0688, which induced a significant antibody response in all bactere-
mia patients and was stably expressed by genetically distinct isolates under different 
culture conditions. The ubiquitous expression of this protein will be a prerequisite for 
any potential vaccine target and our data, together with the previous literature, suggest 
that SA0688 could be a potential vaccine target to interfere with the growth or virulence 
of all S. aureus cells.
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figure s1. Cross-reactivity between leukocidins F and D and hemolysin gamma-B in human serum.
a: Serial dilutions of recombinant leukocidin F (LukF) were pre-incubated with the serum from a non-in-
fected control with high IgG levels against LukF. After incubation, the remaining IgG levels specific against 
Leukocidins D, E, F and S and Hemolysin gamma-B were measured. Note the loss in IgG levels specific for 
LukD and HlgB at lower dilutions of LukF, suggesting immunological cross-talk between these toxin com-
ponents.
b: The same experiment as for Figure S1A, now with serum from a different non-infected control. 
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2
table s1. Overview of gene presence and associated IgA responses induced by bacterial proteins.
Antigen No. of patients with gene 
positive isolates (%)1
No of patients with 
increase in IgA level (%)2
Median fold increase from 
initial to peak level (range
Alpha toxin 22/22 (100%) 17/22 (77%) 1.45 (0.59-4.34)
CHIPS 14/22 (64%) 17/21 (81%) 1.13 (0.52-4.67)
ClfA 22/22 (100%) 19/22 (86%) 1.57 (0.37-19.18)
ClfB 22/22 (100%) 16/20 (80%) 1.31 (0.22-17.9)
Efb 21/22 (96%) 7/7 (100%) 1.29 (1.08-8.32)
EsxA 22/22 (100%) CV>25% ND
EsxB 14/22 (64%) CV>25% ND
ETA 1/22 (5%) 12/16 (75%) 1.35 (0.41-5.33)
ETB 0/22 (0%) 18/22 (82%) 1.39 (0.2-17.25)
FlipR 16/22 (73%) 13/15 (87%) 1.55 (0.5-78.8)
FnbpA 20/22 (91%) 13/16 (81%) 1.36 (0.25-19.11)
FnbpB 7/22 (32%) 12/16 (75%) 1.42 (0.16-6.24)
Glucosaminidase 22/22 (100%) 18/20 (90%) 1.69 (0.63-5.48)
HlgB 17/22 (77%) 16/22 (73%) 1.25 (0.46-4.63)
IsaA 22/22 (100%) 19/21 (91%) 1.43 (0.57-36.52)
IsdA 22/22 (100%) 19/22 (86%) 1.89 (0.61-10.1)
IsdH 21/22 (95%) 18/20 (90%) 1.98 (0.24-25.4)
Lipase 22/22 (100%) 17/21 (81%) 1.56 (0.27-17.79)
LukD 16/22 (72%) 18/22 (82%) 1.34 (0.67-10.32)
LukE 16/22 (72%) 19/22 (86%) 1.36 (0.76-16.65)
LukF 1/22 (5%) 18/22 (82%) 1.32 (0.15-5.16)
LukS 1/22 (5%) 17/21 (81%) 1.33 (0.63-36.67)
LytM 22/22 (100%) 15/21 (71%) 1.36 (0.17-19.11)
Nuc 22/22 (100%) 14/16 (88%) 1.57 (0.11-16.63)
Peptidoglycan ND 6/8 (75%) 1.29 (0.66-3.61)
PrsA 22/22 (100%) 6/6 (100%) 2.715 (1.02-20.83)
PSMa peptides 1-4 ND CV>25% ND
SA0104 16/22 (73%) CV>25% ND
SA0486 17/22 (77%) 11/13 (85%) 1.4 (0.4-23.38)
SA0688 22/22 (100%) 13/14 (93%) 2.07 (0.67-11.31)
SasG 12/22 (55%) 14/15 (93%) 2.51 (0.63-13.02)
SCIN 21/22 (95%) 20/22 (91%) 1.42 (0.85-16.78)
SdrD 18/22 (82%) 16/17 (94%) 1.85 (0.14-7.07)
SdrE 15/22 (68%) 14/15 (93%) 1.46 (0.51-7.03)
SEA 3/22 (14%) 19/21 (91%) 1.58 (0.46-8.69)
SEB 5/22 (23%) 13/17 (77%) 1.32 (0.19-11.95)
SEC 1/22 (5%) 18/22 (82%) 1.28 (0.53-13.82)
SED 2/22 (9%) 18/20 (90%) 1.44 (0.45-3.87)
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table s1. Overview of gene presence and associated IgA responses induced by bacterial proteins. (con-
tinued)
Antigen No. of patients with gene 
positive isolates (%)1
No of patients with 
increase in IgA level (%)2
Median fold increase from 
initial to peak level (range
SEE 0/22 (0%) 12/16 (75%) 1.31 (0.16-24.28)
SEG 11/22 (50%) 18/21 (86%) 1.4 (0.12-3.34)
SEH 0/22 (0%) 15/18 (83%) 1.58 (0.54-10.04)
SEI 11/22 (50%) CV>25% ND
SEJ 2/22 (9%) CV>25% ND
SEM 8/22 (36%) 16/18 (89%) 1.45 (0.24-7.96)
SEN 10/22 (45%) 16/19 (84%) 1.49 (0.23-10.09)
SEO 11/22 (50%) CV>25% ND
SEQ 1/22 (5%) 8/12 (67%) 1.32 (0.43-10.75)
SER 2/22 (10%) 14/18 (78%) 1.41 (0.41-8.32)
SSL1 19/22 (86%) 17/20 (85%) 1.44 (0.63-5.38)
SSL3 20/22 (91%) 16/22 (73%) 1.39 (0.28-4.96)
SSL5 21/22 (95%) 18/22 (82%) 1.44 (0.59-21.96)
SSL9 6/22 (27%) 17/21 (81%) 1.51 (0.21-10.57)
SSL10 14/22 (64%) 18/22 (82%) 1.33 (0.53-6.29)
SSL11 8/22 (36%) 15/20 (75%) 1.53 (0.31-29.5)
TSST1 3/22 (14%) 17/22 (77%) 1.5 (0.58-8.97)
Wall teichoic acid ND 18/22 (82%) 1.17 (4.67-0.52)
1Presence of genes in 22 isolates
2Initial-to-peak fold-increases in IgA levels in 22 bacteremia patients.
CV>25%: Patients for whom the duplicate measurements of the IgA levels had a CV larger than 25% were 
excluded from the analysis. IgA levels for the antigens EsxA, EsxB, PSM alpha 1-4 peptides, SA0104, SEI, 
SEJ and SEO were completely excluded because of very low signal intensities with coefficients of variation 
larger than 25% for a majority of patients.
ND: not determined.
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Characterization of S. aureus bacteraemia
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and in vivo antibody detection 
identifies potential vaccine targets 
against Staphylococcus aureus during 
osteomyelitis
P. Martijn den Reijer, Marjan Sandker, Susan V. Snijders, Mehri 
Tavakol, Antoni P. A. Hendrickx, Willem J. B. van Wamel
Medical Microbiology and Immunology 2017; 206: 11-22
64
Chapter 3
abstract
Currently little is known about the in vivo human immune response against Staphylococ-
cus aureus during a biofilm-associated infection, such as osteomyelitis, and how this re-
lates to protein production in biofilms in vitro. Therefore, we characterized IgG responses 
in 10 patients with chronic osteomyelitis against 50 proteins of S. aureus, analysed the 
presence of these proteins in biofilms of the infecting isolates on polystyrene (PS) and 
human bone in vitro, and explored the relation between in vivo and in vitro data.
IgG levels against 15 different proteins were significantly increased in patients com-
pared to healthy controls. Using a novel competitive Luminex based assay, eight of 
these proteins [(alpha toxin, Staphylococcus aureus formyl peptide receptor-like 1 
inhibitor (FlipR), glucosaminidase, iron-responsive surface determinant A and H, the 
putative ABC-transporter SACOL0688, staphylococcal complement inhibitor (SCIN) and 
Serine-aspartate repeat-containing protein E (SdrE)] were also detected in a majority of 
the infecting isolates during biofilm formation in vitro. However, 4 other proteins were 
detected in only a minority of isolates in vitro while, vice versa, 7 proteins were detected 
in multiple isolates in vitro but not associated with significantly increased IgG levels in 
patients. Detection of proteins was largely confirmed using a transcriptomic approach.
Our data provide further insights into potential therapeutic targets, such as for vac-
cination, to reduce S. aureus virulence and biofilm formation. At the same time, our data 
suggests that either in vitro or immunological in vivo data alone should be interpreted 
cautiously and that combined studies are necessary to identify potential targets.
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introduction
Staphylococcus aureus is the most common causative organism of osteomyelitis [1-3], 
which is defined as an infection of the bone and is associated with significant morbidity 
[1, 4, 5]. Treatment is often difficult and requires surgery in addition to antibiotics [5]. Os-
teomyelitis is associated with the formation of bacterial biofilms [3, 6], which are defined 
as complex communities of bacteria enclosed in a polymer matrix that differ significantly 
in their gene expression and protein production compared to free-living bacteria [7]. Bio-
film formation is believed to increase resistance against antibiotics and the host immune 
system, which further complicates the treatment of such infections [3, 8, 9].
Together with the increasing incidence of resistant S. aureus isolates [10, 11], the 
difficult treatment of osteomyelitis underscores the need for alternative treatment 
strategies. One such strategy is the development of a vaccine [12]. However, so far no 
clinically successful vaccine against S. aureus has been developed, despite the promising 
results of vaccines targeting diverse virulence factors of this pathogen in animal models 
[13-15], including an animal model for osteomyelitis [16]. Possibly, so far clinically evalu-
ated vaccines might have failed because these were based on single antigens, while the 
awareness is currently increasing that multiple virulence factors of S. aureus should be 
targeted to undermine bacterial virulence [12, 13].
Although diverse virulence factors of S. aureus have been associated with biofilm for-
mation [17-21], so far only a limited number of studies has focussed on the presence of 
multiple virulence factors simultaneously in biofilms [22, 23]. In addition, most of these 
studies used in vitro and/or animal models, while it remains unclear whether proteins 
expressed in these models are also involved in infection in humans. Finally, the immuno-
genic potential of proteins that are specifically expressed during a biofilm-associated in-
fection remains unknown, as studies examining the immune response against S. aureus 
in patients have so far mainly focused on acute infections, such as bacteremia [24-29].
The aims of the present study were to characterize IgG responses in 10 patients with 
chronic osteomyelitis against 50 proteins of S. aureus, to analyse the presence of these 
proteins in biofilms of S. aureus isolates from the same patients on polystyrene (PS) and 
human bone in vitro, and to explore the relation between in vivo and in vitro data. All 50 
proteins are functionally well characterized virulence factors which have been a major 
focus of many immunoproteomic studies, including vaccination trails, in both animal 
models [13-15] and humans [25, 29-31]. This study provides further insights into the 
presence and immunogenicity of these proteins during a biofilm-associated chronic 
infection in humans.
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materiaLs and methods
human serum and tissue
All patient serum used in this study was obtained from coded left-over material from 
routine diagnostic blood samples as described previously [29]. This procedure was ap-
proved and the acquisition of additional written consent was waived specifically for this 
study by the Medical Ethics Committee of the Erasmus University Medical Center Rot-
terdam (MEC-2007-106). Human bone was derived from surplus tissue obtained during 
routine orthopaedic surgical procedures and all tissue was directly anonymized upon 
arrival at the laboratory. This procedure was approved and the acquisition of additional 
written consent was waived by the Medical Ethics Committee of the Erasmus University 
Medical Center Rotterdam (MEC-2004-322). None of the authors were involved in the 
direct collection of either blood or tissue from patients. Only qualified physicians (MdR 
and MS) had access to potentially identifying patient information.
Patients
Ten patients diagnosed with chronic osteomyelitis at the Erasmus Medical Center be-
tween march 2007 and march 2011 were included in this study (all male, median age 
62 years, interquartile range (IQR) 49-69 years). Chronic osteomyelitis was defined as a 
history of at least one year of clinical and radiological signs indicative of osteomyelitis 
combined with the isolation of S. aureus from at least one deep bone culture. Isolates 
from 9 patients could be retrieved for this study. The cause of osteomyelitis varied, being 
iatrogenic following surgery (4 patients), fracture or other trauma (3 patients), diabetic 
ulcer (2 patients), or hematologic metastasis from another focus (1 patient). Infections 
were localized in the femur (3 patients), small bones of the foot (3 patients), tibia (2 pa-
tients), ulna and sternum (each 1 patient). Nasal carrier status for S. aureus was not tested.
A median number of 4 serum samples were collected per patient (IQR 2-5) over a 
median period of 26 days following the most recent positive bone culture (IQR 9.5-85.5 
days). Peak antibody levels of each patient were compared with those measured in single 
serum samples of 10 previously described bacteremia patients (80% male, median age 
64 years, IQR 45- 84) and 20 previously described, age-matched controls (all male, me-
dian age 62 years, IQR 57 - 67) who had no record of a clinically apparent infection in at 
least six months [29]. S. aureus nasal carrier status was not tested in patients nor controls.
bacterial strains and genotyping
S. aureus isolates obtained from deep bone cultures were identified on the basis of colony 
and microscopic morphology and Slidex Staph Plus agglutination testing (bioMérieux, 
Marcy l’Etoile, France). Identification was confirmed by spa-PCR and all isolates were 
spa-typed [32]. All isolates were methicillin sensitive as determined by cefoxitin disk 
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diffusion according to the CLSI criteria [33]. Antimicrobial susceptibility to additional 
antibiotics was determined using the VITEK® 2 system with card AST-P549 (bioMérieux)
Isolates were further typed using pulsed-field gel electrophoresis (PFGE) with Sma1-
digested chromosomal DNA as described previously [34]. Relatedness among the PFGE 
profiles was evaluated using Bionumerics software (version 3.0; Applied Maths, Ghent, 
Belgium). Finally, all isolates were screened with PCR for the presence of 50 genes using 
previously described primers [29].
Preparation of human serum and measurement of antibodies
Serum samples were collected in BD Vacutainer® SST II Advance plastic serum tubes, 
which were centrifuged for 3 minutes at 1680g and stored at 4 0C. For long-term use 
serum was aliquoted in 1.5 ml Eppendorf® tubes and stored at -80 0C.
IgG levels against 50 recombinant S. aureus proteins were measured in serum samples 
using a bead-based flow cytometry technique (xMAP®; Luminex® Corporation, Austin, 
TX, USA), as previously described [29]. All proteins are summarized in Table S1. Proteins 
were coupled to xMAP® carboxylated beads (Luminex Corporation) as described previ-
ously [29, 35]. All measurements were performed in duplicate and the median fluores-
cence intensities (MFIs), a semi-quantitative measure of antibody levels, were averaged. 
Duplicate measurements for which the coefficient of variation was larger than 25% 
were excluded from further analysis. All measurements were corrected for non-specific 
background signal by subtracting the MFIs of control beads not coupled to any protein.
Preparation of human bone
Fresh human bone was obtained in the operating room from patients receiving a total 
hip prosthesis, for purposes other than this study, in the Erasmus Medical Center from 
the period of January 2012 until February 2013. All operations were performed by the 
same orthopaedic surgeon (dr. P.K. Bos). After removing the femoral head, a small por-
tion of the surplus tissue was cut using a saw and directly transported to the lab in sterile 
saline. Spongious bone was harvested from the tissue and cut into small pieces fitting 
in a 96 wells plate. The samples were rinsed repeatedly with saline until all blood was 
visibly removed.
biofilm formation on polystyrene and human bone
A routine biofilm model was used as described before [20, 36-38]. Briefly, overnight 
cultures of S. aureus grown on sheep blood agar were suspended in Iscove’s Modified 
Dulbecco’s Medium (IMDM, Life technologies, Carlsbad, CA, USA) without phenol red un-
til an OD660 of 2.0 was reached. One µl of this bacterial suspension was added to 199 µl 
of IMDM in sterile, 96-wells polystyrene plates (Greiner Bio-one GmbH, Kremsmuenster, 
Austria). Duplicate wells not inoculated with bacteria served as sterile controls. Plates 
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were then incubated at 37 0C and gentle shaking at 200rpm for various intervals. Biofilm 
mass was measured by staining with 1% crystal violet. OD was measured at 490 nm.
Alternatively, standard-sized pieces of freshly isolated human bone were washed in 
sterile water and then added to 199 µl of IMDM in the same 96-wells plates in which 
biofilms on PS were grown. One µl of the same bacterial suspension as described above 
was added before incubation. Duplicate wells with bone tissue were not inoculated to 
serve as sterile controls.
multiplex bead assay for assessment of protein levels in biofilms
A previously described multiplex competition Luminex® assay (CLA) was used to in-
directly detect the presence of 50 IgG-accessible proteins in biofilms [39, 40]. In brief, 
biofilms grown on PS and bone were washed once with ice-cold PBS supplemented with 
0.5% (wt/v) sodium azide (Sigma-Aldrich) at 1, 8, 24 or 48 hours to remove non-adherent 
bacteria. Bone tissue with attached biofilms was transferred to a clean well. Biofilms 
were then incubated for 35 min at 8°C and continuous shaking (500 rpm) with 200 µl 
of a 1:200 dilution of polyclonal human IgG (PHG), isolated using the HiTrap™ Protein 
G HP column according to the manufacturer’s guidelines (GE Healthcare Bio-sciences, 
Piscataway, New Jersey, USA), from pooled serum of 40 healthy volunteers [41].
After incubation, the remaining non-bound IgG antibody levels in recovered PHG 
samples were measured using the multiplex bead-based flow cytometry technique 
(xMAP®, Luminex corporation), with recombinant proteins covalently coupled to the 
beads, as described above. As negative controls PHG samples incubated with empty PS 
wells or sterile bone pieces were included in all experiments.
Next, the percentage decrease in the levels of specific IgG antibodies for each protein 
was calculated in relation to the negative control. The percentage decrease can be con-
sidered as a semi-quantitative measure of the protein-specific antibody absorption from 
PHG by the biofilm, thus indirectly reflecting the presence of the particular S. aureus 
protein in the biofilm [39, 40]. The average percentage decrease plus two times the 
standard deviation, obtained at 24 and 48 hours biofilm growth, for two non-S. aureus 
control proteins [Streptococcus pneumoniae putative proteinase maturation protein A 
(PpmA) and human metapneumovirus surface protein (hMPV)] and all S. aureus proteins 
of which genes were not present in an isolate, were chosen as cut-off value (35% at 24 
hrs biofilm growth and 42% at 48 hrs, respectively).
reverse transcriptase Pcr
Biofilms were grown on PS for 8 and 24 hrs in 96-well plates in 200 µl of IMDM. Biofilms 
harvested from 8 wells were washed in PBS, resuspended, pooled and centrifuged at 
4000 rpm for 10 min at 4°C. Pellets were resuspended in 200 µl of RNA protect™ Bacterial 
reagents (Qiagen), stabilized for 5 min and then centrifuged for 10 min at 4°C. The pellet 
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was dissolved in 1 ml of RNA-pro solution (Fast RNA Pro Blue kit, MP Biomedicals) and 
stored at -20°C until use. RNA was isolated using the Fast RNA Pro Blue kit according 
to the manufacturer’s protocol. Each 10 µg of isolated RNA was treated twice with 2 
U TURBO DNase (Ambion, Life Technologies). The reaction was stopped by adding 0.2 
volumes of DNase inactivation reagent (Ambion) and incubation for 2 min at ambient 
temperature. RNA containing supernatants were collected by centrifugation (1.5 min at 
9000 g at ambient temperature) and each 2 µg DNase-treated RNA was treated with 2 
U DNase I (Fermentas, Fisher Scientific). One µg of prepared RNA was transcribed into 
cDNA using 200 U RevertAid H Minus Reverse transcriptase (Fermentas), 4 µl of 5x reac-
tion buffer (Fermentas), 20 U of RiboLock RNase inhibitor (Fermentas) and 2 µl of 10 
mM dNTP mix (Fermentas) in a final volume of 20 µl of DEPC-treated water. This was 
incubated for 60 min at 42°C and then terminated by heating at 70°C for 5 min. For each 
RNA sample a negative control without reverse transcriptase was processed similarly. 
The presence of cDNA in all samples was examined using PCR as described previously 
[29].
cryo scanning electron microscopy
The clinical isolate from one osteomyelitis patients was allowed to form biofilms on 
human bone for 24 hours as described above. Next, S. aureus in bone was fixed for 15 
minutes with 1% (v/v) glutaraldehyde (Sigma) in phosphate buffered saline (PBS) at 
room temperature. Samples were washed twice with PBS to remove excess fixative and 
were subsequently serially dehydrated by consecutive incubations in 1 ml of 25% (v/v) 
and 50% (v/v) ethanol-PBS, 75% (v/v) and 90% (v/v) ethanol-H2O, and 100% ethanol (2x), 
followed by 50% ethanol-hexamethyldisilazane (HMDS) and 100% HMDS (Sigma) and 
air-dried overnight at room temperature. After overnight evaporation of HMDS, bone 
samples were mounted on 12 mm specimen stubs (12 mm, Agar Scientific) and coated 
with gold to 1 nm using a Quorum Q150R sputter coater at 20 mA prior to examination 
with a Phenom PRO Table-top scanning electron microscope (PhenomWorld).
statistics
Mean IgG levels between patient groups and controls were compared using one-way 
ANOVA. All data were logarithmically transformed to obtain equal variances between 
groups, checked with Levene’s test for equality of variances. For proteins that were as-
sociated with a significant difference in the ANOVA analysis, additional least significant 
difference (LSD) post-hoc tests were performed for further group comparisons.
Correlation between biofilm mass and the percentage decrease in specific IgG levels, 
as obtained with CLA, was determined by calculating the non-parametric Spearman’s 
rank correlation coefficient (rs).
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In all cases p-values ≤ 0.05 were considered as statistically signifi cant. IBM® SPSS® 
Statistics version 21 (IBM corporation, Armonk, NY, USA) was used for statistical analysis. 
Graphics were made using Graphpad Prism version 5 (Graphpad Inc. La Jolla, CA, USA).
resuLts
Genetic typing of clinical S. aureus isolates from osteomyelitis patients
Ten patients that were diagnosed with chronic osteomyelitis caused by S. aureus, con-
fi rmed by deep bone culture, were included in this study. S. aureus isolates could be 
retrieved from bone cultures of 9 patients and these were genotyped using spa typing 
and PFGE analysis. Eight out of 9 isolates contained diff erent spa types and PFGE analysis 
revealed an overall lack of relatedness between isolates (Figure 1).
In addition to genetic typing, the presence of genes encoding 50 virulence factors of 
S. aureus were examined in the 9 clinical isolates plus the extensively studied reference 
strain NCTC 8325 using PCR (Table 1, Table S1). Notably, the genes eta and etb, lukS and 
lukF, ssl9, Tst and the genes encoding 13 enterotoxins were only detected in a minority 
of the 10 isolates. The other 31 genes were present in at least half or more of all isolates.
biofi lm formation by clinical S. aureus isolates on polystyrene and human bone
Next, the ability of the 9 clinical isolates and the reference strain NCTC 8325 to form 
biofi lms on polystyrene (PS) and freshly isolated human bone were examined. Using 
crystal violet staining we confi rmed that all isolates were able to stably form biofi lms 
on PS, although the amount of biofi lm mass varied (Figure 2A). Furthermore, using 
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figure 1. Genotypes of 9 clinical isolates from bone cultures.
Pulsed-fi eld gel electrophoresis data and spa types are shown. An isolate of the tenth patient described in 
this study could not be retrieved.
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scanning electron microscopy, layers of tightly adherent bacteria resembling biofilms 
on human bone after 24 hours incubation were visualized for one clinical isolate (Figure 
3A-C). These results indicate the development of mature biofilms on both surfaces.
characterization of igG antibody response against S. aureus proteins in 
osteomyelitis patients
Total IgG levels directed against 50 proteins of S. aureus were prospectively measured 
during variable intervals within the study period (median of 26 days, interquartile range 
9.5 – 85.5 days) in serum samples of the 10 patients (median of 4 samples per patient, 
interquartile range 2 - 5). Measurements for efb, EsxB, PrsA and SA0486 were excluded 
from further analysis due to low signal intensities with coefficients of variation larger 
than 25% between duplicate experiments.
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figure 2. Detection of S. aureus proteins during biofilm formation on PS.
a: Biofilm mass formed on PS by 9 clinical isolates and reference strain NCTC 8325. The levels of remaining 
non-bound IgG directed against specific proteins in PHG after incubation with the biofilms [expressed as 
mean fluorescence intensity (MFI)], indirectly and inversely reflecting protein presence, are shown for b: 
glucosaminidase, c: alpha toxin and d: the non-S. aureus control protein PpmA. Please note the difference 
in range of MFI on the y-axis between Figures b-d. Dashed horizontal lines indicate the average MFI of 
sterile controls. Symbols and error bars indicate mean and SD of two separate experiments.
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In line with previous data [24, 26, 28] the height of all protein-specific IgG levels was 
heterogeneous between patients (Table 2, Table S2), without any clear pattern in the 
course over time (Figure S1). IgG levels remained detectable up to 250 days within the 
study period. Comparison of IgG levels between the osteomyelitis patients, 10 patients 
suffering from a S. aureus bacteremia and 20 age-matched non-infected controls revealed 
that mean IgG levels differed significantly for 15 out of 46 proteins between groups 
(ANOVA p < 0.05, Table 2). Mean IgG levels against 10 proteins [(Staphylococcus aureus 
formyl peptide receptor-like 1 inhibitor (FLIPr), glucosaminidase, gamma-hemolysin B, 
iron-responsive surface determinant A (IsdA), leukocidins D and F, SACOL0699, staphy-
lococcal complement inhibitor (SCIN), and Staphylococcal superantigen-like proteins 3 
and 5 (SSL 3 and 5)] were significantly higher in both osteomyelitis and bacteremia pa-
tients compared to controls, IgG levels against 4 proteins (alpha-toxin, exfoliative toxin 
A (ETA), Serine-aspartate repeat-containing protein E (SdrE) and enterotoxin M) were 
significantly higher only in osteomyelitis patients and IgG levels against 1 protein (IsdH) 
were only higher in bacteremia patients (Table 2). None of the mean protein-specific IgG 
levels differed significantly between osteomyelitis and bacteremia patients. Notably, 
IgG levels against all proteins were readily detectable in the control group and IgG levels 
against the remaining proteins that are not mentioned above did not differ significantly 
between patients and controls (Table S2, Fig. S2).
detection of proteins of S. aureus isolates during biofilm formation on Ps
We used a competitive Luminex-based assay (CLA) [39, 40] to establish the presence of the 
same 50 proteins during biofilm formation by 9 of the infecting isolates described above. 
In line with previous results [39], biofilm mass-dependent absorption of specific IgG for 
several S aureus proteins such as glucosaminidase (Figure 2B) was detected, while no 
such reduction was seen for IgG specific against non S. aureus control proteins such as the 
figure 3. Biofilm formation of S. aureus on human bone.
Cryo scanning electron microscopy of one S. aureus isolate after 24 hours of biofilm formation on human 
bone. Please note the different magnifications indicated by the scale bars, respectively being a: 150 μm, 
b: 40 μm and c: 10 μm.
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putative protease maturation protein A (PpmA) of Streptococcus pneumoniae (Figure 2D). 
Similar to the differences in biofilm mass (Figure 2A), the reduction in IgG levels against 
most proteins, such as alpha toxin, was heterogeneous between isolates (Figure 2C). The 
average amount of formed biofilm mass and the average percentage reduction in IgG 
levels correlated significantly for all proteins (e.g. alpha toxin: rs -0.77, p < 0.0001). Based 
on the percentage decrease in IgG levels against the non-S. aureus control proteins and 
against all S. aureus proteins of which the gene was not found in an isolate, cut-off values 
for protein detection of at least 35% decrease in specific IgG at 24 hrs and 42% at 48 hrs 
biofilm formation were calculated. CLA measurements for four proteins (ESX-1-associated 
factor B (EsxB), extracellular fibrinogen-binding protein (efb), foldase-protein PrsA and 
the putative protein SA0486) were excluded from further analysis due to low MFI’s with 
standard deviations larger than 25% between repeated CLA measurements.
For the 31 genes that were found in at least half of the 10 isolates, 14 proteins were 
detected in the majority of gene-positive isolates at minimally one time point (8, 24 
and/or 48 hours) during biofilm formation on PS (Table 1): the surface proteins clump-
ing factor A and B (ClfA and B), fibronectin-binding protein A (FnbpA), IsdA and H, the 
housekeeping proteins glucosaminidase, immunodominant antigen A (IsaA), lipase, 
nuclease and the putative ABC transporter SACOL0688, the immune-modulators FlipR, 
SCIN and chemotaxis inhibitory protein of S. aureus (CHIPS), and alpha toxin.
For the genes that were found in a minority of isolates, the proteins exfoliative toxin 
A (ETA) and the staphylococcal enterotoxins A, B, D, Q and R were detected in one to 
maximally three gene-positive isolates during biofilm formation on PS (Table S1). Using 
the above mentioned cut-off values, no proteins were detected when the correspond-
ing gene was absent in an isolate.
The lack of detection of several secreted proteins, despite the presence of correspond-
ing genes in isolates (Table S1), prompted us to repeat CLA experiments using the me-
dium covering biofilms instead of biofilms self. Results obtained with medium showed 
similar reduction in IgG levels against all proteins, including secreted proteins such as 
alpha toxin, compared to results obtained with biofilms (Figure S3). This suggests that 
the lack of protein detection is not due to false-negative signals. CLA data were further 
confirmed by the detection of specific mRNA at 8 and/ or 24 hours of biofilm formation 
for all detected proteins (Table 1, Table S1).
detection of proteins of S. aureus isolates during biofilm formation on human 
bone
In an attempt to examine the expression of S. aureus virulence factors in an environment 
that more closely resembles the in vivo conditions during osteomyelitis, we repeated 
the above mentioned experiments with biofilms grown on human bone. Generally, the 
same patterns of reduction in specific IgG levels were observed as for biofilms on PS, 
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including for glucosaminidase, alpha toxin and the PpmA control protein (Figure 4A-C). 
Compared to biofilm formation on PS, similar percentages of non-specific reduction in 
IgG levels were found, prompting us to use the same cut-off values.
For the 31 genes that were found in half or more of the 10 isolates, 15 proteins were 
detected in the majority of gene-positive isolates at minimally one time point (8, 24 and/
or 48 hours) during biofilm formation on human bone (Table 1). These were largely the 
same proteins that were also detected during biofilm formation on PS, with the excep-
tion of IsdH and lipase, which were detected in only a minority of isolates at all time 
points. On the other hand, S. aureus surface protein G (SasG) and SD-repeat containing 
proteins D and E (SdrD and E) were detected in most isolates during biofilm formation 
on bone but not on PS at several time points (Table 1).
Notably, for the genes that were found in a minority of isolates, all Staphylococcal en-
terotoxins were detected in 1 to 4 gene-positive isolates during biofilm formation on bone, 
which were more isolates compared to the results obtained with biofilms on PS (Table S1).
comparison of in vivo antibody responses with in vitro protein detection
For the 31 genes that were found in at least half of the 10 isolates, 8 S. aureus proteins 
were associated with significantly increased IgG levels in patients and detectable in the 
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figure 4. Detection of S. aureus proteins during 
biofilm formation on human bone.
The levels of remaining non-bound IgG directed 
against specific proteins after incubation of PHG 
with biofilms of 9 clinical isolates and strain NCTC 
8325 on bone (expressed in MFI) are shown for a: 
glucosaminidase, b: alpha toxin and c: the non-S. 
aureus control protein PpmA. Dashed horizontal 
lines indicate the average MFI of sterile controls. 
Symbols and error bars indicate mean and SD of 
two separate experiments.
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majority of the gene-positive isolates during biofilm formation on PS and/or bone: alpha 
toxin, FlipR, glucosaminidase, IsdA and H, SACOL0688, SCIN and SdrE. Amongst the less 
common genes, enterotoxin M was associated with significantly increased IgG levels in 
patients and it was detectable in multiple isolates specifically during biofilm formation 
on bone.
In contrast to the above mentioned results, the toxins hemolysin gamma-B and leu-
cocidin D and the immune modulators SSL3 and 5 were associated with significantly 
increased IgG levels in patients but detected in only a minority of gene-positive isolates 
during biofilm formation in vitro. Vice versa, the surface proteins ClfA and B and the 
housekeeping proteins IsaA, lipase and nuclease were detected in a majority of strains 
during biofilm formation in vitro but were not associated with significantly increased IgG 
levels in patients. The latter was also true for the less common enterotoxins B and Q, for 
which genes were present in 3 and 2 isolates, respectively.
discussion
In this study we characterized the IgG response against 50 functionally diverse proteins 
of S. aureus in patients with chronic osteomyelitis. IgG levels against 14 diverse virulence 
factors, such as alpha-toxin, the surface protein IsdA and the housekeeping protein 
glucosaminidase, were significantly increased in osteomyelitis patients compared to 
healthy controls. Interestingly, a comparison with peak IgG levels of patients suffering 
from a S. aureus bacteremia revealed little difference, suggesting that immunological 
exposure to specific virulence factors is similar during both infections. Indeed, bacteria 
residing within a biofilm can dislodge and potentially cause a bacteremia [42]. This 
implicates that it might be difficult to find serological markers that can specifically 
discriminate between a S. aureus osteomyelitis and other sorts of infection. Moreover, 
in the context of identifying potential targets for e.g. vaccination, this implicates that 
results of immunological in vivo studies should be interpreted cautiously when search-
ing for targets that are specifically involved in biofilm formation.
To gain further insight into the involvement of the 50 proteins mentioned above in 
biofilm formation, we screened for the presence of these proteins during biofilm forma-
tion of 9 clinical isolates and reference strain NCTC-8325 on polystyrene (PS) and freshly 
isolated human bone, using a novel competitive Luminex-based assay (CLA). In general 
we observed a clear variation in the reduction of protein-specific IgG levels between 
isolates, which can largely be explained by differences in the amount of biofilm mass 
formed by each isolate. This variability in biofilm mass is in line with previous results, 
which might be related to the different genetic backgrounds of the isolates [43].
78
Chapter 3
For the 31 proteins of which genes were present in at least half of the 9 clinical isolates 
and NCTC 8325, 12 proteins were detected in at least half of all isolates at minimally one 
time point (8, 24 and/or 48 hours) during biofilm formation on both PS and bone. Sev-
eral of these proteins, especially surface proteins such as ClfB and FnbpA, already have a 
known role in biofilm formation [44-46]. In addition, several detected proteins, including 
IsaA, SACOL0688 and glucosaminidase, have been successfully evaluated as vaccine 
targets in animal infection models, some specifically in an osteomyelitis model [16, 47]. 
Our results further indicate the potential use of these proteins as vaccine targets by 
demonstrating their actual production during biofilm formation by genetically diverse 
clinical isolates ex vivo and, based on antibody responses, also during osteomyelitis in 
human patients in vivo .
Although the CLA results between biofilm formation on PS and bone generally agreed 
well, detection of a few proteins differed. Lipase and IsdH were mostly detected on PS 
while the biofilm-associated surface proteins SasG, SdrD and SdrE were mostly detected 
on bone. In addition, also the genetically less common enterotoxins were detected 
relatively more often on bone. The presence of SdrE and D specifically during biofilm 
formation on bone might be explained by bacterial attachment to the calcium-rich 
extracellular matrix, as these proteins are structurally dependable on calcium [48]. 
Although we cannot currently explain the other observed differences, we have dem-
onstrated before using CLA that different circumstances can impact protein detection 
in vitro and ex vivo [39, 40]. In this context, production of some of the above mentioned 
proteins, including diverse enterotoxins, is regulated by the accessory gene regulatory 
(Agr) quorum-sensing system [49, 50]. Possibly, this system is activated differently upon 
interaction of S. aureus with either PS or bone. Lastly, next to culture circumstances also 
the timing of measurement can be influential, as demonstrated by the detection of SasG 
mostly during early biofilm formation (8 hrs), which is in line with its established role 
during the early accumulation phase [51]. Together these findings implicate that results 
from in vitro models should be interpreted cautiously and both timing and circumstances 
during the measurement should be taken into account.
Combination of in vitro and in vivo results suggests that 8 proteins, of which most are 
already discussed above, are both immunogenic in patients and are detectable in the 
majority of clinical isolates during biofilm formation. At the same time some toxins and 
immune modulators were associated with significantly increased IgG levels in patients 
but not detected during biofilm formation in vitro. Possibly, our in vitro biofilm model 
might not adequately reflect the in vivo situation in patients, or the measured IgG levels 
might be mounted against proteins produced by planktonic growing bacteria within 
the patient. Moreover, IgG levels against the leukocidins might be false-positive due 
to the presence of cross-reactive antibodies, which has been established before in our 
assay [29]. In contrast to the above mentioned proteins, other proteins such as the ubiq-
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uitously present clumping factors and IsaA, were detected in vitro but not associated 
with significantly increased IgG levels in patients. This might well be explained by the 
high IgG levels that we found in both healthy controls and in patients, thereby eliminat-
ing any statistically significant difference between groups. Indeed, antibody titers to 
diverse S. aureus proteins appear to be ubiquitously present in the general population 
[24, 28] and this appears to be mostly independent of nasal carrier ship for S. aureus [41]. 
cautiously.
A limitation of the current Luminex assay is that its sensitivity is potentially influenced 
by amino acid sequence diversity, which is described for multiple proteins described in 
this study [52-55]. However, in general sequence diversity has been described within 
certain limits and these differences do not significantly impact our assay sensitivity, 
based on cross-reactivity within our assay as shown earlier for the leukocidin compo-
nents and hemolysin gamma-B [29] and also the more variable, different isotype forms 
of the FnBPA A domain [52] (data in submission). In addition, we only compare average 
IgG levels for each protein separately, further levelling out potential variation in assay 
sensitivity due to protein diversity. Taken together we are confident that the current 
assay allows us to screen for the presence of specific antibodies and proteins [29, 40].
The 50 proteins included in the current assay were chosen based on their established 
roles in S. aureus pathogenesis and the corresponding host immune response. However, 
there are many more e.g. cytosol-based proteins of S. aureus that remain less-charac-
terized in this context, yet could also be potentially interesting therapeutic targets. We 
believe that these proteins will be an interesting addition to future immunoproteomic 
studies, although this is not the focus of the current study.
We conclude that functionally diverse virulence factors of S. aureus are present during 
biofilm formation by genetically diverse isolates on PS and human bone in vitro, and 
that some of these proteins are immunogenic in vivo. These observations merit more 
mechanistic studies to elucidate the function of specific proteins and the regulation of 
their expression during S. aureus biofilm formation. However, the present data further 
suggests that multiple proteins, such as the ubiquitously present and immunogenic IsdA 
or SA0688, could be potential targets for novel agents such as a multi-valent vaccine to 
prevent or treat biofilm-associated infections in patients. Combined studies using both 
in vitro models and immunological assays in patients in vivo can help in identifying novel 
therapeutic targets.
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dashed horizontal line indicates the average MFI 
of sterile controls. Similar results were obtained 
for the other secreted antigens (data not shown).
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figure s2. Comparison of IgG levels between patients and non-infected controls.
Peak IgG levels of 10 patients suffering from either chronic osteomyelitis or bacteremia and 20 non-infected 
age-matched controls are compared for a: alpha toxin and b: LytM. Average IgG levels against alpha toxin dif-
fered significantly between controls and osteomyelitis patients (P value indicated). IgG levels against LytM did 
not significantly differ between groups. The median value and interquartile range are represented by lines.
81
Characterization of S. aureus osteomyelitis
3
ta
bl
e 
s1
. 
D
et
ec
tio
n 
of
 g
en
es
, m
RN
A
 a
nd
 p
ro
te
in
s 
du
rin
g 
bi
ofi
lm
 fo
rm
at
io
n 
of
 1
0 
S.
 a
ur
eu
s s
tr
ai
ns
 o
n 
PS
 a
nd
 h
um
an
 b
on
e.
Pr
ot
ei
n
G
en
e
St
ra
in
s 
w
ith
 g
en
e 
pr
es
en
t1
Bi
ofi
lm
s 
on
 p
ol
ys
ty
re
ne
Bi
ofi
lm
s 
on
 p
ol
ys
ty
re
ne
   
Bi
ofi
lm
s 
on
 h
um
an
 b
on
e
St
ra
in
s 
w
ith
 m
RN
A
 
pr
es
en
t1
St
ra
in
s 
w
ith
 s
ig
ni
fic
an
t r
ed
uc
tio
n 
in
 
sp
ec
ifi
c 
Ig
G
1
St
ra
in
s 
w
ith
 s
ig
ni
fic
an
t r
ed
uc
tio
n 
in
 
sp
ec
ifi
c 
Ig
G
1
 
 
 
 
8 
hr
s
24
 h
rs
 
8 
hr
s
24
 h
rs
48
 h
rs
 
8 
hr
s
24
 h
rs
48
 h
rs
A
lp
ha
 to
xi
n
hl
a
10
 
10
10
 
5
7
9
 
6
6
8
CH
IP
S
ch
ps
7
 
4
4
 
3
5
7
 
6
5
6
Cl
fA
cl
fA
10
 
4
4
 
3
6
10
 
7
9
10
Cl
fB
cl
fB
10
 
10
10
 
2
7
9
 
5
8
8
Ef
b
ef
b
10
 
10
10
 
N
D
N
D
N
D
 
N
D
N
D
N
D
Es
xB
es
xB
10
 
5
5
 
N
D
N
D
N
D
 
N
D
N
D
N
D
ET
A
et
a
1
 
-
-
 
-
-
1
 
-
1
1
ET
B
et
b
-
 
N
D
N
D
 
N
D
N
D
N
D
 
N
D
N
D
N
D
Fl
ip
R
flr
9
 
7
5
 
0
4
5
 
3
5
5
Fn
bA
fn
bA
10
 
10
10
 
-
2
5
 
1
5
6
Fn
bB
fn
bB
5
 
5
5
 
1
3
2
 
-
2
1
G
lu
co
sa
m
in
id
as
e
At
l
10
 
10
10
 
10
10
10
 
10
10
10
H
lg
B
hl
gB
9
 
9
9
 
-
-
-
 
-
1
-
Is
aA
is
aA
10
 
10
10
 
10
10
10
 
10
10
10
Is
dA
is
dA
9
 
9
9
 
9
9
9
 
4
8
9
Is
dH
is
dH
10
 
10
10
 
3
3
6
 
2
2
1
Li
pa
se
lip
10
 
10
10
 
1
6
8
 
1
2
1
Lu
kD
lu
kD
8
 
8
8
 
0
2
4
 
1
3
4
Lu
kE
lu
kE
8
 
8
8
 
0
2
3
 
0
1
1
Lu
kF
lu
kF
-
 
N
D
N
D
 
N
D
N
D
N
D
 
N
D
N
D
N
D
Lu
kS
lu
kS
-
 
N
D
N
D
 
N
D
N
D
N
D
 
N
D
N
D
N
D
82
Chapter 3
ta
bl
e 
s1
. 
D
et
ec
tio
n 
of
 g
en
es
, m
RN
A
 a
nd
 p
ro
te
in
s 
du
rin
g 
bi
ofi
lm
 fo
rm
at
io
n 
of
 1
0 
S.
 a
ur
eu
s s
tr
ai
ns
 o
n 
PS
 a
nd
 h
um
an
 b
on
e.
 (c
on
tin
ue
d)
Pr
ot
ei
n
G
en
e
St
ra
in
s 
w
ith
 g
en
e 
pr
es
en
t1
Bi
ofi
lm
s 
on
 p
ol
ys
ty
re
ne
Bi
ofi
lm
s 
on
 p
ol
ys
ty
re
ne
   
Bi
ofi
lm
s 
on
 h
um
an
 b
on
e
St
ra
in
s 
w
ith
 m
RN
A
 
pr
es
en
t1
St
ra
in
s 
w
ith
 s
ig
ni
fic
an
t r
ed
uc
tio
n 
in
 
sp
ec
ifi
c 
Ig
G
1
St
ra
in
s 
w
ith
 s
ig
ni
fic
an
t r
ed
uc
tio
n 
in
 
sp
ec
ifi
c 
Ig
G
1
Ly
tM
ly
tM
10
 
10
10
 
1
1
4
 
1
4
2
N
uc
nu
c
8
 
5
1
 
7
7
8
 
7
8
8
Pr
sA
pr
sA
10
 
10
10
 
N
D
N
D
N
D
 
N
D
N
D
N
D
SA
CO
L0
48
6
sa
co
l0
48
6
6
 
5
5
 
N
D
N
D
N
D
 
N
D
N
D
N
D
SA
CO
L0
68
8
M
nt
C
10
 
10
10
 
9
10
10
 
10
10
10
Sa
sG
sa
sG
7
 
6
6
 
1
1
1
 
7
4
2
SC
IN
sc
n
10
 
9
8
 
9
9
9
 
9
9
9
Sd
rD
sd
rD
7
 
5
5
 
1
1
3
 
2
6
6
Sd
rE
sd
rE
7
 
7
6
 
1
1
3
 
5
5
5
SE
A
se
a
2
 
2
2
 
0
0
2
 
2
2
2
SE
B
se
b
3
 
3
3
 
1
2
3
 
3
3
3
SE
C
se
c
-
 
N
D
N
D
 
N
D
N
D
N
D
 
N
D
N
D
N
D
SE
D
se
d
1
 
1
1
 
1
1
1
 
1
1
1
SE
E
se
e
-
 
N
D
N
D
 
N
D
N
D
N
D
 
N
D
N
D
N
D
SE
G
se
g
3
 
3
3
 
-
-
-
 
1
2
1
SE
H
se
h
1
 
1
1
 
-
-
-
 
1
1
1
SE
I
se
i
4
 
3
3
 
-
-
-
 
3
3
3
SE
M
se
m
4
 
4
3
 
-
-
-
 
4
2
3
SE
N
se
n
4
 
4
4
 
-
-
-
 
1
1
1
SE
O
se
o
4
 
4
4
 
-
-
-
 
-
1
-
SE
Q
se
q
2
 
2
2
 
1
2
2
 
2
2
2
SE
R
se
r
1
 
1
1
 
0
1
1
 
1
1
1
83
Characterization of S. aureus osteomyelitis
3
ta
bl
e 
s1
. 
D
et
ec
tio
n 
of
 g
en
es
, m
RN
A
 a
nd
 p
ro
te
in
s 
du
rin
g 
bi
ofi
lm
 fo
rm
at
io
n 
of
 1
0 
S.
 a
ur
eu
s s
tr
ai
ns
 o
n 
PS
 a
nd
 h
um
an
 b
on
e.
 (c
on
tin
ue
d)
Pr
ot
ei
n
G
en
e
St
ra
in
s 
w
ith
 g
en
e 
pr
es
en
t1
Bi
ofi
lm
s 
on
 p
ol
ys
ty
re
ne
Bi
ofi
lm
s 
on
 p
ol
ys
ty
re
ne
   
Bi
ofi
lm
s 
on
 h
um
an
 b
on
e
St
ra
in
s 
w
ith
 m
RN
A
 
pr
es
en
t1
St
ra
in
s 
w
ith
 s
ig
ni
fic
an
t r
ed
uc
tio
n 
in
 
sp
ec
ifi
c 
Ig
G
1
St
ra
in
s 
w
ith
 s
ig
ni
fic
an
t r
ed
uc
tio
n 
in
 
sp
ec
ifi
c 
Ig
G
1
SS
L1
ss
l1
10
 
9
8
 
-
-
1
 
-
1
1
SS
L3
ss
l3
10
 
10
9
 
-
-
1
 
-
1
1
SS
L5
ss
l5
6
 
5
6
 
-
-
-
 
-
1
-
SS
L9
ss
l9
2
 
-
-
 
-
-
-
 
-
-
-
SS
L1
0
ss
l1
0
5
 
1
2
 
-
-
-
 
-
1
1
SS
L1
1
ss
l1
1
5
 
1
2
 
1
1
2
 
-
-
-
TS
ST
1
Ts
t
-
 
N
D
N
D
 
N
D
N
D
N
D
 
N
D
N
D
N
D
1 N
um
be
r o
f i
so
la
te
s i
n 
w
hi
ch
 re
sp
ec
tiv
el
y 
th
e 
ge
ne
, m
RN
A
 o
r p
ro
te
in
 w
as
 d
et
ec
te
d 
ar
e 
sh
ow
n.
 - 
in
di
ca
te
s t
ha
t t
he
 g
en
e,
 m
RN
A
 o
r p
ro
te
in
 w
as
 n
ot
 d
et
ec
te
d 
in
 a
ny
 is
ol
at
e.
N
D
: n
ot
 d
et
er
m
in
ed
 d
ue
 to
 lo
w
 s
ig
na
l i
nt
en
si
tie
s 
w
ith
 c
oe
ffi
ci
en
ts
 o
f v
ar
ia
tio
n 
la
rg
er
 th
an
 2
5%
 b
et
w
ee
n 
du
pl
ic
at
e 
ex
pe
rim
en
ts
.
84
Chapter 3
ta
bl
e 
s2
. 
S.
 a
ur
eu
s p
ro
te
in
-s
pe
ci
fic
 Ig
G
 le
ve
ls
 in
 c
on
tr
ol
s 
an
d 
pa
tie
nt
 g
ro
up
s.
A
nt
ig
en
Fu
nc
tio
na
l c
la
ss
M
ea
n 
Ig
G
 le
ve
l 
co
nt
ro
l p
at
ie
nt
s 
(±
 
SD
; N
=2
0)
M
ea
n 
Ig
G
 le
ve
l 
ba
ct
er
em
ia
 p
at
ie
nt
s 
(±
 S
D
; N
=1
0)
1
M
ea
n 
Ig
G
 le
ve
l 
os
te
om
ye
lit
is
 
pa
tie
nt
s 
(±
 S
D
; 
N
=1
0)
1
P 
va
lu
e 
A
N
O
VA
2
P 
va
lu
e 
Po
st
-h
oc
 a
na
ly
si
s3
A
lp
ha
 to
xi
n
to
xi
n
88
95
 (±
 4
41
9)
11
61
0,
9 
(±
 5
11
7)
14
88
4,
3 
(±
37
49
)
0,
03
7
0,
01
1 
(o
st
eo
m
ye
lit
is
)
CH
IP
S
im
m
m
un
e 
m
od
ul
at
or
65
78
 (±
31
81
)
77
88
 (±
28
54
)
86
70
 (±
30
03
)
0,
10
5
 
Cl
fA
su
rf
ac
e 
pr
ot
ei
n
23
75
 (±
25
80
)
29
35
 (±
26
39
)
26
01
 (±
17
58
)
0,
75
3
 
Cl
fB
su
rf
ac
e 
pr
ot
ei
n
17
36
 (±
17
06
)
22
44
 (±
18
93
)
27
75
 (±
17
51
)
0,
32
1
 
Ef
b
im
m
m
un
e 
m
od
ul
at
or
N
D
N
D
N
D
N
D
 
Es
xB
ho
us
ek
ee
pi
ng
N
D
N
D
N
D
N
D
 
ET
A
to
xi
n
89
3 
(±
14
25
)
12
38
 (±
19
46
)
28
74
 (±
41
78
)
0,
02
6
0,
00
7 
(o
st
eo
m
ye
lit
is
)
ET
B
to
xi
n
11
94
 (±
15
79
)
57
5 
(±
78
7)
12
10
 (±
21
07
)
0,
40
1
 
Fl
ip
R
im
m
m
un
e 
m
od
ul
at
or
18
64
 (±
15
69
)
44
90
 (±
34
85
)
36
56
 (±
21
43
)
0,
00
7
0,
01
9 
(o
st
eo
m
ye
lit
is
 +
 b
ac
te
re
m
ia
)
Fn
bA
su
rf
ac
e 
pr
ot
ei
n
33
2 
(±
35
8)
59
6 
(±
57
7)
68
6 
(±
12
48
)
0,
07
9
 
Fn
bB
su
rf
ac
e 
pr
ot
ei
n
59
9 
(±
62
5)
58
7 
(±
84
0)
43
9 
(±
27
5)
0,
65
6
 
G
lu
co
sa
m
in
id
as
e
ho
us
ek
ee
pi
ng
52
73
 (±
28
27
)
86
78
0 
(±
36
12
)
83
77
 (±
38
82
)
0,
00
5
0,
01
9 
(o
st
eo
m
ye
lit
is
 +
 b
ac
te
re
m
ia
)
H
lg
B
to
xi
n
63
28
 (±
42
90
)
10
83
8 
(±
29
24
)
10
91
7 
(±
36
27
)
0,
00
2
0,
00
7 
(o
st
eo
m
ye
lit
is
 +
 b
ac
te
re
m
ia
)
Is
aA
ho
us
ek
ee
pi
ng
61
02
 (±
36
76
)
93
73
 (±
49
30
)
78
60
 (±
55
26
)
0,
24
0
 
Is
dA
su
rf
ac
e 
pr
ot
ei
n
37
22
 (±
45
32
)
65
34
 (±
39
93
)
50
16
 (±
27
56
)
0,
00
6
0,
02
3 
(o
st
eo
m
ye
lit
is
 +
 b
ac
te
re
m
ia
)
Is
dH
su
rf
ac
e 
pr
ot
ei
n
82
5 
(±
86
7)
25
79
 (±
31
30
)
27
32
 (±
44
07
)
0,
03
4
0,
01
1 
(b
ac
te
re
m
ia
)
Li
pa
se
ho
us
ek
ee
pi
ng
/ t
ox
in
40
72
 (±
25
50
)
65
57
 (±
41
97
)
71
55
 (±
44
12
)
0,
25
1
 
Lu
kD
to
xi
n
63
11
 (±
39
88
)
95
12
 (±
35
14
)
93
69
 (±
35
81
)
0,
02
4
0,
04
4 
(o
st
eo
m
ye
lit
is
 +
 b
ac
te
re
m
ia
)
Lu
kE
to
xi
n
88
59
 (±
43
27
)
11
74
3 
(±
36
21
)
11
51
0 
(±
34
94
)
0,
08
7
 
Lu
kF
to
xi
n
11
05
 (±
88
0)
18
51
 (±
77
2)
20
25
 (±
91
7)
0,
00
1
0,
00
5 
(o
st
eo
m
ye
lit
is
 +
 b
ac
te
re
m
ia
)
Lu
kS
to
xi
n
83
82
 (±
46
59
)
10
98
8 
(±
40
31
)
10
51
8 
(±
39
15
)
0,
12
7
 
85
Characterization of S. aureus osteomyelitis
3
ta
bl
e 
s2
. 
S.
 a
ur
eu
s p
ro
te
in
-s
pe
ci
fic
 Ig
G
 le
ve
ls
 in
 c
on
tr
ol
s 
an
d 
pa
tie
nt
 g
ro
up
s. 
(c
on
tin
ue
d)
A
nt
ig
en
Fu
nc
tio
na
l c
la
ss
M
ea
n 
Ig
G
 le
ve
l 
co
nt
ro
l p
at
ie
nt
s 
(±
 
SD
; N
=2
0)
M
ea
n 
Ig
G
 le
ve
l 
ba
ct
er
em
ia
 p
at
ie
nt
s 
(±
 S
D
; N
=1
0)
1
M
ea
n 
Ig
G
 le
ve
l 
os
te
om
ye
lit
is
 
pa
tie
nt
s 
(±
 S
D
; 
N
=1
0)
1
P 
va
lu
e 
A
N
O
VA
2
P 
va
lu
e 
Po
st
-h
oc
 a
na
ly
si
s3
Ly
tM
ho
us
ek
ee
pi
ng
95
0 
(±
17
06
)
11
71
 (±
15
00
)
90
0 
(±
12
95
)
0,
97
1
 
N
uc
ho
us
ek
ee
pi
ng
/ t
ox
in
24
12
 (±
26
97
)
44
30
 (±
36
12
)
32
15
 (±
18
82
)
0,
13
2
 
Pr
sA
ho
us
ek
ee
pi
ng
N
D
N
D
N
D
N
D
 
SA
CO
L0
48
6
ho
us
ek
ee
pi
ng
N
D
N
D
N
D
N
D
 
SA
CO
L0
68
8
ho
us
ek
ee
pi
ng
83
9 
(±
65
0)
38
49
 (±
42
90
)
25
72
 (±
24
32
)
0,
00
1
0,
00
5 
(o
st
eo
m
ye
lit
is
 +
 b
ac
te
re
m
ia
)
Sa
sG
su
rf
ac
e 
pr
ot
ei
n
39
1 
(±
67
3)
27
0 
(±
29
3)
29
9 
(±
26
9)
0,
78
6
 
SC
IN
im
m
m
un
e 
m
od
ul
at
or
36
65
 (±
33
22
)
79
39
 (±
38
05
)
75
45
 (±
37
82
)
<0
,0
00
0,
00
2 
(o
st
eo
m
ye
lit
is
 +
 b
ac
te
re
m
ia
)
Sd
rD
su
rf
ac
e 
pr
ot
ei
n
66
8 
(±
48
0)
13
06
 (±
16
20
)
99
2 
(±
11
58
)
0,
43
7
 
Sd
rE
su
rf
ac
e 
pr
ot
ei
n
29
3 
(±
29
8)
39
9 
(±
38
5)
65
1 
(±
44
1)
0,
02
6
0,
00
7 
(o
st
eo
m
ye
lit
is
)
SE
A
to
xi
n
32
19
 (±
33
00
)
31
99
 (±
31
35
)
36
69
 (±
28
42
)
0,
57
1
 
SE
B
to
xi
n
29
96
 (±
30
16
)
39
69
 (±
39
06
)
46
13
 (±
37
14
)
0,
24
4
 
SE
C
to
xi
n
91
64
 (±
43
34
)
80
98
 (±
44
07
)
91
57
 (±
37
39
)
0,
63
3
 
SE
D
to
xi
n
86
6 
(±
90
9)
13
22
 (±
13
38
)
17
94
 (±
22
49
)
0,
23
1
 
SE
E
to
xi
n
13
44
 (±
20
24
)
11
90
 (±
14
93
)
12
66
 (±
14
28
)
0,
74
9
 
SE
G
to
xi
n
74
5 
(±
96
6)
90
7 
(±
19
13
)
95
8 
(±
11
36
)
0,
65
1
 
SE
H
to
xi
n
20
44
 (±
19
20
)
15
84
 (±
16
67
)
30
79
 (±
27
99
)
0,
21
9
 
SE
I
to
xi
n
66
4 
(±
53
9)
12
68
 (±
16
61
)
20
09
 (±
15
61
)
0,
15
7
 
SE
M
to
xi
n
52
6 
(±
54
2)
11
55
 (±
15
95
)
13
22
 (±
96
6)
0,
02
8
0,
01
1 
(o
st
eo
m
ye
lit
is
)
SE
N
to
xi
n
67
7 
(±
91
0)
66
5 
(±
99
5)
70
3 
(±
11
41
)
0,
96
7
 
SE
O
to
xi
n
12
0 
(±
65
)
22
3 
(±
31
7)
36
1 
(±
41
6)
0,
06
0
 
SE
Q
to
xi
n
11
20
 (±
15
99
)
19
00
 (±
30
39
)
32
74
 (±
39
07
)
0,
37
2
 
86
Chapter 3
ta
bl
e 
s2
. 
S.
 a
ur
eu
s p
ro
te
in
-s
pe
ci
fic
 Ig
G
 le
ve
ls
 in
 c
on
tr
ol
s 
an
d 
pa
tie
nt
 g
ro
up
s. 
(c
on
tin
ue
d)
A
nt
ig
en
Fu
nc
tio
na
l c
la
ss
M
ea
n 
Ig
G
 le
ve
l 
co
nt
ro
l p
at
ie
nt
s 
(±
 
SD
; N
=2
0)
M
ea
n 
Ig
G
 le
ve
l 
ba
ct
er
em
ia
 p
at
ie
nt
s 
(±
 S
D
; N
=1
0)
1
M
ea
n 
Ig
G
 le
ve
l 
os
te
om
ye
lit
is
 
pa
tie
nt
s 
(±
 S
D
; 
N
=1
0)
1
P 
va
lu
e 
A
N
O
VA
2
P 
va
lu
e 
Po
st
-h
oc
 a
na
ly
si
s3
SE
R
to
xi
n
12
65
 (±
19
85
)
83
4 
(±
11
87
)
15
01
 (±
34
36
)
0,
86
9
 
SS
L1
im
m
m
un
e 
m
od
ul
at
or
27
94
 (±
22
81
)
48
48
 (±
34
56
)
48
87
 (±
34
77
)
0,
11
7
 
SS
L3
im
m
m
un
e 
m
od
ul
at
or
46
79
 (±
30
68
)
81
86
 (±
47
46
)
69
55
 (±
36
73
)
0,
01
1
0,
04
2 
(o
st
eo
m
ye
lit
is
 +
 b
ac
te
re
m
ia
)
SS
L5
im
m
m
un
e 
m
od
ul
at
or
19
29
 (±
13
07
)
46
75
 (±
33
15
)
39
32
 (±
28
27
)
0,
00
1
0,
01
4 
(o
st
eo
m
ye
lit
is
 +
 b
ac
te
re
m
ia
)
SS
L9
im
m
m
un
e 
m
od
ul
at
or
68
35
 (±
35
75
)
92
40
 (±
37
35
)
88
92
 (±
40
48
)
0,
11
5
 
SS
L1
0
im
m
m
un
e 
m
od
ul
at
or
30
51
 (±
40
38
)
50
32
 (±
38
93
)
54
25
 (±
40
38
)
0,
17
5
 
SS
L1
1
im
m
m
un
e 
m
od
ul
at
or
10
87
 (±
15
40
)
13
32
 (±
12
97
)
17
93
 (±
21
49
)
0,
42
5
 
TS
ST
1
to
xi
n
82
17
 (±
66
46
)
78
65
 (±
39
42
)
91
10
 (±
40
57
)
0,
54
5
 
1 O
nl
y 
th
e 
pe
ak
 Ig
G
 le
ve
ls
 o
f p
at
ie
nt
s 
w
er
e 
in
cl
ud
ed
 fo
r c
om
pa
ris
on
.
2 P
 v
al
ue
 o
f A
N
O
VA
 te
st
 c
om
pa
rin
g 
al
l t
hr
ee
 p
at
ie
nt
 g
ro
up
s. 
P 
va
lu
es
 <
 0
.0
5 
w
er
e 
co
ns
id
er
ed
 a
s 
si
gn
ifi
ca
nt
.
3 P
 v
al
ue
 o
f p
os
t-
ho
c 
te
st
s 
w
ith
 L
SD
 a
re
 s
ho
w
n 
(p
at
ie
nt
 g
ro
up
(s
) w
ith
 s
ig
ni
fic
an
tly
 h
ig
he
r m
ea
n 
Ig
G
 le
ve
l(s
) c
om
pa
re
d 
to
 c
on
tr
ol
s 
ar
e 
in
di
ca
te
d)
.
N
D
: n
ot
 d
et
er
m
in
ed
 d
ue
 to
 lo
w
 s
ig
na
l i
nt
en
si
tie
s 
w
ith
 c
oe
ffi
ci
en
ts
 o
f v
ar
ia
tio
n 
la
rg
er
 th
an
 2
5%
 b
et
w
ee
n 
du
pl
ic
at
e 
ex
pe
rim
en
ts
.
87
Characterization of S. aureus osteomyelitis
3
references
 1. Berendt T, Byren I. Bone and joint infection. Clin Med. 2004;4(6):510-8.
 2. Wright JA, Nair SP. Interaction of staphylococci with bone. Int J Med Microbiol. 2010;300(2-3):193-204.
 3. Brady RA, Leid JG, Calhoun JH, Costerton JW, Shirtliff ME. Osteomyelitis and the role of biofilms in 
chronic infection. FEMS Immunol Med Microbiol. 2008;52(1):13-22.
 4. Lazzarini L, De Lalla F, Mader JT. Long Bone Osteomyelitis. Curr Infect Dis Rep. 2002;4(5):439-45.
 5. Lew DP, Waldvogel FA. Osteomyelitis. Lancet (London, England). 2004;364(9431):369-79.
 6. Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME. Staphylococcus aureus 
biofilms: properties, regulation, and roles in human disease. Virulence. 2011;2(5):445-59.
 7. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. 
Clinical microbiology reviews. 2002;15(2):167-93.
 8. Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov. 
2003;2(2):114-22.
 9. Lewis K. Riddle of biofilm resistance. Antimicrobial agents and chemotherapy. 2001;45(4):999-1007.
 10. Sakoulas G, Moellering RC, Jr. Increasing antibiotic resistance among methicillin-resistant Staphy-
lococcus aureus strains. Clinical infectious diseases : an official publication of the Infectious 
Diseases Society of America. 2008;46 Suppl 5:S360-7.
 11. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, et al. Emergence of 
vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus 
aureus Working Group. The New England journal of medicine. 1999;340(7):493-501.
 12. Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clinical infectious 
diseases : an official publication of the Infectious Diseases Society of America. 2012;54(4):560-7.
 13. Otto M. Novel targeted immunotherapy approaches for staphylococcal infection. Expert opinion 
on biological therapy. 2010;10(7):1049-59.
 14. Pier GB. Will there ever be a universal Staphylococcus aureus vaccine? Human vaccines & im-
munotherapeutics. 2013;9(9):1865-76.
 15. Proctor R. Is there a future for a Staphylococcus aureus vaccine? Vaccine.
 16. Brady RA, O’May GA, Leid JG, Prior ML, Costerton JW, Shirtliff ME. Resolution of Staphylococcus 
aureus biofilm infection using vaccination and antibiotic treatment. Infection and immunity. 
2011;79(4):1797-803.
 17. Beenken KE, Spencer H, Griffin LM, Smeltzer MS. Impact of extracellular nuclease production on 
the biofilm phenotype of Staphylococcus aureus under in vitro and in vivo conditions. Infection 
and immunity.
 18. Corrigan RM, Rigby D, Handley P, Foster TJ. The role of Staphylococcus aureus surface protein 
SasG in adherence and biofilm formation. Microbiology. 2007;153(Pt 8):2435-46.
 19. Geoghegan JA, Monk IR, O’Gara JP, Foster TJ. Subdomains N2N3 of fibronectin binding protein 
A mediate Staphylococcus aureus biofilm formation and adherence to fibrinogen using distinct 
mechanisms. J Bacteriol. 2013;195(11):2675-83.
 20. Luong TT, Lei MG, Lee CY. Staphylococcus aureus Rbf activates biofilm formation in vitro 
and promotes virulence in a murine foreign body infection model. Infection and immunity. 
2009;77(1):335-40.
 21. Otto M. Staphylococcal biofilms. Curr Top Microbiol Immunol. 2008;322:207-28.
 22. Brady RA, Leid JG, Camper AK, Costerton JW, Shirtliff ME. Identification of Staphylococcus aureus 
proteins recognized by the antibody-mediated immune response to a biofilm infection. Infection 
and immunity. 2006;74(6):3415-26.
88
Chapter 3
 23. Gil C, Solano C, Burgui S, Latasa C, Garcia B, Toledo-Arana A, et al. Biofilm matrix exoproteins 
induce a protective immune response against Staphylococcus aureus biofilm infection. Infection 
and immunity. 2014;82(3):1017-29.
 24. Dryla A, Prustomersky S, Gelbmann D, Hanner M, Bettinger E, Kocsis B, et al. Comparison of an-
tibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected 
patients. Clin Diagn Lab Immunol. 2005;12(3):387-98.
 25. Holtfreter S, Kolata J, Broker BM. Towards the immune proteome of Staphylococcus aureus - The 
anti-S. aureus antibody response. Int J Med Microbiol. 2010;300(2-3):176-92.
 26. Jacobsson G, Colque-Navarro P, Gustafsson E, Andersson R, Mollby R. Antibody responses in 
patients with invasive Staphylococcus aureus infections. European journal of clinical microbiol-
ogy & infectious diseases : official publication of the European Society of Clinical Microbiology. 
2010;29(6):715-25.
 27. Verkaik NJ, Boelens HA, de Vogel CP, Tavakol M, Bode LG, Verbrugh HA, et al. Heterogeneity of 
the humoral immune response following Staphylococcus aureus bacteremia. European journal of 
clinical microbiology & infectious diseases : official publication of the European Society of Clinical 
Microbiology. 2010;29(5):509-18.
 28. Vytvytska O, Nagy E, Bluggel M, Meyer HE, Kurzbauer R, Huber LA, et al. Identification of vaccine 
candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics. 
2002;2(5):580-90.
 29. den Reijer PM, Lemmens-den Toom N, Kant S, Snijders SV, Boelens H, Tavakol M, et al. Character-
ization of the humoral immune response during Staphylococcus aureus bacteremia and global 
gene expression by Staphylococcus aureus in human blood. PloS one. 8(1):e53391.
 30. Broker BM, van Belkum A. Immune proteomics of Staphylococcus aureus. Proteomics. 
2011;11(15):3221-31.
 31. Stentzel S, Sundaramoorthy N, Michalik S, Nordengrun M, Schulz S, Kolata J, et al. Specific serum 
IgG at diagnosis of Staphylococcus aureus bloodstream invasion is correlated with disease pro-
gression. J Proteomics. 2015;128:1-7.
 32. Harmsen D, Claus H, Witte W, Rothganger J, Claus H, Turnwald D, et al. Typing of methicillin-resis-
tant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat 
determination and database management. Journal of clinical microbiology. 2003;41(12):5442-8.
 33. Wayne P. Performance standards for antimicrobial susceptibility testing: 16th informational 
supplement. Clinical and Laboratory Standards Institute (CLSI). , 2006.
 34. Koning S, van Belkum A, Snijders S, van Leeuwen W, Verbrugh H, Nouwen J, et al. Severity of 
nonbullous Staphylococcus aureus impetigo in children is associated with strains harboring 
genetic markers for exfoliative toxin B, Panton-Valentine leukocidin, and the multidrug resistance 
plasmid pSK41. Journal of clinical microbiology. 2003;41(7):3017-21.
 35. Martins TB, Augustine NH, Hill HR. Development of a multiplexed fluorescent immunoassay for the 
quantitation of antibody responses to group A streptococci. J Immunol Methods. 2006;316(1-2):97-106.
 36. Heilmann C, Gerke C, Perdreau-Remington F, Gotz F. Characterization of Tn917 insertion 
mutants of Staphylococcus epidermidis affected in biofilm formation. Infection and immunity. 
1996;64(1):277-82.
 37. Lim Y, Jana M, Luong TT, Lee CY. Control of glucose- and NaCl-induced biofilm formation by rbf in 
Staphylococcus aureus. J Bacteriol. 2004;186(3):722-9.
 38. Van Wamel WJ, Hendrickx AP, Bonten MJ, Top J, Posthuma G, Willems RJ. Growth condition-de-
pendent Esp expression by Enterococcus faecium affects initial adherence and biofilm formation. 
Infection and immunity. 2007;75(2):924-31.
89
Characterization of S. aureus osteomyelitis
3
 39. den Reijer PM, Haisma EM, Lemmens-den Toom NA, Willemse J, Koning RA, Demmers JA, et al. 
Detection of Alpha-Toxin and Other Virulence Factors in Biofilms of Staphylococcus aureus on 
Polystyrene and a Human Epidermal Model. PloS one. 2016;11(1):e0145722.
 40. Hansenova Manaskova S, Bikker FJ, Veerman EC, van Belkum A, van Wamel WJ. Rapid detection 
and semi-quantification of IgG-accessible Staphylococcus aureus surface-associated antigens 
using a multiplex competitive Luminex assay. J Immunol Methods. 2013;397(1-2):18-27.
 41. Verkaik NJ, de Vogel CP, Boelens HA, Grumann D, Hoogenboezem T, Vink C, et al. Anti-staphylo-
coccal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus 
aureus. The Journal of infectious diseases. 2009;199(5):625-32.
 42. Otto M. Staphylococcal infections: mechanisms of biofilm maturation and detachment as critical 
determinants of pathogenicity. Annu Rev Med. 2013;64:175-88.
 43. Croes S, Deurenberg RH, Boumans ML, Beisser PS, Neef C, Stobberingh EE. Staphylococcus aureus 
biofilm formation at the physiologic glucose concentration depends on the S. aureus lineage. 
BMC Microbiol. 2009;9:229.
 44. Abraham NM, Jefferson KK. Staphylococcus aureus clumping factor B mediates biofilm formation 
in the absence of calcium. Microbiology. 2012;158(Pt 6):1504-12.
 45. O’Neill E, Pozzi C, Houston P, Humphreys H, Robinson DA, Loughman A, et al. A novel Staphylococ-
cus aureus biofilm phenotype mediated by the fibronectin-binding proteins, FnBPA and FnBPB. J 
Bacteriol. 2008;190(11):3835-50.
 46. Speziale P, Pietrocola G, Foster TJ, Geoghegan JA. Protein-based biofilm matrices in Staphylococci. 
Front Cell Infect Microbiol. 2014;4:171.
 47. van den Berg S, Bonarius HP, van Kessel KP, Elsinga GS, Kooi N, Westra H, et al. A human mono-
clonal antibody targeting the conserved staphylococcal antigen IsaA protects mice against 
Staphylococcus aureus bacteremia. Int J Med Microbiol. 2015;305(1):55-64.
 48. Josefsson E, McCrea KW, Ni Eidhin D, O’Connell D, Cox J, Hook M, et al. Three new members of 
the serine-aspartate repeat protein multigene family of Staphylococcus aureus. Microbiology. 
1998;144 ( Pt 12):3387-95.
 49. Sato’o Y, Hisatsune J, Nagasako Y, Ono HK, Omoe K, Sugai M. Positive Regulation of Staphylococ-
cal Enterotoxin H by Rot (Repressor of Toxin) Protein and Its Importance in Clonal Complex 81 
Subtype 1 Lineage-Related Food Poisoning. Appl Environ Microbiol. 2015;81(22):7782-90.
 50. Tseng CW, Stewart GC. Rot repression of enterotoxin B expression in Staphylococcus aureus. J 
Bacteriol. 2005;187(15):5301-9.
 51. Geoghegan JA, Corrigan RM, Gruszka DT, Speziale P, O’Gara JP, Potts JR, et al. Role of surface 
protein SasG in biofilm formation by Staphylococcus aureus. J Bacteriol. 2010;192(21):5663-73.
 52. Loughman A, Sweeney T, Keane FM, Pietrocola G, Speziale P, Foster TJ. Sequence diversity in the A 
domain of Staphylococcus aureus fibronectin-binding protein A. BMC Microbiol. 2008;8:74.
 53. McCarthy AJ, Lindsay JA. Genetic variation in Staphylococcus aureus surface and immune eva-
sion genes is lineage associated: implications for vaccine design and host-pathogen interactions. 
BMC Microbiol. 2010;10:173.
 54. McCarthy AJ, Lindsay JA. Staphylococcus aureus innate immune evasion is lineage-specific: a 
bioinfomatics study. Infect Genet Evol. 2013;19:7-14.
 55. Ziebandt AK, Kusch H, Degner M, Jaglitz S, Sibbald MJ, Arends JP, et al. Proteomics uncovers 
extreme heterogeneity in the Staphylococcus aureus exoproteome due to genomic plasticity and 
variant gene regulation. Proteomics. 10(8):1634-44.

15
2
6
3
7
4
8
A
Chapter 4
Detection of alpha-toxin and other 
virulence factors in biofilms of 
Staphylococcus aureus on polystyrene 
and a human epidermal model
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abstract
background & aim: The ability of Staphylococcus aureus to successfully colonize (a)bi-
otic surfaces may be explained by biofilm formation and the actions of virulence factors. 
The aim of the present study was to establish the presence of 52 proteins, including viru-
lence factors such as alpha-toxin, during biofilm formation of five different (methicillin 
resistant) S. aureus strains on Leiden human epidermal models (LEMs) and polystyrene 
surfaces (PS) using a competitive Luminex-based assay.
results: All five S. aureus strains formed biofilms on PS, whereas only three out of five 
strains formed biofilms on LEMs. Out of the 52 tested proteins, six functionally diverse 
proteins (ClfB, glucosaminidase, IsdA, IsaA, SACOL0688 and nuclease) were detected in 
biofilms of all strains on both PS and LEMs. At the same time, four toxins (alpha-toxin, 
gamma-hemolysin B and leukocidins D and E), two immune modulators (formyl peptide 
receptor-like inhibitory protein and Staphylococcal superantigen-like protein 1), and 
two other proteins (lipase and LytM) were detectable in biofilms by all five S. aureus 
strains on LEMs, but not on PS. In contrast, fibronectin-binding protein B (FnbpB) was 
detectable in biofilms by all S. aureus biofilms on PS, but not on LEMs. These data were 
largely confirmed by the results from proteomic and transcriptomic analyses and in case 
of alpha-toxin additionally by GFP-reporter technology.
conclusion: Functionally diverse virulence factors of (methicillin-resistant) S. aureus are 
present during biofilm formation on LEMs and PS. These results could aid in identifying 
novel targets for future treatment strategies against biofilm-associated infections. 
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introduction
Staphylococcus aureus is the causative agent of a variety of infections with gener-
ally significant morbidity and mortality. The incidence of both hospital and commu-
nity acquired infections caused by methicillin-resistant S. aureus (MRSA) has increased 
significantly in the last decades [1–3]. Unfortunately, the treatment of such infections 
is becoming increasingly complex as current antibiotics may be less effective due to 
resistance development and biofilm formation [4]. As the number of newly approved 
antimicrobial agents continues to decrease [5,6], alternative strategies for prevention 
and/or treatment of bacterial colonization and infection, such as a vaccines [7] and 
antimicrobial peptides [8], are urgently needed. To date no clinically successful vaccine 
against S. aureus has been developed, despite the promising results of vaccines target-
ing diverse virulence factors of this pathogen in animal models [9,10]. Currently, the 
awareness that multiple virulence factors of S. aureus should be targeted for any vaccine 
or other strategy to be successful is increasing [9]. Moreover, some relation between the 
expression of antibodies against S. aureus virulence factors and protection from infec-
tion has been made [11].
The capacity of S. aureus to cause infections is attributed to its vast array of virulence 
factors which include adhesive surface proteins, secreted immune modulators, enzymes 
and toxins [7]. Moreover, many infections such as those of (wounded) skin, mucosae and 
artificial surfaces [12] are believed to involve biofilm formation by S. aureus. Biofilms 
are defined as complex communities of bacteria encased in an extracellular polymeric 
matrix and biofilm formation is believed to contribute to bacterial virulence, reduced 
susceptibility to antibiotics [13–15] and reduced clearance by the immune system. 
Despite the plethora of studies examining the involvement of biofilm formation [16](1, 
2) and/or single virulence factors [17,18] in e.g. skin infections, so far only a few studies 
has focussed on the involvement of multiple virulence factors in association with biofilm 
formation by S. aureus during infection [19,20].  
Biofilm formation by S. aureus on polystyrene (PS) has been extensively characterized 
before [21,22]. However, biofilm formation on human biotic surfaces is much less char-
acterized and the associated pathogen-host interactions are unclear. Earlier we reported 
that Leiden epidermal models (LEMs) mimic the human skin in many ways, including 
epidermal morphology and barrier properties [23]. In addition, full thickness human 
skin equivalents have been used to study skin colonization by (methicillin resistant) S. 
aureus [24,25].
The aim of the current study was to establish the presence of 52 proteins, includ-
ing virulence factors such as alpha-toxin, during biofilm formation by five different 
(methicillin-resistant) S. aureus strains on LEMs and PS. Using the novel competitive 
Luminex-based assay (CLA; [26] we detected six proteins (ClfB, glucosaminidase, IsdA, 
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IsaA, SACOL0688 and nuclease) in biofilms of all biofilm-forming strains on the two 
surfaces. At the same time, surface- and strain-dependent differences were found for 
the presence of a wide range of other proteins, such as immune modulators and toxins 
like alpha-toxin.
materiaLs and methods
ethics statement
Human serum was obtained from healthy volunteers who gave written consent for use 
of serum solely for research purposes within the department of Medical Microbiology 
and Infectious Diseases at the Erasmus MC Rotterdam. Serum was coded, pooled and has 
been used for this and earlier studies [27,28]. The original list with documented volun-
teer names was only accessible to qualified physicians within the department, amongst 
the current authors only including PMdR. This sampling procedure was approved by the 
Medical Ethics Committee of the Erasmus Medical Center Rotterdam (MEC-2007-106, 
addendum 2) [28]. All primary human skin cells from healthy donors used by the Depart-
ment of Dermatology are isolated from surplus tissue collected according to article 467 
of the Dutch Law on Medical Treatment Agreement and the Code for proper Use of Hu-
man Tissue of the Dutch Federation of Biomedical Scientific Societies [29]. According to 
article 467, coded anonymous surplus tissue can be used if no objection is made by the 
patient. All patients were informed of the possibility that surplus tissue could be used for 
scientific research and all patients were offered the opportunity to give written refusal 
to this. Only tissue from patients who did not opt out was used. None of the authors 
were involved in the tissue sampling and only birth date, gender and skin type of the 
subjects were documented. These data were only accessible to EMH and PHN. Because 
this procedure, as published previously [8,24-25], is in accordance with national law and 
additional approval of an ethics committee regarding scientific use of surplus tissue is 
not required, we did not seek specific approval by our ethics committee. The Declaration 
of Helsinki principles were followed when working with human tissue.
Staphylococcus aureus strains
The following S. aureus strains were used in this study: methicillin-resistant strains 
LUH14616 (sequence type 247), a kind gift of dr. S. Croes [30]; LUH15051 (ST 239) ob-
tained from dr. M.E.O.C. Heck, (Laboratory of Infectious Diseases and Screening, RIVM, 
Bilthoven, The Netherlands); USA300 strain Sac042w (ST 8) described earlier [31]; a strain 
derived from an impetigo patient LUH15091 (ST121) within the Erasmus Medical Center 
and NCTC 8325-4 (ST 8). All strains were typed using multi locus sequence typing (MLST) 
[27,32]. Before usage the strains were grown on sheep blood agar plates (Biomerieux).
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biofilm formation on polystyrene plates
A routine biofilm model was used as described before [21,22]. In short, overnight 
plate cultures of S. aureus were re-suspended in Iscove’s Modified Dulbecco’s Medium 
(IMDM, Life technologies, Carlsbad, CA, USA) without phenol red until an optical density 
(OD, 660nm) of 2 was reached. IMDM medium was chosen because of its significant 
impact on detectable levels of bacterial proteins, e.g. IsdA, ClfB and Efb, expressed by 
S. aureus biofilms on PS [26]. One µl of this bacterial suspension was added to 199 µl of 
TSB supplemented with 0.5% (wt/v) glucose and 3% (wt/v) NaCl or IMDM without any 
supplement in sterile 96-wells PS plates (Greiner Bio-one). Plates were then incubated at 
37oC with gentle shaking at 200 rpm for various intervals. Biofilm mass was measured by 
staining with 1% crystal violet. OD was measured at 490 nm.
Leiden epidermal models
The epidermis and dermis of pieces of fresh plastic surgery surplus skin were enzymati-
cally and mechanically separated, and each layer was subsequently digested to obtain 
single-cell suspensions [33]. The keratinocytes were cultured in keratinocyte medium, 
i.e. 3 parts DMEM (Gibco/Invitrogen) and 1 part Ham’s F12 medium supplemented with 
5% (v/v) fetal bovine serum (FBS; HyClone/Greiner), 0.5 µm hydrocortisone, 1 µm iso-
proterenol, 0.1 µm insulin (all from Sigma–Aldrich, Zwijndrecht, The Netherlands), 100 
U/ml penicillin and 100 µg/ml streptomycin (both from Invitrogen). Leiden epidermal 
models (LEMs; Fig 1A) were made with these primary human keratinocytes as described 
before [34]. Briefly, one day before generation of the models, medium of the keratino-
cyte cultures was switched to Dermalife (Lifeline Cell Technology) supplemented with 
penicillin (10,000 U/ml) and streptomycin (10 mg/ml). The next day 2×105 keratinocytes 
were seeded onto a filter insert (0.4 µM Costar inserts; Corning) in 12-well plates in this 
Dermalife medium. Three days thereafter the apical medium was removed, leaving the 
keratinocytes air-exposed. The medium under the filter insert was switched to CnT-02-
3D medium (CellnTech) mixed with keratinocyte medium supplemented with 2.4×10−2 
μM bovine serum albumin and lipids/antibiotics as described above. One day before 
bacterial inoculation of the LEMs, the medium was switched to this medium without 
antibiotics. All experiments were performed on 10-day air-exposed cultures.
colonization of Leiden epidermal model
LEMs were exposed for 1 h at 37°C in 7.3% CO2 to 300 μl of a log-phase bacterial sus-
pension containing 3.3x105 CFU/ml. Next, the non-adherent bacteria were removed 
by aspiration and at different intervals thereafter, the viable detachable bacteria were 
collected in 1 ml of PBS, and serially diluted, and 50 μl of these samples were plated onto 
diagnostic sensitivity test (DST) agar plates (Oxoid) to determine the number of CFU. To 
assess the number of adherent bacteria, a model was cut in two equally sized pieces. 
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One piece was used for histology and the other was homogenized in PBS using a glass 
Potter-Elvehjem tissue homogenizer, and the homogenates were subsequently serially 
diluted and plated as described above. The lower limits of detection for detachable and 
adherent bacteria were 20 and 40 CFU/LEM, respectively.
histology
One biopsy of each model was fixed in 4% (v/v) formaldehyde, dehydrated, and em-
bedded in paraffin. Next, paraffin blocks were cut into 5-μm sections, deparaffinized, 
rehydrated, and then stained with hematoxylin and eosin (H&E) staining.
cryo scanning electron microscopy
For the morphological study of (methicillin resistant) S. aureus biofilms on LEM or PS by 
cryo-scanning electron microscopy (SEM), specimens were quickly frozen in liquid ni-
trogen slush and transferred directly to the cryo-transfer attachment (Gatan Alto2500). 
Samples were sublimated at -90 in high vacuum for 5 min and subsequently sputter-
coated with a layer of 20 nm gold/paladium and examined in a JEOL JSM6700F scanning 
electron microscope.
multiplex bead assay for assessment of the presence of proteins during S. 
aureus biofilm formation
A multiplex competitive Luminex assay [26] (CLA) with minor modifications was used 
to indirectly detect the presence of 52 IgG-accessible proteins in bacterial cultures (all 
bacterial proteins are listed in Table S1). In brief, log-phase cultures of S. aureus were di-
luted 1:200 and incubated in PS wells for 1, 8, 24 and 48 hrs. After washing with ice-cold 
PBS supplemented with 0.5% (wt/v) sodium azide (Sigma-Aldrich), adherent bacteria 
residing in biofilms on PS or LEMs were incubated at 8°C and continuous shaking (500 
rpm) with 200 µl of a 1:200 dilution of polyclonal human IgG (PHG), isolated using the 
HiTrap™ Protein G HP column according to the manufacturer’s guidelines (GE Healthcare 
Bio-sciences, Piscataway, New Jersey, USA), from pooled serum of 40 healthy volunteers 
(19 non-nasal carriers, 6 intermittent and 15 persistent nasal carriers of S. aureus as 
determined earlier [35]. After 35 min incubation the PHG samples were recovered from 
biofilms. The remaining non-bound IgG antibody levels in these samples, specifically 
directed against 52 proteins of S. aureus, were measured using a multiplex bead-based 
flow cytometry technique (xMAP®, Luminex corporation) wherein recombinant proteins 
were covalently coupled to the beads as described previously [27,28,36]. As negative 
controls PHG samples incubated with empty PS wells or sterile LEMs were included in 
all experiments.
Next, the percentage decrease in the levels of specific IgG antibodies for each protein 
was calculated in relation to the negative control. The percentage decrease can be 
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considered a semi-quantitative measure of the protein-specific antibody absorption 
from PHG by the biofilm, thus indirectly reflecting the presence of the particular S. 
aureus protein by the biofilm [26]. The average percentage decrease plus two times the 
standard deviation, obtained at 8, 24 and 48 hours biofilm growth, for the three non-S. 
aureus control proteins and all S. aureus proteins of which genes were not present in 
LUH14616 were chosen as cut-off value (35% at 8 and 24 hrs biofilm growth and 40% at 
48 hrs, respectively).
In case of bacteria adherent to LEMs, the same protocol was followed with the single 
modification that PHG samples were directly incubated on top of the LEM. To determine 
the presence of S. aureus proteins in culture supernatants, growth medium that covered 
biofilms grown on PS was analyzed using the same protocol, with the modification that 
medium was removed at designated time points and incubated with PHG samples in 
sterile wells. 
reverse transcriptase Pcr
Early biofilms (8 and 16 hrs) were grown in 96-well plates (Cellstar culture plates, Greiner 
Bio-One) in 200 µl of IMDM (Gibco). Biofilms were resuspended, pooled and centrifuged 
at 4000 rpm for 10 min at 4°C. Pellets were resuspended in 200 µl of RNA protect™ Bacte-
rial reagents (Qiagen), stabilized for 5 min and then centrifuged for 10 min at 4°C. The 
pellet was dissolved in 1 ml of RNA-pro solution (Fast RNA Pro Blue kit, MP Biomedicals) 
and stored at -20°C until use. RNA was isolated using the Fast RNA Pro Blue kit according 
to the manufacturer’s protocol. Each 10 µg of isolated RNA was treated twice with 2 
U TURBO DNase (Ambion, Life Technologies). The reaction was stopped by adding 0.2 
volumes of DNase inactivation reagent (Ambion) and incubation for 2 min at ambient 
temperature. RNA containing supernatants were collected by centrifugation (1.5 min at 
9000 g at ambient temperature) and each 2 µg DNase-treated RNA was treated with 2 
U DNase I (Fermentas, Fisher Scientific). One µg of prepared RNA was transcribed into 
cDNA using 200 U RevertAid H Minus Reverse transcriptase (Fermentas), 4 µl of 5x reac-
tion buffer (Fermentas), 20 U of RiboLock RNase inhibitor (Fermentas) and 2 µl of 10 
mM dNTP mix (Fermentas) in a final volume of 20 µl of DEPC-treated water. This was 
incubated for 60 min at 42°C and then terminated by heating at 70°C for 5 min. For each 
RNA sample a negative control without reverse transcriptase was processed similarly. 
The presence of cDNA in all samples was examined using PCR as described previously 
[27].
Proteomics
A total of 48 biofilms of strain LUH14616 were grown for 8 hours in PS wells as described 
above, resuspended in 200 μl of PBS per well, pooled and spun down at 4,000 rpm for 
5 min. The resulting pellet was resuspended in 50 μl of PBS, mixed with 50 μl of Laemni 
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buffer and heated for 5 min at 95°C. Fifty μl of this suspension containing denatured 
proteins were run on a 15% SDS gel (Biorad) and gel lanes were cut into ~1 mm slices. 
Lanes were subjected to in-gel reduction with dithiothreitol, alkylation with chloroacet-
amide and digestion with trypsin (Promega, Leiden, The Netherlands). Nanoflow LC-MS/
MS was performed on an 1100 series capillary LC system (Agilent Technologies) coupled 
to an LTQ Orbitrap XL mass spectrometer (Thermo), operating in positive mode and 
equipped with a nanospray source. Mass spectra were acquired in continuum mode; 
fragmentation of the peptides was performed in data-dependent mode by CID. Peak 
lists were automatically created from raw data files using the Proteome Discoverer (ver-
sion 1.3; Thermo). The Mascot search algorithm (version 2.2, MatrixScience) was used 
for searching against the Uniprot database (release 2013_06.fasta, taxonomy: S. aureus, 
strains USA300, Newman, NCTC 8325-4 and COL). The peptide tolerance was set to 10 
ppm and the fragment ion tolerance was set to 0.8 Da. A maximum number of 2 missed 
cleavages by trypsin were allowed and carbamido-methylated cysteine and oxidized 
methionine were set as fixed and variable modifications, respectively. The Mascot score 
cut-off value for a positive protein hit was set to 65. Individual peptide MS/MS spectra 
with Mascot scores below 25 were checked manually and either interpreted as valid 
identifications or discarded.
construction of the hla promotor upstream of GfPuvr
S. aureus strains LUH14616 and Sac042w containing a vector with an hla promotor 
upstream of GFPuvr were prepared as described earlier [36] with some modifications. 
First, the promotor of hla was amplified using primers hlapr1 (cggaattcgatatttctatgta-
atggca) and hlapr2 (gctctagacttctatttttttgaacgat) and as a template DNA from S. aureus 
strain Newman. Next, the amplification product was ligated into the EcoRI XbaII site of 
pALC1484 (a kind gift from dr A.L. Cheung, Dartmouth College, New Hampshire, US) and 
cloned into E. coli DH10beta. From positive colonies on LB agar supplemented with 50 
µg of ampicillin/ml, recombinant plasmids were isolated, checked by PCR and sequenc-
ing, and then electroporated into S. aureus RN4220. Finally, from positive colonies on 
BHI agar supplemented with 10 µg of chloramphenicol/ml, plasmids were isolated and 
electroporated into S. aureus LUH14616 and Sac042w. As positive and negative control 
we electroporated respectively pWVW 163, a plasmid containing a phage promotor 
yielding a strong, constant expression of GFP, and pALC1484, an empty vector [37], into 
the same S. aureus strains as described above.
data analysis
All data were analysed using Microsoft Excel version 2010 and graphics were made us-
ing Graphpad Prism version 5 (Graphpad Inc. La Jolla, CA, USA).
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resuLts
biofilm formation by mrsa strain Luh14616 on Lems and Ps
Firstly, the ability of the clinical isolate MRSA LUH14616 to form biofilms on both the hu-
man skin model (Leiden Epidermal Model: LEM, schematically represented in Figure 1A), 
and polystyrene (PS) was examined. This MRSA strain was able to adhere to and stably 
colonize both surfaces, as reflected by an increase in bacterial counts on LEM (Figure 
1B) and an increase in crystal violet staining on PS (Figure 1E) within the first 24 hrs after 
inoculation. Interestingly, haematoxylin-eosin staining of the colonized LEMs showed 
that the bacteria adhered to the stratum corneum and formed small colonies after 16 
hrs, but did not invade the epidermis (Figure 1C). To further examine biofilm formation 
by MRSA strain LUH14616 on these surfaces, bacterial colonization on LEM (Figure 1D) 
and PS (Figure 1F) was visualized with scanning electron microscopy. Results revealed 
a tightly adherent layer of bacteria on both LEMs and PS after 24-48 hrs, indicating the 
development of a mature biofilm on both surfaces. Biofilm-associated bacteria on LEM 
appeared to be completely encased in an extracellular matrix (Figure 1D), while bacteria 
on PS appeared to be incompletely encased (Figure 1F).
detection of toxins, immune modulators and other proteins of mrsa strain 
Luh14616 during biofilm formation on Ps
We used a competitive Luminex-based assay (CLA) to establish the presence of 52 bacte-
rial proteins during biofilm formation by MRSA strain LUH14616 on polystyrene (PS).
In line with previous results [26], biofilm mass-dependent absorption of specific IgG 
for several S. aureus proteins, such as IsdA (Figure 2A), FnbpB (Figure 2C) and glucosa-
minidase by biofilms was detected, while no such reduction was seen for the levels of 
IgG antibodies directed against control proteins, e.g. the protein derived from human 
metapneumovirus (hMPV) (Figure 2B). Based on the percentage decrease in the levels of 
IgG directed against the three non-S. aureus control proteins and against the 28 S. aureus 
proteins of which genes were not found in LUH14616 using PCR, cut-off values of at least 
35% decrease in specific IgG at 24 hrs biofilm growth and 40% at 48 hrs were calculated. 
CLA measurements for five proteins [ESX-1-associated factors EsxA and EsxB, iron sur-
face determinants H (IsdH), Staphylococcal enterotoxin J (SEJ) and foldase-protein PrsA] 
were excluded from further analysis due to low MFI’s with standard deviations larger 
than 25% between repeated CLA measurements.
Using the above mentioned cut-off values, we detected 8 proteins in 24 hrs and 48 
hrs-old S. aureus biofilms: the surface proteins fibronectin-binding protein B (FnbpB), 
CflB, glucosaminidase, iron-responsive surface determinant A (IsdA), immunodominant 
antigen A (IsaA), SACOL0688, nuclease, and the immune modulator Efb (Table 1). In 
addition, a significant decrease in the levels of IgG specifically directed against chemo-
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taxis inhibitory protein of S. aureus (CHIPS) with 48 hrs-old biofilms, but not 24 hrs-old 
biofilms, was observed. No significant decrease in the levels of specific IgG for 15 other 
proteins, despite the presence of corresponding genes in LUH14616 such as for alpha 
toxin, was observed (Figure 2D).
Additional experiments showed that the secreted proteins alpha-toxin, HlgB, FLIPr 
and SSL1 could neither be detected in the growth medium covering biofilms, excluding 
figure 1. Biofilm formation by S. aureus LUH14616 on LEMs and PS surfaces.
a: Schematic representation of LEM. b: Bacterial counts were performed on LEM exposed to LUH14616 for 
various intervals. Adherent bacteria are represented by open symbols and non-adherent/loosely adherent 
bacteria by closed symbols. Results are displayed as the mean and SD of four experiments.
c: Haematoxilin and eosine staining of LEMs at various intervals after inoculation with LUH14616. Arrows 
indicate microcolonies, scale bars = 50 μm. d: Cryo scanning electron microscopy of LEMs colonized with 
LUH14616 for various intervals. Photographs are representative for three different keratinocyte donors. e: 
Biofilm formation by LUH14616 on PS in IMDM medium. Results are the mean and SEM of three experi-
ments. f: Cryo scanning electron microscopy of S. aureus LUH14616 biofilms formed on PS at 24 and 48 hrs 
after adherence to wells. Scale bars =1 μm.
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the possibility of false-negative signals for these secreted proteins (Figure S1). CLA data 
were further validated by confirming the presence of 7 out of the 8 detected proteins in 
early (8 hrs) biofilms using mass-spectrometry, while mRNA was detected for 5 of these 
proteins in early biofilms.
detection of toxins, immune modulators and other proteins of mrsa strain 
Luh14616 during biofilm formation on Lems
Next we screened for the presence of the same 52 proteins in biofilms of LUH14616 
grown on LEM. Similar to biofilms grown on PS we observed time dependent absorption 
of antibodies against diverse antigens such as IsdA (Figure3A) and glucosaminidase, 
whereas no such reduction was observed for antibodies directed against the non-S. 
aureus control proteins (Figure3B) and the proteins of which the gene was not found in 
LUH14616. This prompted us to use the same cut-off values.
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figure 2. Detection of S. aureus proteins during biofilm formation of LUH14616 on PS.
Closed symbols indicate the mean fluorescence intensity (MFI, left Y-axis), reflecting the level of remaining 
non-bound IgG directed against specific proteins after incubation of PHG with the biofilms, while open 
symbols indicate biofilm mass (OD490 nm, right Y-axis). Both are plotted against the time of biofilm growth 
(hrs).
Results are shown for a: IsdA, b: control protein of human metapneumovirus (hMPV), c: FnbpB and d: 
alpha toxin. Dashed horizontal lines indicate the average MFI of sterile controls. Symbols and error bars 
indicate mean and SD of four experiments.
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Thirteen proteins were detected in 24 and 48 hrs-old biofilms on LEMs (Table 1): the 
surface proteins clumping factor B (CflB), glucosaminidase, IsdA, IsaA, glycyl-glysine 
endopeptidase (LytM), and SACOL0688; the toxins alpha-toxin (Figure3D), gamma-
hemolysin B (HlgB), leukocidins (Luk) D and E, lipase and nuclease; and the immune 
modulator formyl peptide receptor-like inhibitory protein (FLIPr). In addition, CHIPS and 
staphylococcal superantigen-like protein 1 (SSL 1) were detected in 48 hrs biofilms, but 
not 24 hrs biofilms. In contrast to biofilms on PS, no significant reduction was observed 
for antibodies against FnbpB at any time point (Figure3C). 
detection of proteins during biofilm formation on Lems and Ps by different S. 
aureus strains
To determine whether the results obtained for MRSA LUH14616 are representative for 
other S. aureus strains, experiments with 24 hrs-old biofilms of an additional set of four, 
genetically diverse S. aureus strains were performed: i.e. LUH15051, LUH15091, the 
USA300 strain Sac042w, and NCTC 8325-4. Results revealed considerable variance in 
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figure 3. Detection of S. aureus proteins during biofilm formation of LUH14616 on LEMs. Closed symbols 
indicate the mean fluorescence intensity (MFI, left Y-axis), reflecting the level of remaining non-bound IgG 
directed against specific proteins after incubation of PHG with the bacterial biofilms, while open symbols 
indicate biofilm mass (OD490 nm, right Y-axis). Both are plotted against the time of biofilm growth (hrs). Re-
sults are shown for a: IsdA, b: control protein of human metapneumovirus (hMPV), c: FnbpB and d: alpha 
toxin. Dashed horizontal lines indicate the average MFI of sterile controls. Symbols and error bars indicate 
mean and SD of four experiments, respectively.
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biofilm mass formed on the PS plates and LEMs among the different strains (Figures 
4A-C). Interestingly, strains 8325-4 and LUH15091 formed a significant biofilm on PS, but 
not on LEMs. The latter two strains were therefore excluded from further analyses. The 
same cut-off values were used as for LUH14616.
In agreement with the results for LUH14616, the proteins ClfB, IsdA, IsaA, SACOL0688 
and glucosaminidase were detected in 24 hrs-old biofilms of LUH15051 and Sac042w on 
both PS and LEMs (Table S1). In addition, the toxins HIgB, LukD and E and the immune 
modulator SSL1 were detected in biofilms of both strains only on LEMs, while FnBPB 
was detected only on PS. In contrast to results obtained with LUH14616, we addition-
ally detected the proteins CHIPS, efb, lipase and lytM (in biofilms of both LUH15051 
and Sac042w) and alpha-toxin and FLipR (Sac042w only) on both surfaces. Finally, we 
detected SEA in biofilms of LUH15051 and Sac042w on respectively LEMS and PS, while 
SdrD was detected for both strains on LEMS.
figure 4. Biofilm formation by 5 different S. aureus strains on LEMs and PS surfaces.
a: Biofilm formation after 24 hrs on PS was measured by crystal violet staining. b: Hematoxylin and eosine 
staining of LEMs 24 hrs after exposure to S. aureus 8325-4, LUH15091, LUH15051, LUH14616 or Sac042w, 
arrows indicate S. aureus. Photographs are representative for three different experiments. Scale bars = 50 
µm. c: The number of viable bacteria present on epidermal models after 24 hrs inoculation was determined 
microbiologically (CFU/LEM). Results are boxplots showing the median and range. Results are means and 
SEM of three to five experiments.
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alpha-toxin expression by mrsa strains Luh14616 and sac042w during biofilm 
formation on Lems and Ps
The differential detection of alpha-toxin, an important virulence factor during skin infec-
tions caused by S. aureus, in biofilms of different strains on LEMs and PS was further 
investigated using GFP-reporter technology. Visualization of alpha-toxin produced by 
S. aureus was performed by using strains LUH14616 and Sac042w transformed with a 
vector containing the promoter for hla, coupled to GFP. Using fluorescence microscopy, 
small microcolonies of these bacteria were observed that did not express hla after 4 
hrs of colonization of epidermal models (Figure 5A), whereas at 24 hrs of colonization 
LUH14616 highly expressed hla, as indicated by the green fluorescent signal (Figure 5B). 
In contrast to results seen at the protein level, hla expression by LUH14616 was also 
visualized after 24 hrs of colonization of polystyrene (Figure S2), suggesting that the 
figure 5. Expression of hla by S. aureus LUH14616 and Sac042w during biofilm formation on LEMs.
LUH14616 and Sac042w containing hla-GFP (hla), empty vector (empty vec) or a construct yielding con-
stant GFP expression (GFP), a: at 4 hrs and b: at 24 hrs after bacterial colonization of LEMs. LEMs were 
incubated for 4 or 24 hrs with the different bacterial strains, subsequently fixed in 1% paraformaldehyde, 
and stained with DAPI. hla expressing bacteria are presented in green, DAPI staining is presented in blue. 
Scale bars = 50 µm.
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gene is transcribed but not translated and/or that protein is rapidly degraded. Similar re-
sults were obtained for Sac042w, although this was less pronounced than for LUH14616 
(Figure 5B, Figure S2).
discussion
In this study we established the presence of 52 proteins in biofilms of five genetically 
different S. aureus strains on two different types of surfaces, i.e. Leiden epidermal modes 
(LEMs) and polystyrene (PS). We detected six functionally diverse proteins in biofilms 
of three different strains on both surfaces. Several of these proteins, including ClfB, 
glucosaminidase and SA0688, have been previously associated with biofilm formation 
[38-41], although so far not on a human biotic surface. In this context, surface- and 
strain-dependent differences in the presence of a wide range of proteins, including 
alpha-toxin, were found. The detection of multiple toxins (HlgB, LukD/E and alpha toxin) 
in biofilms of multiple strains on LEMs, but not PS, indicates surface specific protein 
expression. This implicates that currently used biofilm models, such as those on PS, 
might not adequately reflect biofilm formation on a more complex surface, such as the 
human skin. However, we should realize that the biofilms on LEMs and PS were formed 
under different conditions, i.e. submerged in culture medium for biofilms on PS and on 
an air-exposed, dry surface in case of biofilm formation on LEMs.
Biofilm formation by strain LUH14616 on LEMs and PS was confirmed using EM. In-
terestingly, bacteria in a biofilm on LEM but not on PS were completely encased by an 
extracellular matrix, indicating a phenotypic difference in bacterial biofilm formation 
on the two models. However, in the current study we did not characterize the material 
encasing bacteria in more detail, e.g. using immunoelectron microscopy [42].
The detection of S. aureus toxins, most notably alpha-toxin, in biofilms on LEMs is 
in agreement with their well-established roles in the pathogenesis of skin infections 
[18,43]. The cytolytic pore-forming alpha-toxin [44] lyses human cells including skin 
tissue, interferes with the innate and adaptive immune responses in a murine skin 
infection model [45], and is essential for biofilm development on mucosal surfaces [46]. 
Interestingly, in human skin, the filaggrin protein may inhibit alpha-toxin’s cytotoxicity 
by its ability to regulate the secretion of sphingomyelinase [47]. In line with this, >90% 
of the atopic dermatitis (AD) patients, who often have reduced filaggrin expression, are 
colonized by S. aureus [48], whereas about 25% of the normal population is persistently 
colonized by this bacterium [49]. Moreover, S. aureus strains isolated from AD patients 
displayed a higher alpha-toxin production than strains from healthy controls, while the 
amount of alpha-toxin produced was correlated with disease severity [50].
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The other toxins detected in biofilms in this study, including HlgB and the leukocidins 
D/ E, have also been associated with S. aureus skin colonization and infection. This is sup-
ported by data from both murine models [51,52] and clinical-epidemiological studies 
[53,54]. Other data also supports the presence of other, non-toxin proteins detected in 
this study. For instance, the detected lipase might support the persistence of S. aureus in 
the fatty secretions of mammalian skin [55,56]. A recent study demonstrated that lipases 
are essential for S. aureus biofilm formation [55].
The PHG used in this study to establish bacterial protein presence consisted of a previ-
ously described pool of serum from both nasal and non-nasal carriers of S. aureus [35]. 
Specific IgG against all tested proteins was detected in PHG and these IgG levels were gen-
erally higher than in serum from individual patients suffering from a S. aureus bacteremia 
[27] (unpublished data). Combined with the high sensitivity of the Luminex assay [57, 58] 
we think that it is unlikely that the current CLA would not detect antibody absorption by 
IgG-accessible proteins. However, future studies using other antibody sources (e.g. specific 
monoclonal antibodies) might further increase the sensitivity of this assay.
A limitation of the PHG used in this study is the aspecific decrease in IgG that was 
observed against leukocidins S and F, while genes for these proteins were not present in 
strain LUH14616 and proteomics data could not confirm the presence of HlgB or Luk D/E 
in 8-hrs biofilms on PS. The known immunological cross-reactivity between Luk D/E, S/F 
and HlgB [59,60] may explain these conflicting findings. In addition, an incomplete pro-
tein library used during mass-spec analysis might explain why CLA results for a particular 
protein could not be confirmed. Additional mass-spectrometry should be performed on 
mature biofilms on LEMs to confirm or exclude the presence of these proteins.
Expression on LEMs of hla, the gene encoding alpha toxin, was confirmed for two 
strains using GFP reporter technology. The low levels of hla expression by the USA300-
derived strain Sac042w may be explained by strain-specific traits [61], possibly caused 
by mutations in upstream regulators such as sarA [62]. Interestingly, for strain LUH14616 
hla expression was also observed on PS, while CLA nor mass-spectrometry detected al-
pha toxin at the protein level on this surface. This suggests that hla is transcribed but not 
translated and/or that the protein is rapidly degraded by the bacteria on PS, which has 
been observed previously for other S. aureus strains during planktonic growth [63-65].
Regulation of hla and other genes for S. aureus virulence factors is influenced by many 
factors, including the accessory gene regulatory locus (Agr), RNAIII [66], downstream 
transcription factors Rot [67,68], SarA and -S and Sae [69]. In this connection, we noted 
that several proteins detected during biofilm formation on LEMs, including alpha-toxin, 
LytM, SSLs and Spa are (indirectly) regulated by RNAIII [66,70]. Moreover, RNAIII can also 
directly interfere with mRNA of LytM leading to its down-regulation [71]. Therefore, it 
may well be that the quorum sensing system of AgrA/RNAIII of S. aureus is activated 
differently upon interaction of S. aureus with either LEMs or PS, leading to up- or down-
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regulation of specific genes depending on the surface. However, further studies includ-
ing quantitative mass-spectrometry and transcriptomic analysis are necessary to clarify 
the role of the diverse regulatory systems [72-74] involved in the expression of hla and 
other genes during biofilm formation on LEMs.
In the context of new anti-infective therapies, such as vaccines, our data indicate that 
diverse proteins of S. aureus in biofilms are accessible to human IgG. Although biofilm-
associated bacteria are thought to be more resistant to antimicrobials and effectors of the hu-
man immune system [13–15], our data suggests that, in addition to animal models [40], also 
vaccine-boosted human antibodies can target biofilms. Further insights into the functionality 
of antibodies, specifically in regard to (the inhibition of) biofilm growth, are required.
Alternatively, it may be interesting to choose an anti-virulence based therapy, for 
example by targeting interfering RNAs, such as RNAIII that affect the expression of many 
virulence factors [75]. For example, the RnpA- inhibitor RNPA1000, was shown to have in 
vitro antimicrobial effect against S. aureus (and other gram positive pathogens). More-
over, this enzyme dose-dependently protected against the pathogenesis of S. aureus 
in a mouse infection model [76]. Based on our data such an anti-virulence therapy may 
be effective against biofilms on skin of e.g. AD patients colonized by S. aureus, but not 
against biofilms on abiotic surfaces, such as that of a colonized catheter. 
We conclude that functionally diverse virulence factors of (methicillin-resistant) S. 
aureus are present during biofilm formation on PS and LEMs. We specifically confirmed 
the presence of alpha-toxin during biofilm formation of MRSA strains LUH14616 and 
Sac042w on LEMs. In addition, the presence of several toxins, including alpha-toxin, 
immune modulators and other proteins appear to differ depending on the studied 
strain and surface. These observations merit more mechanistic studies to elucidate 
the function of specific proteins and the regulation of their expression within S. aureus 
biofilms. However, the present data further suggests that specific proteins, such as the 
ubiquitously present IsdA or SA0688, could be potential targets for novel agents to 
prevent biofilm formation and/or to reduce biofilm formation not only in animal models 
but also on human biotic surfaces.
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figure s1. Detection of S. aureus toxins and immune-modulators in 24 hrs biofilms of LUH14616 and sur-
rounding medium.
Results are shown for a: alpha-toxin, b: HlgB, c: FlipR, and d: SSL1. Remaining non-bound IgG specific 
against the different proteins was separately measured after incubation of PHG with biofilms on PS and 
after incubation with the IMDM culture medium covering the biofilms. Closed squares indicate IgG mea-
surements from the biofilm samples and open triangles indicate measurements from medium samples. 
Biofilm mass on PS is indicated by open squares, which are plotted on the right Y-axis. Dashed horizontal 
lines indicate average MFI of sterile controls. Results are presented as the mean of 2-4 experiments.
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figure s2. Expression of hla by S. aureus LUH14616 and Sac042w during biofilm formation on PS.
LUH14616 and Sac042w containing hla-GFP (hla), an empty vector or a construct yielding constant GFP 
expression (GFP), at 4 hrs and 24 hrs after bacterial colonization of PS. hla expressing bacteria are presented 
in green.
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abstract
background: Staphylococcus aureus is an important pathogen in cystic fibrosis (CF). 
However, it is not clear which factors are associated with worse lung function in patients 
with persistent S. aureus airway cultures. Our main hypothesis was that patients with 
high S. aureus density in their respiratory specimens would more likely experience wors-
ening of their lung disease than patients with low bacterial loads.
methods: Therefore, we conducted an observational prospective longitudinal multi-
center study and assessed the association between lung function and S. aureus bacterial 
density in respiratory samples, co-infection with other CF-pathogens, nasal S. aureus 
carriage, clinical status, antibiotic therapy, IL-6- and IgG-levels against S. aureus virulence 
factors.
results: 195 patients from 17 centers were followed; each patient had an average of 
7 visits. Data were analyzed using descriptive statistics and generalized linear mixed 
models. Our main hypothesis was only supported for patients providing throat speci-
mens indicating that patients with higher density experienced a steeper lung function 
decline (p<0.001). Patients with exacerbations (n = 60), S. aureus small-colony variants 
(SCVs, n = 84) and co-infection with Stenotrophomonas maltophilia (n = 44) had worse 
lung function (p = 0.0068; p = 0.0011; p = 0.0103). Patients with SCVs were older (p = 
0.0066) and more often treated with trimethoprim/sulfamethoxazole (p = 0.0078). IL-6 
levels positively correlated with decreased lung function (p<0.001), S. aureus density in 
sputa (p = 0.0016), SCVs (p = 0.0209), exacerbations (p = 0.0041) and co-infections with 
S. maltophilia (p = 0.0195) or A. fumigatus (p = 0.0496).
conclusions: In CF-patients with chronic S. aureus cultures, independent risk factors for 
worse lung function are high bacterial density in throat cultures, exacerbations, elevated 
IL-6 levels, presence of S. aureus SCVs and co-infection with S. maltophilia.
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introduction
Cystic fibrosis (CF) patients suffer from recurrent bacterial airway infections, which often 
lead to respiratory insufficiency and reduced life expectancy [1]. Staphylococcus aureus 
is one of the most frequently isolated pathogens from the airways of these patients 
[2–4]. Recent studies have shown the importance of S. aureus in young children with CF 
by way of eliciting an increased inflammatory response measured in broncho-alveolar 
lavages [5–9]. Thirty percent of the general population are persistent nasal carriers of S. 
aureus and this percentage is even higher in CF patients [10–12]. Nasal carriers have been 
shown to have a higher risk for S. aureus infections, but a lower rate of lethal infections 
[13]. It is often difficult to decide whether culturing S. aureus in respiratory specimens 
from CF patients is merely caused by colonization or whether this is also associated 
with worsening lung disease requiring antibiotic treatment. To support clinical decision, 
interleukin-6 levels in blood, which have been shown to increase in CF patients during 
airway inflammation [14], may serve as a potential marker for severity of inflammation.
In the present study, our goal was to determine risk factors associated with worse lung 
function in CF patients older than six years, who had been persistently colonized by S. 
aureus. We thus conducted a prospective observational longitudinal multi-center study 
(ClinicalTrials.gov: NCT00669760). We hypothesized that patients with high bacterial 
loads of S. aureus in airway specimens were more likely to experience worse lung func-
tion compared to patients with lower bacterial loads. Secondary objectives were the 
association between lung function and S. aureus nasal carriage in CF patients, the role of 
blood IL-6 levels and IgG levels against 44 S. aureus virulence factors, presence of small 
colony variants (SCVs) of S. aureus and co-infection with other CF-related pathogens 
such as Stenotrophomonas maltophilia, methicillin-resistant S. aureus (MRSA), Aspergillus 
fumigatus, Achromobacter xylosoxidans and Mycobacterium abscessus on lung function.
materiaLs and methods
study design
We conducted an observational prospective multicenter study to evaluate risk factors 
for worse lung function in patients with persistent S. aureus airway cultures older than 6 
years. The treating physicians recruited CF patients for the study by using the following 
definitions for persistence from the medical records: 1. Patients presented with at least 
2 positive cultures 6 months apart within one year before recruitment, or 2. half of the 
respiratory samples the year before recruitment were S. aureus positive. The first patient 
was recruited in June 2008, the last patient finished the observation period in February 
2010. At each visit throat or sputum cultures were obtained and sent to the central study 
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laboratory located in Münster, Germany. On the basis of a study investigating chronic 
bronchitis patients [15], we hypothesized that CF-patients with high loads (in sputa 
≥1x106CFU/ml; in throat cultures semi-quantitative score ≥3) of S. aureus in their airway 
specimens are more likely to experience worsening of lung disease due to S. aureus than 
patients with low bacterial loads. To rule out an impact of P. aeruginosa or Burkholderia 
cepacia complex (BCC) on lung function, patients with cultures of these two pathogens 
were excluded. We defined exacerbation by evaluating clinical symptoms established by 
Fuchs et al. for the assessment of exacerbation [16]. If a patient met at least four out of 11 
evaluated symptoms, the clinical status was determined as exacerbation.
Secondary objectives included the association between nasal S. aureus carriage, the 
level of IL-6, the presence of S. aureus small colony variants (SCVs) and the co-culture of 
other important CF pathogens such as S. maltophilia, A. xylosoxidans, A. fumigatus and 
M. abscessus and the risk for exacerbation or worse lung function.
inclusion criteria
CF Individuals older than six years were included with persistent S. aureus airway cul-
tures one year before recruitment.
enrolment and follow-up
Patients identified as persistently colonized by S. aureus as defined by our inclusion 
criteria were enrolled in this study by their attending CF specialists. If P. aeruginosa 
or BCC were cultured for more than 6 months during the study period, patients were 
excluded from further analysis. Patients were followed for a period of 21 months with 
regular visits (usually every 3 months). Sputum samples were spontaneously produced. 
There were no requirements for induced sputum cultures. Blood samples were taken 
from patients once yearly and/or at exacerbations. An ethical statement was obtained at 
the main study center with the central laboratory in Münster, Germany (2007-496-f-S). 
Other ethical statements have been obtained from the Universitätsklinikum Tübingen 
450/2008B02, Martin-Luther-Universität Halle Wittenberg hm/bu, Ärztekammer Ham-
burg MC039/09 and the Universitätsklinikum Dresden. All other ethic committees at 
the Ruhr Universität Bochum, Universitätsklinik Essen, Medizinische Hochschule Han-
nover, Universitätsklinikum Jena, Charité Universitätsmedizin Berlin, Campus Virchow 
Klinikum, Kinderkrankenhaus Osnabrück, Universitätsklinik Innsbruck, Universitätsklinik 
Düsseldorf, Park Schönefeld Klinik Kassel and the Universitätsklinikum Leipzig waived 
their approval. Written informed consent was obtained from all patients and parents, if 
patients were younger than 18 years. Clinical trial registered with www.clinicaltrials.gov 
(NCT00669760).
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investigated fuchs criteria and clinical report forms (crfs) [16]
At every visit patients performed lung function tests assessed as forced expiratory 
volume in 1 second (FEV1). Other recorded clinical parameters included the presence 
of fatigue, malaise or lethargy, sinus discharge, cough and hemoptysis as well as spu-
tum volume or color. These data were documented by the treating physicians in CRFs, 
together with CFTR genotype, pancreas sufficiency/insufficiency, physical and radio-
graphic findings on examination of the chest, body mass index and antibiotic therapy. 
The CRFs were sent together with the respiratory specimens to the central laboratory in 
Münster, Germany.
microbiology
All airway and blood samples obtained from patients were sent to the central study 
laboratory (Medical Microbiology, Münster, Germany) within 24 hours and were cul-
tured according to standard procedures for CF airway cultures [17,18]. All samples were 
streaked on Columbia sheep blood agar (Becton Dickinson, Heidelberg, Germany), Mac-
Conkey agar for Gram-negative bacteria (Becton Dickinson, Heidelberg, Germany), SAID 
chromogenic agar for S. aureus, (bioMerieux, Nürtingen, Germany), all incubated for 
48h at 37°C; on chocolate agar (Mast Diagnostica, Reinfeld, Germany) for Haemophilus 
influenzae, incubated for 48h at 37°C with 5% CO2; on BCSA agar (bioMerieux, Nürtingen, 
Germany) for Burkholderia cepacia complex, incubated at 30°C for 10 days, and on Kim-
mig agar for fungi. In case of mucoid consistency, sputa were incubated with sputasol 
(dithiotreitol, Oxoid, Wesel, Germany) for 30 min at 37°C and homogenized by vortexing 
and vigorous pipetting before further processing. Quantitative cultures of sputa were 
performed by serial dilution of 500μl of sputum in 4.5ml 0.85% NaCl according to stan-
dard procedures. Semi-quantitative analysis was performed for throat and nasal cultures 
and for sputa of less than 500μl sputum. A score of 1 was assigned to single S. aureus 
colonies on the primary agar plate, a score of 2 to medium density and a score of 3 to 
highly dense numbers of S. aureus colonies on the primary agar plate, respectively. SCVs 
were identified by sub-culturing isolates of interest from Columbia blood and SAID agar 
on Columbia blood agar (incubated at 37°C) and on Schaedler agar (incubated at 37°C 
with 5% CO2) for 24h [19]. All isolates, which displayed small colony size on Columbia 
blood and normal size on Schaedler agar were identified as SCVs, which was further con-
firmed by a positive catalase and positive Pasteurex Staph Plus test (BIO-RAD, München, 
Germany). In case of negative results, isolates were identified by 16S-RNA sequencing.
measurements of anti-staphylococcal antibodies
The levels of IgG antibodies against 44 staphylococcal antigens in serum samples of CF 
patients and 53 healthy nasal carriers, who consisted of volunteers of the Institute of 
Medical Microbiology and medical students, were measured using a bead-based flow 
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cytometry technique (xMAP®; Luminex Corporation) as previously described [20,21]. All 
examined antigens are given in Table S3.
iL-6 measurements
The assay was characterized by intra-assay precisions of 4.2%, 1.6% and 2.0% at low, 
medium and high analyte levels, respectively. The minimum detectable dose of IL-6 was 
less than 0.7 pg/mL.The cut-off value for IL-6 (12 pg/mL) corresponds to the highest 
IL-6 level observed in a control population of 40 apparently healthy individuals and is 
very close to the cut-off value of 15 pg/mL, which has been suggested in previously 
published studies [23, 24].
statistical analysis
Patient data were collected longitudinally. The baseline patient characteristics were 
analyzed by standard descriptive statistics. Categorical variables were described by 
absolute and relative frequencies. Continuous variables were described by median and 
range. The following variables were computed:
Lung function (FEV1% predicted) was determined on the basis of Quanjer et al. [22]. 
SCV status (never/ever) of the patients was positive (ever), if SCVs were detected in 
specimens at any visit. Carrier status was deemed positive, if in at least at 50% of visits 
S. aureus nasal carriage was detected. Exacerbation status (never/ever) was calculated 
using the symptoms defined by Fuchs [16]. A visit with Fuchs score in excess of 4 was 
defined as an exacerbation visit. Patients exhibiting at least one exacerbation visit were 
assigned to the exacerbation ever group. S. aureus density [sputa: high (<106CFU/ml and 
low <106CFU/ml according to Mensa and Trilla for patients with chronic bronchitis;[15] 
nasal and throat swabs: high >/ = +++; low + or ++)] was determined based on quantita-
tive and semi-quantitative data per visit. Patients’ co-infection status (never/ever) with 
MRSA, S. maltophilia and A. fumigatus was determined by compiling information from 
all visits.
Outcome parameters of interest were bacterial density (high/low) in different speci-
mens, lung function (FEV1% predicted) and interleukin-6 (IL-6) levels.
Cross-sectional analyses, e.g. at baseline, were performed using Mann-Whitney-U 
tests from continuous variables and Chi-Squared tests, or Fisher’s exact tests for cat-
egorical variables. Longitudinal analyses were performed to assess the effect of different 
explanatory variables on the outcome parameters. To model patient progress over time 
we used generalized linear mixed models (GLMM). Bacterial density was modelled by a 
binary distribution. FEV1% proved to be normally distributed. IL-6 levels were skewed 
to the right and a log-normal distribution was used to fit the data. The canonical link 
function was used. For all models, a random effect for the individual progress of each 
patient over the study time (days from first visit) was included using sp(pow) as covari-
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ance structure. All models were age and gender adjusted, if not otherwise specified. 
Studentized residual plots were used to examine model requirements.
To analyze the functional dependency of FEV1% on IL-6 levels a polynomial model 
was used: FEV1 = β1 × [IL6]β2. The model coefficients were fitted using only baseline 
measurement using procnlin in SAS.
Each variable for the specific IgG measurements was tested for normal distribution 
using histogram plots, Q-Q plots and the Kolmogorov-Smirnov test. For the comparison 
of the IgG levels between patients and healthy controls the multiple testing problem 
was controlled by Bonferroni correction. Age and gender adjusted GLMM were used to 
analyse specific IgG-responses according to carrier status (yes/no), density (high/low) in 
sputa, SCV (ever/never) including a random effect for repeated measurement. q-values 
were Bonferroni–Holm adjusted p-values to control the FDR on the multiple significance 
level of 5%. IgG-levels were modelled as continuous factors. Odds ratios (OR) were inter-
preted as a factor, by which the risk for carriage/high-density/SCV was changed per 100 
units in antigen levels. For an association of IL-6 and FEV1% predicted with IgG-levels, 
estimates were interpreted as mean change in IL-6 per 1 unit in IgG-levels.
The local significance level for all performed tests was α = 0.05. 95%-confidence inter-
vals are given, where appropriate. Statistical tests are performed exploratory and can be 
interpreted as hypothesis generating. Statistical analysis was performed using SPSS (v. 
22, IBM) and SAS (v. 9.4, SAS Institute, Cary, NC).
resuLts
demographics and statistics
A total of 195 patients were recruited from 16 German centers and one CF center in 
Austria, which take care of 1980 CF patients. Thirteen of 195 patients r were excluded 
due to the chronic culture (> 6 months) of P. aeruginosa (n = 12) or BCC (n = 1) during the 
study period. Cystic fibrosis transmembrane regulator (CFTR) genotypes were reported 
for 173 of 195 patients, see Table 1. Patients with non-p.Phe508del CFTR genotypes (n = 
48; 27.7%) were overrepresented compared to the German CF patient population (Table 
1, p<0.0001). The median age of patients was 16 years (range 5.8 y– 42 y). A preponder-
ance of male to female subjects compared to the gender ratio of the German CF registry 
was reported (Table 1, p<0.001).
The mean number of all visits was seven (range 1–18). Clinical data of patients at 
baseline are shown and compared with national data concerning German CF patients in 
Table 1. Lung function decline was -1.2717 FEV1% predicted per years of age calculated 
for the study group at the first visit (CI -1.6676/-0.7235; p<0.0001).
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age-bacterial density association
For 98 patients at least one sputum (n = 446, range 1–14) was available for analysis, while 
for 97 patients only throat cultures (n = 663, range 1–11) were available. The age of patients 
at the time of the first positive S. aureus sputum culture was significantly associated with 
S. aureus density in sputa, indicating that older patients had significantly higher bacte-
rial loads in sputa compared to younger patients (p = 0.018). Patients with low bacterial 
density in sputa were on average 19.2 years of age, while patients with high bacterial loads 
were 22.2 years of age, respectively. There was no association between age and S. aureus 
density for patients with only throat (p = 0.7016) or nasal cultures (p = 0.411).
bacterial density and lung function
Bacterial density according to specimens is shown in Table 2. No significant association, 
adjusted for age and sex, was reported between S. aureus density and FEV1% predicted 
in neither patients with sputum (p = 0.5151) nor throat cultures (p = 0.185). There was 
also no association of FEV1% predicted with BMI-quantiles for both groups (p = 0.4352; 
p = 0.1007) neither at baseline nor during the study period.
However, bacterial density in throat specimens was significantly associated with 
annual lung function decline. Patients with high density lost 1.428% FEV1 per year com-
pared to patients with low density, Figure 1 (0.8626%FEV1; p<0.001 of the interaction 
of age and density). We could not observe similar associations with respect to bacterial 
density in sputum cultures and lung function decline (data not shown).
table 1. Characteristics of study patients compared to the German CF population.
Characteristics study patients1 German CF-patients p-value
number of patients 195 4456  
Age (years) 16 (5.8 - 42) 20 (6-70) <0.001
Male 120 (61%) 2121 (48%) <0.001 
Ex. panc. suff.2 22 (11%) 1426 (32%) <0.001
FEV1 (% predicted) 84.1 (13-121) 72.0 (10-145) <0.001
BMI-Quantils 25% (0.07%-100%) 27% (0.05%-100%)   0.007
Genotype3 173 3832  
F508del homo4 85 (49%) 1863 (49%) <0.001 
F508del hetero§§ 40 (23%) 1429 (37%)   
others 48 (28%) 540 (14%)   
1Age, FEV1, BMI and exacerbation numbers are reported as median (range), respectively. Exocrine pancreat-
ic sufficiency and genotype are reported as absolute frequencies (relative frequencies). We did not exclude 
one patient, who was 5.8 years at the first visit, but was 6.1 years at the second visit with seven reported 
visits throughout the study period, 2exocrine pancreatic sufficiency, 3Cftr genotype of patients available, 
4F508del homozygous, 5F508del heterozygous
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The Figs 1–5 show observed FEV1% predicted measurements over study time (days 
from first visit). Lines represent the LOESS-fit including 95% confidence intervals of the 
predicted values of the generalized linear mixed model.
table 2. Positive airway specimens according to S. aureus density
Specimens Low density <1x106CFU/ml
score 1, 21
High density ≥1x106CFU/ml
score ≥32
Sum
       
Nasal swabs 517 (68.7) 236 (31.3) 753
Nasal lavage 26 (76.5) 8 (23.5) 34
Throat swabs 545 (69.7) 237 (30.3) 782
Sputa 166 (42.1) 228 (57.9) 394
All 1254 (63.9) 709 (36.1) 1963
1low bacterial density of sputum (<1x106CFU/ml) and throat cultures (score 1 and 2)
2high bacterial density of sputum (≥1x106 CFU/ml) and throat cultures (score ≥3)
figure 1. Patients with throat cultures with high bacterial density experience a more rapid lung function 
decline.
Patients with high bacterial density in throat specimens are indicated by red squares (fitted model predic-
tion represented by dashed line), patients with low bacterial density in throat specimens by blue circles 
(solid line).
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Patients with exacerbations have worse lung function
Sixty of 195 patients (31%; 55% male) experienced exacerbations with a mean number 
of 0.384 exacerbations per patient (range 0, 4). The age distribution of patients with 
and without exacerbation did not differ significantly (assessed at baseline, p = 0.5182, 
S1 Table). Using a longitudinal multivariable model adjusted for age and sex our data 
showed that patients with exacerbations have worse lung function of 5.40% FEV1% 
predicted (95%CI 1.50 to 9.30 FEV1%) less compared to patients without exacerbations 
(p = 0.0068, Figure 2). Patients with exacerbations have a lung function decline per year 
of age of 1.22% FEV1% predicted (95%CI 0.94 to 1.50 FEV1%) compared to 0.88% FEV1% 
(95%CI 0.64 to 1.12 FEV1%) predicted in patients without exacerbations (p = 0.0018). 
Patients with exacerbations received more antibiotics than patients without exacerba-
tions (p = 0.037, OR = 1.175). For patients with exacerbations antibiotic treatment was 
reported at five visits (mean 4.3), while for patients without exacerbations at three visits 
(mean 3.43, p = 0.021), respectively.
figure 2. Patients with exacerbations have worse lung function.
Patients with exacerbation are indicated by red squares (fitted model prediction represented by dashed 
line), patients without exacerbation by blue circles (solid line).
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Patients with S. aureus nasal carriage
Since persistent nasal S. aureus carriers differ from non-carriers in terms of severe S. aureus 
infections [10], we determined the nasal carriage status of our study patients to analyze 
its impact on CF lung disease. CF patients with persistent nasal carriage (n = 122, 62.6%) 
were more likely male patients compared to patients without persistent nasal carriage (p = 
0.00075, S1 Table) and had significantly more nasal cultures with high bacterial loads (p = 
0.0255). S. aureus nasal carriers had better lung function throughout the study compared 
to non-carriers with a difference of 5.758 FEV1% predicted (95%CI 1.84 to 9.68; p = 0.0042; 
Figure 3). It is noteworthy that female nasal carriers experienced better lung function 
throughout the study period compared to male carriers (p = 0.0064, age-adjusted).
Patients with S. aureus scVs
To determine the impact of S. aureus SCVs on lung disease data were analyzed in rela-
tion to the culture of SCVs in airway specimens, which were cultured from 84 patients 
(43%) at least once. Patients with SCVs were significantly older (p = 0.0066), had lower 
FEV1% predicted at baseline (p = 0.0133) and during the study period (p = 0.0337, age 
and gender adjusted; lower lung function of 4.099 FEV1% predicted (95%CI 0.32 to 7.88 
figure 3. Patients with S. aureus nasal carriage have better lung function.
S. aureus nasal carriers are indicated by blue squares (fitted model prediction represented by solid line), 
non-nasal carriers by red circles (dashed line).
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FEV1%) compared to patients without SCVs (Figure 4). Within a multivariable model 
also including antibiotic treatment, the association of SCVs with worse lung function 
was still significant (p = 0.0433, lower lung function in patients with SCVs of 3.89 FEV1% 
predicted, 95%CI 0.12 to 7.66 FEV1%). In addition, patients with SCVs were more likely 
treated with trimethoprim/sulfamethoxazole (TMP/SMX) compared to patients without 
SCVs (p = 0.0078).
Patients with co-infecting pathogens
To assess the effect of co-infecting pathogens on lung function, we analyzed data of 
patients according to co-infection by important CF pathogens. Patients with S. malto-
philia (n = 44) were more likely female (p = 0.0078), less likely nasal S. aureus carriers (p = 
0.0003), more likely co-infected with SCVs (p<0.0001), experienced more exacerbations 
(p = 0.0165) and worse lung function of -3.72% FEV1% predicted throughout the study 
period (Figure 5, p = 0.0053, 95%CI -6.33 to -1.10). Patients with A. fumigatus (n = 60) 
were older (p<0.0001) and more likely co-infected by SCVs (p = 0.0001).
figure 4. Patients with SCVs have worse lung function.
Patients with SCVs are indicated by red squares (fitted model prediction represented by dashed line), pa-
tients without SCVs by blue circles (solid line).
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iL-6 levels
Since interleukin-6 levels have been shown to be helpful as a potential marker for sever-
ity of inflammation [14], we determined IL-6 in sera of the study patients. An inverse 
association between IL-6 levels and FEV1% predicted with worse lung function being 
associated with higher IL-6 at baseline (p<0.001, Figure 6). IL-6 levels were also associ-
ated with S. aureus density in sputa (p = 0.0016; difference of 0.6031 pg/ml in patients 
with high versus low S. aureus density), but not with bacterial density in throat or nasal 
cultures. Moreover, a significant increase in IL-6 levels in patients with exacerbations 
(p = 0.0411; difference of 0.2104 pg/ml), SCVs (p = 0.0209; difference 0.2287 pg/ml), S. 
maltophilia (p = 0.0195; difference 0.2622 pg/ml) or with A. fumigatus (p = 0.0496; 0.2256 
pg/ml) was documented. In addition, significantly more CF patients with high bacterial 
loads displayed elevated IL-6 levels above the upper normal limit of 12 pg/ml [14,23,24] 
compared to patients with sputa containing low bacterial loads (p = 0.0142).
figure 5. Patients with culture of S. maltophilia have worse lung function.
Patients with S. maltophilia are indicated by red squares (fitted model prediction represented by dashed 
line), patients without S. maltophilia by blue circles (solid line).
There was a strong association between FEV1% predicted and bacterial density and cumulative clinical 
symptoms according to Fuchs criteria [16] for patients who expectorated sputa (95 patients, max. 9 visits; p 
= 0.0661, S1 Fig), but not for patients with throat cultures (167 patients, max. 9 visits).
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humoral response towards S. aureus
Recently, the height of S. aureus toxin-specific IgG-levels has been associated with the 
presence of S. aureus in airway specimens of CF patients, the severity of exacerbations 
and with FEV1% predicted [25]. To expand on these results, we measured IgG-levels 
against 44 different virulence factors of S. aureus (Supplemental Materials) in single 
serum samples of 182 CF patients and included the results in our analysis. Furthermore, 
IgG-levels of patients were compared to those of 53 healthy adult volunteers with per-
sistent nasal S. aureus carriage. IgG-levels against 15 out of 44 analysed antigens were 
significantly higher in patients compared to controls (p<0.001, Table 3). It is noteworthy 
that IgG-levels against 22 virulence factors were significantly and positively associated 
with IL-6 levels in all CF patients and, in line with previous data, IgG-levels against 18 
virulence factors were significantly and inversely associated with FEV1% predicted (S2 
Table). A significant positive association between specific IgG-levels and nasal carriage, 
presence of SCVs and exacerbations for respectively 14, 16 and 7 antigens (S2 Table) 
was reported. Finally, no significant differences were found in IgG-levels of patients 
expectorating sputum with high and low bacterial loads (S2 Table).
figure 6. Higher IL-6 is associated with lower FEV1% predicted.
Scatterplot of baseline measurements (n = 88) of all patients with blood samples provided at the first visit. 
The fit line shows the results of a non-linear regression model. Dark shaded areas show 95% confidence 
band, lighter shaded area shows 95% prediction band.
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discussion
Using a generalized linear mixed model our data only seem to support our main hy-
pothesis stating that S. aureus density has an impact on lung function for patients who 
provided throat swabs since we could show that patients with higher bacterial density 
in throat cultures experienced a steeper lung function decline compared to patients 
with low bacterial density in these airway specimens (Figure 1). However, a closer look 
at our data showed that this effect was mostly carried by older patients, who provided 
throat cultures. The effect was lost, if only the group of patients younger than 20 years 
was analyzed, which is why these results should be interpreted carefully. Yet a trend 
of worse lung function of patients with high S. aureus density in sputa compared to 
patients with low S. aureus density was observed during the study period if cumulative 
clinical symptoms according to Fuchs were included in the linear mixed model analysis 
(p = 0.0661, S1 Fig).
With our inclusion and exclusion criteria a subgroup of patients was selected that dif-
fered from the German CF population by a preponderance of male patients (61.5%) and 
table 3. Significant specific IgG levels against S. aureus antigens in CF patients compared to healthy con-
trols.
Antigen Mean IgG level 
patients (± SE)1
Mean IgG level 
controls (± SE)1
p value2,5 Correlation coefficient of 
IgG and IL-6 levels3
p value4,||
Efb 4605 (±210) 2089 (±208) < 0.0001 0.010 0.840
Glucosaminidase 14992 (±250) 11567 (±571) < 0.0001 0.147 0.002
HlgB 13621 (±174) 9878 (±407) < 0.0001 0.061 0.197
IsaA 13288 (±413) 10479 (±678) 0.0009 0.207 < 0.0001
IsdA 10701 (±250) 7638 (±429) < 0.0001 0.304 < 0.0001
LukD 14176 (±248) 11485 (±464) < 0.0001 0.14 0.003
LukE 14272 (±238) 11720 (±474) < 0.0001 0.169 < 0.0001
LukF 4079 (±121) 2718 (±243) < 0.0001 0.169 < 0.0001
LukS 14097 (±239) 7134 (±524) < 0.0001 0.206 < 0.0001
LytM 6576 (±308) 3555 (±380) 0.0001 0.27 < 0.0001
Nuc 14405 (±271) 4752 (±493) < 0.0001 0.0837 0.0795
SA0688 3063 (±259) 760 (±116) < 0.0001 0.355 < 0.0001
SSL5 2589 (±128) 1616 (±111) < 0.0001 -0.020 0.669
SSL9 8910 (±194) 7568 (±306) 0.0009 0.079 0.098
Wall teichoic acid 2491 (±124) 319 (±117) < 0.0001 0.109 0.025
1Average IgG levels are given in mean fluorescence activity (MFI).
2p-values of difference between 182 patients and 53 healthy controls (Mann-Whitney U test)
3Spearman’s rank correlation coefficients were calculated for IgG- and IL-6 levels in all patients.
4p-values of correlation between IgG and IL-6
5adjusted p-values (Bonferroni correction)
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overrepresentation of non-p.Phe508del CFTR genotypes (27.7%). The fact that our study 
patients experienced a mean lung function decline of -1.2717 FEV1% predicted per years 
of age are consistent with German registry data that carriers of non-F508del genotypes 
become later in life colonized with P. aeruginosa than F508del compound heterozygotes 
and homozygotes and experience a milder course of the disease[26]. Nevertheless, our 
study patients still fit into the general CF-population with a lung function decline of 1 
to 3 FEV1% points per year as previously described [27,28] and do therefore not differ in 
terms of severity of the clinical disease.
Recently, in a retrospective single center study Ahlgren et al. compared CF patients, 
who were colonized with S. aureus or P. aeruginosa only, or neither of these pathogens 
[29]. In their study, which also included more male patients (n = 55%), 24% of 84 patients 
were colonized by S. aureus [29]. In conjunction with our data this may suggest that 
male patients are more likely colonized by S. aureus only and are more likely resistant to 
colonization or infection caused by P. aeruginosa.
Several studies have shown that persistent nasal S. aureus carriers are at increased risk 
for severe S. aureus infections, but have a survival advantage during sepsis [13]. We thus 
determined the impact of nasal S. aureus carriage in CF patients on disease progression. 
Nasal carriage was higher than in other studies assessing nasal carriage as a risk factor 
for S. aureus infection [30,31] both in healthy persons [32] and in CF patients [11], but 
comparable to the study of Goerke et al. [11,12]. This is most likely attributable to the 
pre-selection on the basis of our inclusion criteria with the requirement of S. aureus 
persistence in patients’ airways.
During the study period the number of patients experiencing at least one pulmonary 
exacerbation was somewhat lower in our study compared to the study by Sanders et al. 
(31% versus 40%), who determined the association of frequency of exacerbations and 
subsequent lung function decline in more than 8.000 CF patients retrospectively [33]. 
This observation is most likely due to the fact that we excluded patients with chronic 
P. aeruginosa infection who have been shown to experience a more severe course of 
disease [34].
Our data thus clearly show that the culture of SCVs was independent of P. aeruginosa 
co-infection, but associated with advanced age, lower lung function and treatment 
with TMP/SMX at both base line and during the study period. Recently, Wolter et al. 
showed that the recovery of SCVs in airway specimens is independently associated with 
worse lung function in children [35]. Further studies also indicate that the detection of 
S. aureus SCVs was associated with persistence of S. aureus in airway specimens [19], 
advanced age [36], worse lung function [35–37] and co-infection with P. aeruginosa 
[35,36]. However, in our study we ruled out any impact of P. aeruginosa by excluding 
patients with persistent P. aeruginosa infection. In future analyses, it will be investigated 
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if special geno- or phenotypes of S. aureus have an impact on the clinical status of the 
patients.
In our study, patients co-infected by S. maltophilia differed from patients without S. 
maltophilia. They were most likely female, not S. aureus nasal carriers, co-infected with 
S. aureus SCVs and experienced more exacerbations. While Goss et al. [38] did not find 
any impact of S. maltophilia on lung function, Waters et al. have recently shown that 
S. maltophilia represented an independent risk factor for pulmonary exacerbations 
[39], when patients were persistently colonized with S. maltophilia. Although we did 
not distinguish between S. maltophilia cultured once or persistently, co-infection by S. 
maltophilia clearly had a negative impact on the clinical status of our patients.
Also, patients co-infected by A. fumigatus significantly differed from patients without 
A. fumigatus with respect to age and prevalence of SCVs. Surprisingly, patients with 
A. fumigatus exhibited a better lung function (data not shown) compared to patients 
without the fungus. This is in contrast to the results reported by Amin et al. [40] showing 
worse lung function for 37 out of 230 CF patients with persistent A. fumigatus infection. 
This discrepancy may be due to the fact that we did not distinguish between intermit-
tent and chronic infection. It may also be explained by a sampling effect as we primarily 
cultured A. fumigatus from a small number of mostly A. fumigatus-positive older patients.
Recently, Horsley et al. documented IL-6 as a key biomarker of inflammation in CF 
patients with exacerbations [14]. We found that IL-6 levels were significantly correlated 
with S. aureus density in sputa, and with the presence of exacerbations, SCVs, S. malto-
philia or A. fumigatus. Thus, these results suggest that IL-6 is a highly sensitive marker for 
lung disease. IL-6 may potentially be used to identify patients, which might benefit from 
initiation of antibiotic therapy.
CF patients mounted higher IgG-levels against numerous virulence factors of S. aureus 
compared to healthy controls. Such an immune response against S. aureus is compa-
rable to those of patients that exhibited S. aureus bacteremia or osteomyelitis [20]. The 
fact that the adaptive immune system produces specific antibodies against S. aureus 
underlines that persistently colonized CF patients are immunologically challenged by S. 
aureus although these specific antibodies cannot resolve S. aureus persistence. While no 
significant association between bacterial density in airway specimens of CF patients and 
IgG-levels was reported, we found a significant association of many specific IgG-values 
with IL-6-levels, worse lung function, nasal carriage and the culture of SCVs. The latter 
confirms and expands on another recent study that demonstrated a significant inverse 
association between S. aureus toxin-specific IgG-levels and lung function in CF patients 
[25]. In contrast to our results, this previous study also showed a significant association 
between the culture of S. aureus in airway specimens and IgG-levels, albeit bacterial 
density was not quantified as it was done in our study.
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There are several limitations to our study. First, our inclusion and exclusion criteria 
selected a sub-group of CF patients, which do not reflect the entire CF population. 
However, lung function data of our patients were comparable to other studies [27,41]. 
Our data should thus provide meaningful results for the general CF population. Second, 
our selected patient group did experience somewhat less exacerbations compared to 
groups with P. aeruginosa infection, which makes it more difficult to detect significant 
clinical differences between groups using exacerbation as an outcome measure. Third, 
the technique of obtaining throat swabs in the different centres by different nurses or 
physicians could have influenced the microbiological results of the throat swab cultures. 
Fourth, it seems that our study was underpowered to show significant results for the 
association between S. aureus density and worse lung function of patients, who were 
able to expectorate sputum. Since S. aureus is the most prevalent CF-related pathogen 
in children, we included patients in our study who were not able to expectorate sputum. 
We hypothesized that the determination of bacterial densities would be of equal value 
for throat swabs and sputa. Our patient number calculation was based on this hypoth-
esis. However, there was no association between bacterial density and lung function for 
patients with throat swabs, but a trend for patients with high bacterial density in sputa if 
cumulative clinical symptoms for exacerbation were included in the analysis (P = 0.0661, 
S1 Fig).
To conclude, our results suggest that the presence of exacerbations, non-nasal S. au-
reus carriage, female gender, the presence of S. aureus SCVs, co-infection with S. malto-
philia or specific anti-staphylococcal IgG- and IL-6 levels are independent risk factors 
for worse lung function in CF patients with persistent S. aureus infection. Our findings 
may help to identify S. aureus patients at risk for more severe airway infections resulting 
in worse lung function and will be of value for designing future prospective studies to 
guide antibiotic therapy in patients chronically infected with S. aureus.
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suPPLementaL data
 
figure s1. FEV1% predicted over study time by sputum density.
The fi gure shows observed FEV1% predicted measurements over study time (days from fi rst visit). Lines 
represent the LOESS-fi t including 95% confi dence intervals of the predicted values of the generalized linear 
mixed model. Patients with high bacterial density in sputum are indicated by red squares, patients with 
low bacterial density in sputum are indicated by blue circles. The fi tted model prediction is coloured ac-
cordingly.
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table s1. Clinical characteristics of patients at baseline: incidence of Stenotrophomonas and Aspergillus.
Characteristics With S. 
maltophilia
Without S. 
maltophilia
p-value With A. 
fumigatus
Without A. 
fumigatus
p-value
# of patients 44 151   60 (31%) 135 (69%)  
Age (years) 15.78 13.51 0.0847‡ 18.10 12.85 <0.0001‡
  (7.33-36.37) (5.82-41.58)   (8.99-41.58) (5.82-40.70)  
Male 20 (45.45%) 100 (66.23%) 0.0127§ 34 (56.67%) 86 (63.7%) 0.3512§
Ex. panc.suff. 2 (4.55%) 20 (13.61%) 0.0986§ 7 (11.86%) 15 (11.36) 0.9202§
FEV1 80.05 85.89 0.2071‡ 80.41 85.60 0.2698‡
(% predicted) (38.96-120.57) (13.18-118.05) (37.56-120.57) (13.18-118.05)
BMI-Quantils 23% 25% 0.8861‡ 23% 27% 0.2332‡
(5%-92%) (0.068%-100%) (1%-97%) (0.068%-100%)
Genotype 171     171    
F508del homo 20 (52.63%) 64 (48.12%) 0.8861§ 26 (49.06%) 58 (49.15%) 0.9988§
F508del hetero 8 (21.05%) 31 (23.31%)   12 (22.64%) 27 (22.88%)  
others 10 (26.32%) 38 (28.57%)   15 (28.3%) 33 (27.97%)  
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table s2. Staphylococcal specific IgG-levels according to the different patient groups.
Antigen Mean IgG level 
patients (± SE)1
Mean IgG level 
controls (± SE)1
p value2,3 Mean IgG level 
high bacterial 
density (± SE)4
Mean IgG level 
low bacterial 
density (± SE)5
p 
value2, 3
Alpha toxin 14405 (±271) 13902 (±511) 0.2653 14430 (±345) 14493 (±282) 0.8085
CHIPS 11492 (±220) 11019 (±349) 0.104 11546 (±319) 11617 (±254) 0.6691
ClfA 5168 (±237) 4302 (±436) 0.081 5617 (±322) 5222 (±262) 0.3415
ClfB 4587 (±222) 4092 (±338) 0.3809 5221 (±321) 4562 (±214) 0.2075
Efb 4605 (±210) 2089 (±207) < 0.0001 4610 (±290) 4698 (±236) 0.6336
ETA 3999 (±447) 2043 (±424) 0.1180 3868 (±532) 3884 (±421) 0.7338
ETB 613 (±113) 320 (±94) 0.0032 532 (±135) 341 (±48) 0.7725
FlipR 5708 (±251) 4834 (±400) 0.0784 6203 (±333) 5487 (±277) 0.0931
FnbpA 2922 (±201) 2534 (±300) 0.6167 3116 (±252) 2979 (±194) 0.1881
FnbpB 967 (±79) 1327 (±215) 0.1306 1286 (±144) 1036 (±71) 0.2802
Glucosaminidase 14992 (±250) 11567 (±571) < 0.0001 15507 (±308) 15174 (±256) 0.2996
HlgB 13621 (±174) 9878 (±407) < 0.0001 13705 (±235) 13624 (±206) 0.7169
IsaA 13288 (±413) 10479 (±678) 0.0009 13963 (±595) 12654 (±466) 0.0524
IsdA 10701 (±250) 7638 (±428) < 0.0001 11133 (±283) 10871 (±283) 0.0732
IsdH 3220 (±238) 3643 (±380) 0.0910 3281 (±296) 2816 (±207) 0.0981
Lipase 9979 (±317) 8237 (±629) 0.0104 10318 (±439) 9266 (±361) 0.0761
LukD 14176 (±248) 11485 (±463) < 0.0001 14598 (±314) 13916 (±292) 0.0789
LukE 14272 (±238) 11720 (±473) < 0.0001 14752 (±305) 13998 (±287) 0.0819
LukF 4079 (±133) 2718 (±243) < 0.0001 4526 (±200) 4144 (±147) 0.0892
LukS 14097 (±133) 7134 (±524) < 0.0001 11068 (±396) 10586 (±295) 0.1873
LytM 6576 (±367) 3555 (±380) 0.0001 7059 (±492) 6248 (±382) 0.0542
Nuc 14405 (±271) 4752 (±492) < 0.0001 10852 (±503) 9881 (±394) 0.0707
SA0486 446 (±26) 341 (±42) 0.0397 450 (±43) 488 (±41) 0.5357
SA0688 3063 (±259) 759 (±116) < 0.0001 3449 (±346) 3177 (±220) 0.1731
SasG 569 (±70) 636 (±132) 0.1847 623 (±95) 388 (±50) 0.1852
SCIN 10872 (±247) 9657 (±388) 0.0043 11226 (±321) 10470 (±277) 0.0655
SdrD 1084 (±80) 694 (±76) 0.0507 1108 (±105) 937 (±65) 0.2933
SdrE 3139 (±201) 1992 (±221) 0.0253 3513 (±275) 3351 (±199) 0.2916
SEA 3835 (±320) 3613 (±425) 0.2544 4398 (±437) 3539 (±321) 0.1111
SEC 7390 (±441) 8714 (±809) 0.1350 6901 (±581) 6878 (±473) 0.9446
SED 1106 (±118) 1292 (±268) 0.0498 1150 (±153) 1115 (±135) 0.1178
SEE 1333 (±183) 879 (±136) 0.8113 1416 (±214) 1039 (±142) 0.1334
SEG 2047 (±184) 1225 (±270) 0.0544 1941 (±190) 1790 (±190) 0.4405
SEH 2290 (±291) 2174 (±359) 0.0113 2128 (±382) 1950 (±281) 0.9851
SEO 368 (±40) 400 (±51) 0.0266 476 (±79) 394 (±48) 0.5521
SER 1548 (±243) 2001 (±580) 0.3882 1755 (±377) 1436 (±264) 0.2225
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Estimated 
effect 
on IL-6 
levels6
p value3 Estimated 
effect on 
FEV1%7
p value3 OR nasal 
carrier 
status9
p 
value3
OR SCV 
presence9
p 
value3
OR 
exacerbation10
p value3
-1.33E-6 0,9226 -0,00013 0,6506 1,010 0,0008 0,996 0,2112 0,995 0,0993
0,000019 0,2173 -0,00073 0,0185 1,003 0,4282 1,000 0,9999 1,002 0,4990
-0,00002 0,1179 0,000514 0,1104 1,009 0,0174 1,011 0,0011 1,001 0,6727
3.208E-6 0,8616 0,002079 <.0001 1,005 0,2808 0,995 0,2333 0,995 0,2456
0,000034 0,0650 -0,00071 0,0531 0,995 0,2490 1,001 0,7260 1,000 0,9118
0,000026 0,0173 -0,00061 0,0033 1,004 0,0741 1,000 0,9101 1,001 0,7047
0,000161 0,0014 -0,00700 <.0001 1,032 0,0743 1,014 0,2320 1,002 0,8706
0,000020 0,2025 -0,00040 0,1852 1,009 0,0149 0,999 0,8526 0,998 0,5126
0,000031 0,1775 0,000222 0,6310 1,010 0,0723 1,010 0,0723 1,014 0,0060
0,000053 0,3988 -0,00199 0,1150 0,991 0,5160 1,010 0,4724 0,964 0,0216
0,000061 <.0001 -0,00090 0,0014 1,003 0,3082 1,010 0,0047 1,004 0,2303
0,000063 0,0027 -0,00109 0,0088 1,003 0,4992 1,010 0,0290 1,003 0,5584
0,000032 0,0003 -0,00064 0,0002 1,004 0,0300 1,001 0,6861 1,002 0,2518
0,000085 <.0001 -0,00152 <.0001 1,010 0,0028 1,009 0,0083 1,000 0,9086
0,000063 0,0010 -0,00039 0,3074 0,998 0,7124 1,003 0,4299 1,002 0,6094
0,000032 0,0055 -0,00025 0,2749 1,002 0,5068 1,003 0,2340 1,003 0,2450
0,000052 0,0003 -0,00128 <.0001 1,003 0,4125 1,008 0,0195 1,001 0,7464
0,000067 <.0001 -0,00136 <.0001 1,000 0,9943 1,012 0,0012 1,007 0,0323
0,000100 0,0002 -0,00305 <.0001 0,998 0,7741 1,003 0,5710 1,013 0,0254
0,000064 <.0001 -0,00169 <.0001 0,995 0,0700 1,009 0,0015 1,004 0,1382
0,000054 <.0001 -0,00069 0,0014 0,999 0,7773 1,007 0,0030 1,005 0,0361
0,000022 0,0242 -0,00021 0,2689 1,007 0,0011 1,004 0,0409 0,997 0,1049
4.081E-6 0,9519 0,000285 0,8300 0,971 0,1795 0,995 0,7294 1,004 0,7859
0,000113 <.0001 -0,00217 <.0001 1,000 0,9754 1,008 0,0314 1,007 0,0570
0,000016 0,7673 0,001484 0,1590 1,002 0,8445 1,049 0,0157 1,006 0,5492
0,000039 0,0060 -0,00063 0,0241 1,009 0,0032 1,006 0,0684 0,995 0,1129
0,000138 0,0160 -0,00145 0,1950 0,973 0,0260 1,029 0,0232 0,985 0,2246
0,000068 0,0010 -0,00179 <.0001 1,003 0,4736 1,013 0,0059 1,000 0,9768
-0,00001 0,3454 -0,00007 0,7599 1,005 0,1021 1,004 0,0935 0,997 0,2508
-9.9E-6 0,2951 0,000269 0,1366 1,000 0,9743 1,000 0,9411 0,999 0,6049
0,000018 0,6231 0,001490 0,0377 1,010 0,2704 0,998 0,7832 0,999 0,8861
-6.43E-7 0,9820 -0,00057 0,2779 1,014 0,0608 1,015 0,0193 0,997 0,6557
0,000091 0,0005 -0,00108 0,0264 1,029 0,0003 1,005 0,3829 0,998 0,7464
-0,00001 0,3834 -0,00047 0,0986 0,991 0,0039 1,009 0,0071 1,007 0,0249
0,000185 0,0452 0,001048 0,5874 1,094 0,0135 0,991 0,6676 0,944 0,0436
0,000024 0,2410 0,000166 0,6522 1,007 0,1954 0,999 0,7642 1,007 0,0955
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table s2. Staphylococcal specific IgG-levels according to the different patient groups. (continued)
Antigen Mean IgG level 
patients (± SE)1
Mean IgG level 
controls (± SE)1
p value2,3 Mean IgG level 
high bacterial 
density (± SE)4
Mean IgG level 
low bacterial 
density (± SE)5
p 
value2, 3
SSL1 6856 (±410) 5684 (±683) 0.2735 7623 (±542) 6359 (±424) 0.0571
SSL3 5561 (±216) 5123 (±313) 0.4604 5737 (±285) 5621 (±245) 0.5586
SSL5 2589 (±128) 1616 (±111) < 0.0001 2639 (±170) 2575 (±139) 0.8226
SSL9 8910 (±194) 7568 (±305) 0.0009 9114 (±252) 8917 (±235) 0.5563
SSL10 8754 (±306) 9870 (±552) 0.0869 9107 (±420) 8520 (±336) 0.2516
SSL11 3127 (±255) 2698 (±347) 0.8779 3310 (±334) 2969 (±267) 0.0839
TSST1 7981 (±487) 9076 (±646) 0.499 7585 (±634) 7602 (±545) 0.6607
Wall teichoic 
acid
2491 (±124) 319 (±16) < 0.0001 2182 (±119) 2038 (±119) 0.2623
1 Mean fluorescence intensity (MFI) of IgG levels are shown. MFI values between 182 patients and 53 
healthy controls are compared.
2p values of difference between patient and controls groups (Mann-Whitney U test)
3adjusted p-values (Bonferroni correction)
4Mean IgG levels of 228 cases expectorating sputum with high bacterial density
5Mean IgG levels of 166 cases expectorating sputum with low bacterial density
6IgG levels are modelled as continuous factors. Estimated effects are interpreted as mean change in IL6 per 
1 unit of IgG levels. Significant effects are marked bold.
7IgG levels are modelled as continuous factors. Estimated effects are therefore interpreted as mean change 
in FEV1% predicted per 1 unit of IgG levels. Significant effects are marked bold.
8Odds ratios (OR) are interpreted as factor by which the risk to be a nasal carrier is changed per 100 units 
of IgG levels. Significant OR are marked bold.
9Odds ratios (OR) are interpreted as factor by which the risk to ever be SCV positive is changed per 100 
units of IgG levels. Significant OR are marked bold.
10Odds ratios (OR) are interpreted as factor by which the risk to ever experience an exacerbation is changed 
per 100 units of IgG levels. Significant OR are marked bold.
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5
Estimated 
effect 
on IL-6 
levels6
p value3 Estimated 
effect on 
FEV1%7
p value3 OR nasal 
carrier 
status9
p 
value3
OR SCV 
presence9
p 
value3
OR 
exacerbation10
p value3
0,000021 0,0277 -0,00029 0,1199 1,009 0,0002 1,001 0,7920 1,002 0,2828
3.401E-6 0,8398 -0,00051 0,1235 0,996 0,2676 0,995 0,1844 0,988 0,0017
0,000023 0,4368 -0,00015 0,7957 1,013 0,0480 0,981 0,0052 0,997 0,5820
0,000034 0,0620 0,000681 0,0570 1,002 0,5567 1,000 0,9684 0,997 0,3912
0,000020 0,1071 0,000239 0,3165 0,999 0,6832 0,996 0,1613 1,000 0,9705
3.79E-6 0,8488 -0,00154 0,0001 1,006 0,2167 0,994 0,1617 0,992 0,0788
-7.19E-6 0,3762 0,000148 0,3554 1,004 0,0283 0,999 0,4654 0,998 0,1558
0,000070 0,0147 -0,00228 <.0001 1,008 0,2084 1,006 0,3328 1,012 0,0588
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abstract
The Fibronectin binding protein A (FnBPA) is a cell-surface associated protein of 
Staphylococcus aureus which mediates adherence to the host extracellular matrix and is 
important for bacterial virulence. Previously, substantial sequence diversity was found 
among strains in the fibrinogen-binding A domain of this protein and 7 different iso-
types were described. In this study we identify five different FnbpA A domain isotypes 
in 22 clinical S. aureus isolates, obtained from the same number of patients suffering 
from bacteraemia. Using a bead-based Luminex technique, we establish the presence 
of total IgG directed against the 7 previously described FnbpA isotypes in all patients at 
the onset and during the subsequent time course of bacteremia (median of 10 serum 
samples per patient over a median of 35 days). A significant increase in IgG against the 
FnbpA A domain, including the isotype carried by the infecting strain, is observed in 
only three out of 22 patients (14%) after the onset of bacteremia. Using a Luminex-based 
FnBPA-fibrinogen binding assay we find that pre-incubation of recombinant FnBPA iso-
types with IgG from diverse patients does not interfere with binding to fibrinogen. This 
observation is confirmed using an alternative Luminex-based assay and ELISA.
importance: Despite the many in vitro and murine in vivo studies examining the role 
of FnBPA, the actual presence of this virulence factor during infection in humans is less 
established. Furthermore, it is currently unknown to what extent sequence variation in 
virulence factors such as FnBPA affects the human antibody response and the ability of 
antibodies to interfere with FnBPA function. In this study we establish the ubiquitous 
presence of human IgG against FnBPA, indicating the importance of this virulence 
factor during S. aureus pathogenesis. Despite this ubiquitous presence of IgG, we find 
that most patients do not normally mount a significantly increased antibody response 
against FnBPA after the onset of bacteraemia, indicating lack of expression and/ or im-
mune evasion by FnBPA during this infection. Finally, human antibodies do not interfere 
with FnBPA-fibrinogen binding. These observations should be taken into account during 
the development of novel vaccination approaches.
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6
introduction
Staphylococcus aureus (S. aureus) can both colonize human squamous epithelial surfaces 
[1, 2] and cause infections that are associated with significant morbidity and mortality, 
including bacteraemia [3-5]. The success of S. aureus to colonize and infect its human 
host is attributed to many virulence factors, including surface proteins such as the 
fibronectin-binding protein A (FnBPA) [6]. This protein is encoded by the fnbA gene [7, 
8] and is expressed by most strains of S. aureus [9]. FnBPA has been shown to contribute 
to disease in diverse animal models of infection diseases [10-12] and it has several 
functions. FnBPA promotes binding to fibrinogen, elastin and fibronectin [13-15] and it 
mediates both adhesion to and invasion of endothelial and epithelial cells [16, 17]. The 
protein also promotes biofilm formation [18, 19]. These latter functions of FnBPA are 
considered to help S. aureus in evading antibiotics and the host immune response [16, 
17, 20].
The many functions of FnBPA have made it a potentially interesting target for vaccina-
tion approaches against S. aureus. However, although FnBPA has been successfully used 
as a vaccine target in animal models [17, 21, 22], so far this has not led to a valid vaccine 
in humans. Several factors might contribute to this failure, such as the (lack of ) presence 
of FnBPA during invasive infection, which, despite the plethora of studies examining 
the role of FnBPA in vitro and in animal models in vivo, has been less established in vivo 
in humans. Another factor might involve the substantial sequence diversity found in 
the fibrinogen binding A domain of FnBPA [23], with seven different protein variants 
(isotypes) sharing only 66 to 76% amino acid identity identified so far [24, 25]. Although 
all these isotypes bind fibrinogen with similar affinity, murine monoclonal antibodies 
raised against different isotypes exhibit only limited cross reactivity [25]. The effect of 
this sequence diversity on the human antibody response against FnBPA remains unclear 
and has not been taken into account in previous vaccination studies, including both 
animal models and clinical trials, nor in in our previous studies characterizing patient an-
tibody responses [26-28]. Yet if such sequence diversity in FnBPA among clinical strains 
of S. aureus is present and would affect the human antibody response, this should be 
taken into account during the development of future vaccines.
It is currently also unknown whether natural antibodies against FnBPA, produced in 
patients after the onset of infection, can interfere with the binding between FnBPA and 
fibrinogen. Interestingly, it was previously shown that IgG obtained from patients with 
S. aureus infections did not interfere with the binding between fibronectin and recom-
binant FnBPA fragments or whole S. aureus cells, respectively [29]. On the other hand, 
rabbit monoclonal antibodies against S. aureus FnBP fragments did inhibit fibronectin 
binding [30], and rabbit polyclonal antibodies raised against clumping factor B, another 
surface protein of S. aureus mediating bacterial adherence, also blocked binding to 
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fibrinogen [31]. Thus, the ability of naturally occurring antibodies to block the binding 
between S. aureus and constituents of the extracellular matrix remains uncertain.
The aims of this study were to further characterize sequence diversity in the A do-
main of FnBPA among 22 clinical strains isolated from the blood of the same number 
of patients suffering from bacteraemia, to characterize the antibody responses against 
different isotypes in each patient, and to ascertain the ability of human antibodies to 
interfere with binding between FnBPA and fibrinogen.
resuLts
Variation of the fnbPa a domain in clinical S. aureus isolates
We determined the prevalence of the seven known isotypes (I-VII) of the FnBPA A domain 
[24, 25] among twenty-two S. aureus strains isolated from the blood of patients suffer-
ing from bacteremia. The FnBPA A domain of each strain was sequenced and genomic 
sequences were compared together with those of previously described reference strains 
for each isotype.
Five isotypes were found among the twenty-two isolates: five strains encoded isotype 
I (92.7 to 100% amino acid (AA) identity to reference strain 382), five strains isotype II 
(96 to 100% AA identity to reference strain 3011), five strains isotype III (97.1 to 97.4% 
AA identity to reference strain 182) and six strains encoded isotype IV (91.9 to 97.1% AA 
identity to reference strain P1). One strain encoded isotype V (97.5% AA identity to refer-
ence strain 3110). The genetic relationships of the fnbA A domain of all strains, including 
the reference strains, is summarized in figure 1. Strains with the same fnbA isotype also 
shared similar spa types, while the single strain encoding isotype V had spa type t8930.
Since the isotype of the FnBPA A domain is primarily determined by the highly 
divergent N2N3 subdomains [25], recombinant proteins of these subdomains were ex-
pressed for each isotype. These proteins were covalently coupled to color-coded beads 
in a Luminex set-up, allowing the simultaneous quantification of different antibodies 
directly in serum samples to characterize patient antibody responses against these vari-
able subdomains.
characterization of igG response against fnbPa isotypes in bacteremia 
patients
Total IgG levels against all seven FnBPA A domain isotypes were prospectively measured 
in serum samples from patients after the onset of bacteremia (median of 10 serum 
samples per patient over a median of 35 days). Although patients were infected with a 
strain carrying one particular isotype, we observed that total IgG from all patients de-
tectably bound all seven isotypes (Figure 2). However, the height of IgG levels, especially 
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against the more common isotypes I to IV and isotype V, varied considerably between 
patients (Figure 3). This is in line with the heterogeneity observed previously in patient 
antibody responses after the onset of infection by our and other groups [26, 27, 32, 33].
In 18 out of 22 patients, the IgG levels directed against all isotypes did not signifi cantly 
change after the onset of bacteremia (Figure 2A, Table S1) and we could not identify 
a specifi c increase in IgG against the isotype carried by the infecting strain. IgG levels 
against FnBPA did increase in the remaining four patients after the onset of bacteremia 
(patients 4, 15, 17 and 20; Table S1), with a signifi cant 10-fold or higher increase observed 
in three patients (patients 4, 15 and 17). Interestingly, in two out of these latter patients 
(patients 4 and 15), predominantly IgG levels against the isotype of the infecting strain 
increased (fi gure 2B). In the third patient (patient 17), a concomitant, comparable in-
crease in IgG levels against multiple FnBPA isotypes was observed (Table S1).
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14  t012 
5    t021 
II    (strain 3011) 
1    t209 
11  t2094 
7     t179 
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I      (strain 382) 
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20  15  10   5   0 
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figure 1. Genetic relationships of fnbA A domain between strains.
fnbA gene segments encoding the entire FnBPA A domain were sequenced from 22 clinical isolates. Num-
bers indicate patient number, followed by the Spa type of each strain. Sequences were aligned together 
with those of reference strains for the fnbA isotypes I to VII.
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fnbPa isotypes bind human fibrinogen
To ascertain the ability of human antibodies, purified from the patients described above, 
to interfere with binding between FnBPA and fibrinogen, we developed a Luminex-
based FnBPA-fibrinogen binding assay. After covalently coupling recombinant FnBPA 
isotype proteins to beads, we confirmed that all seven isotypes were able to bind R-PE 
labeled human fibrinogen in a dose-dependent and saturable manner (Supplementary 
figure 1A). This binding was further confirmed by a competition assay using R-PE labeled 
and unlabeled fibrinogen, showing that the amount of bound PE-labeled fibrinogen 
decreased at increasing concentrations of unlabeled fibrinogen (Supplementary figure 
1B). Specific binding of fibrinogen by the FnBPA isotypes was confirmed by the lack of 
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figure 2. Course of IgG levels against FnBPA isotypes following bacteremia.
a: representative course of IgG levels against 7 FnBPA isotypes (I to VII) following the onset of bacteremia 
(day 0, defined as the day of the first blood culture positive for S. aureus) in patient 1, infected with a strain 
carrying isotype II. b: same plot for patient 15, infected with a strain carrying isotype V. Data points repre-
sent the mean of two separate measurements per serum sample.
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figure 3. Variation in peak IgG levels against FnBPA isotypes after the onset of bacteremia.
Scatter plot showing the distribution of peak IgG levels against all 7 FnbPA isotypes (I to VII) in 22 patients 
suffering from bacteremia. Each point represents one patient and horizontal lines represent the median 
and interquartile ranges, respectively.
157
Human antibody response against FnBPA
6
fibrinogen binding observed for the SD-repeat containing protein E (SdrE) and iron-
responsive surface determinant A (IsdA), which have low to no affinity for fibrinogen, 
respectively [34].
human igG does not inhibit binding between fnbPa isotypes and fibrinogen
Next, we investigated if purified IgG, isolated from bacteremia patients, could interfere 
with the binding between the FnBPA isotypes and fibrinogen. We confirmed that total 
IgG purified from five different patients, each infected with a strain carrying a differ-
ent FnBPA isotype, and from polyclonal human IgG (PHG) obtained from non-infected 
volunteers, bound FnBPA isotypes I to V in a specific and dose-dependent manner 
(supplementary figure 2A and B). Human IgG did not noteworthy bind to fibrinogen 
(data not shown).
After pre-incubation of FnBPA isotypes I to V with the IgG from either PHG or patients, 
resulting FnBPA-bound IgG was allowed to bind PE-labeled fibrinogen. Based on 
results as shown in Supplementary figure 1A we chose a standard concentration of 1 
μg PE-labeled fibrinogen per reaction. Pre-incubation of FnBPA isotypes I to V with IgG 
from neither PHG nor patients interfered with the binding of this protein to PE-labeled 
fibrinogen, regardless of the IgG dilution (Figure 4A and B). The amount of fibrinogen 
bound by the isotypes after pre-incubation with IgG dilutions did not significantly differ 
compared to controls without pre-incubation with IgG (one-way ANOVA, significance 
level of P ≤ 0.05). Varying the starting concentration of fibrinogen did not affect these 
results, nor did simultaneous incubation of fibrinogen, IgG and FnBPA isotypes (data not 
shown).
To rule out the possibility that the coupling of FnBPA isotypes to the xMAP® beads 
could somehow affect protein structure and thereby alter binding sites for IgG, which 
could alternatively explain the lack of interference by IgG as described above, we per-
formed two alternative assays. In the first Luminex-based assay, fibrinogen coupled to 
beads was incubated with PE-labeled, free recombinant isotype II and III. We confirmed 
a dose-dependent and saturable binding between the free FnBPA isotypes and immo-
bilized fibrinogen (data not shown). Subsequently, we pre-incubated the free isotype II 
and III with IgG from PHG or from one of the patients, followed by incubation with the 
immobilized fibrinogen. In line with the results described above, fibrinogen binding by 
both isotypes was not inhibited by any dilution of IgG (figure 5A). The amount of bound 
PE-labeled FnBPA after pre-incubation with IgG did not significantly differ compared 
to controls without pre-incubation with IgG (one-way ANOVA, significance level of P ≤ 
0.05).
The results described above were further confirmed using ELISA, wherein isotype I 
and V were immobilized onto 96-wells plates and incubated with fibrinogen. Again, 
pre-incubation of both isotypes with a concentration range of IgG from neither PHG nor 
158
Chapter 6
patients affected the amount of bound fibrinogen (Figure 5B). As a control, we incubated 
fibrinogen with an increasing concentration of recombinant Clumping Factor A (ClfA) of 
S. aureus, which also binds to the same site on the fibrinogen r-chain as FnBPA, and 
measured the binding of fibrinogen to immobilized FnbpA. As expected, ClfA inhibited 
fibrinogen binding to FnbpA (Figure 5C).
discussion
We found that most patients suffering from serious invasive S. aureus infections do 
not respond to the microbial challenge by increasing production of pre-existing IgG 
antibody titers directed against the A domain of the most common FnBPA isotypes, 
including the isotype carried by the infecting strain. Only 3 out of 22 patients (14%) 
mounted a significantly increased antibody response against FnBPA after the onset of 
bacteraemia, which was predominantly directed against the isotype of the infecting 
strain in two patients. The immunoglobulins obtained from these and other patients, 
as well as from healthy volunteers, were not able to interfere with the binding between 
FNBPA and human fibrinogen in vitro.
In line with previous results we found that fnbpa isotypes I to IV were the most com-
mon among clinical isolates [25]. Total IgG from patients could detectably bind these 
isotypes and was ubiquitously present at the onset of bacteremia. Firstly, this ubiquitous 
presence of IgG against FnBPA suggests an important role of this virulence factor in 
the pathogenesis of S. aureus, presumably during colonization of the host and the 
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figure 4. Pre-incubation of FnBPA isotypes with human IgG does not prevent binding of fibrinogen.
a: The most common isotypes I to V, coupled to beads, were pre-incubated in this Luminex setup with a 
dilution range of IgG purified from Polyclonal Human IgG (PHG). Binding of a fixed concentration of PE-
labeled fibrinogen was then measured. b: Results of the same experiment using dilution ranges of IgG 
purified from different patients. Each isotype was pre-incubated with IgG from a patient that was infected 
with a strain carrying that isotype (e.g., patient 19 was infected with a strain carrying isotype I).
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early stages of infection. This is in line with the importance attributed to FnBPA during 
bacterial attachment, colonization and infection in in vitro and in vivo animal models as 
described by other authors [6, 11, 12]. 
Secondly, our results shed new light on the human antibody response towards FnBPA. 
Pre-existing IgG levels that were detected at the onset of bacteremia against all isotypes 
-including that of the infecting strain- did not notably change during the course of 
infection in 18 out of 22 patients. This is in line with our previous results obtained with 
the same sera, showing that most virulence factors of S. aureus do not induce uniform 
increases in antibody titers after the onset of bacteremia [26]. Notably, these patients 
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figure 5. Confirmation of the inability of human IgG to prevent binding between FnBPA isotypes and 
fibrinogen.
a: PE-labeled, free FnBPA isotypes II and III were pre-incubated with a dilution range of total IgG from either 
PHG or from patients 14 and 18 (who were infected with strains carrying isotype II and III, respectively).   
Protein-antibody complexes were then allowed to bind fibrinogen coupled to Luminex beads. b: Using an 
alternative ELISA, pre-incubation of fibrinogen with IgG from patient 15 (infected with a strain carrying iso-
type V) did not clearly affect subsequent binding to coated FnBPA isotype V. Similar results were obtained 
for isotype I (not shown). c: Using the same ELISA, pre-incubation with ClfA, instead of IgG, did inversely 
decrease the amount of remaining fibrinogen bounded to FnBPA isotype V.
All data points represent the mean of two separate measurements and are expressed as Mean Fluoresence 
Itensity (MFI) for a; or as Optical Density at 450 nM for b and c.
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were not immunosuppressed at the time of infection and some virulence factors did 
induce a significant antibody response. Why other virulence factors, including FnBPA, 
do not uniformly induce a significant antibody response upon infection is currently 
unknown. Possibly, active manipulation of the host adaptive immune response by S. 
aureus plays a role [35, 36], or perhaps immunogenic epitopes of the FnBPA A domain 
are normally not exposed to the host adaptive immune system during infection due 
to the many interactions of this protein with host extracellular proteins [37]. Finally, it 
could be that FnBPA is only expressed infrequently on the surface of S. aureus during 
the course of bacteremia, although fnbpa mRNA was detectable during in vitro bacterial 
growth in human blood in our previous study [26]. Interestingly, of the three patients 
that did mount a significant antibody response against FnBPA, one patient was infected 
with a strain carrying the rare isotype V. Although speculative, perhaps this isotype is 
associated with less effective immune manipulation, more immunogenic exposure 
towards the host humeral immune system and/ or higher expression during bacteremia. 
We currently do not know to what extent circulating antibodies differ in specificity 
for the different isotypes. On one hand, as opposed to the limited cross reactivity ob-
served previously for murine monoclonal antibodies raised against different isotypes 
[25], natural human, polyclonal antibodies might possess cross-reactivity for different 
isotypes. This would be in line with our previous findings, wherein the same patient 
IgG was found to cross-react between the structurally similar leukocidin and gamma 
hemolysin toxin components [26]. Cross-reactivity could explain the simultaneous rise 
in IgG against multiple isotypes that was observed in two patients. On the other hand, 
the observation of de novo antibody production specifically against the isotype carried 
by the infecting strain in one patient suggest that specific, non-cross reacting antibodies 
may be present as well.
The functionality of antibodies against FnBPA remains another subject of debate. 
Although data from antibodies raised in animal models suggest that they do block 
binding between S. aureus surface proteins and fibronectin [30, 31, 38], other studies, 
including those with human antibodies, do not show any interference with binding to 
fibronectin [29, 39]. Our results are in line with the latter, demonstrating no apparent 
effect at any dilution of human IgG, purified from multiple patients –even from those 
with a significant antibody response against the isotype carried by the infecting strain, 
on binding between fibrinogen and FnBPA. A molecular explanation for this observa-
tion is currently lacking. Possibly, FnBPA binds with higher affinity to fibrinogen than 
to antibodies, or the functional binding domain remains immunologically hidden until 
the ligand is bound [29]. Alternatively, since FnBPA directly complexes with its ligand in 
vivo, ligand binding might induce a conformational change leading to the exposition 
of other, non-functional binding sites for antibodies. Presence of these Ligand Induced 
Binding Sites (LIBS) antibodies against FnBPA has been demonstrated in patients suffer-
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ing from S. aureus endocarditis [40]. Finally, it has even been suggested that antibody 
binding might stabilize the interaction between FnBPA and fibrinogen [29], thereby 
actually enhancing binding, as observed for the binding of the FnbA of Streptococcus 
dysgalactiae to fibronectin when pre-incubated with mouse antibodies [39]. Antibod-
ies against FnBPA could have other functions than interfering with ligand binding. For 
instance, antibodies can assist in the opsonization of S. aureus [41] or in augmenting 
microbicidal killing by phagocytes [42].
We confirmed the inability of IgG to block FnBPA-fibrinogen binding with three al-
ternative assays, to rule out that the coupling of either protein to xMAP® beads could 
somehow affect correct antibody binding, for instance due to conformational changes. 
Of note is that the measured mean fluorescence intensities (MFIs) in the Luminex setups 
were much higher when free PE-labeled FnBPA isotypes were used instead of PE-labeled 
fibrinogen. Possibly, the large size of fibrinogen [43] would allow only a few PE-labeled 
molecules to bind to FnBPA-coated beads, while the other way around relatively many, 
smaller sized, PE-labeled FnBPA proteins could bind to fibrinogen coated beads. Alterna-
tively, the coupling efficacy of both proteins to beads might differ. We currently do not 
know what the efficacy of the coupling reactions are, however, even if coupling efficien-
cies would differ the interpretation of our inhibition experiments remains unchanged.
With regard to the attractiveness of FnBPA as a vaccine target our results can be inter-
preted twofold. On the one hand, we and others found that FnBPA-specific IgG is already 
circulating prior to the onset of clinical infection, probably resulting from multiple prior 
exposures to S. aureus, yet this immune state does not confer protection from clinical 
disease [23, 26, 44, 45]. Furthermore, the inability of human IgG to block the binding be-
tween FnBPA and fibrinogen would argue against the use of FnBPA as a vaccine target. 
On the other hand, future vaccination strategies that are based on recombinant protein 
variants of FnBPA might induce novel, more protective antibodies against functionally 
important epitopes that are not normally targeted by the humoral immune response. 
Furthermore, in vitro production of antibodies against these functionally important 
epitopes might also be beneficial in the context of passive immunization. This rationale 
is supported by previous work demonstrating that serum from unvaccinated human 
subjects was unable to block the interaction between Clumping factor A (ClfA) and 
fibrinogen, while antibodies elicited by a recombinant ClfA-containing vaccine could 
block this binding [46]. Moreover, the level of functional antibody titres, able to block Cl-
fA-fibrinogen binding in vitro, could directly be correlated to protection against S. aureus 
infection in an animal model in vivo [47]. Further studies into the specific interactions 
between the FnBPA A domain and antibodies, and their functional consequences, are 
needed to further elucidate the potential of this protein as a vaccine target in humans.
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methods
ethics statement
All patient serum samples used in this study were obtained from coded left-over mate-
rial from routine diagnostic blood samples. In concordance with the guidelines of the 
Erasmus University Medical Hospital and the Dutch federation of Biomedical Scientific 
Societies (Federatie van Medische Wetenschappelijke Verenigingen), all Erasmus MC 
patients are routinely informed of the possibility that left-over material from diagnostic 
samples can be used, albeit anonymously, for scientific research; all patients are rou-
tinely offered the opportunity to opt out in writing. Serum samples used in this study 
were only obtained from patients who did not object to the use of left-over material for 
scientific research and, in addition, gave verbal consent. This procedure was approved 
and the acquisition of additional written consent was waived specifically for this ret-
rospective study by the Medical Ethics Committee of the Erasmus University Medical 
Center Rotterdam (MEC-2007-106, addendum 2). All serum samples were coded and 
only qualified physicians of the department of Medical Microbiology and Infectious 
Diseases had access to the original patient data.
bacterial strains and patients
Serum samples and S. aureus isolates were obtained from 22 patients diagnosed with 
bacteremia, as described previously [26]. In brief, bacteremia was defined as the isola-
tion of S. aureus from at least one blood culture set. Starting from the first positive blood 
culture, a median number of 10 (interquartile range 5-17) serum samples were collected 
per patient over a median period of 34.5 (interquartile range 15-50) days.
sequencing of fnbA a domains
DNA was isolated from strains using the QIAamp® DNA mini kit (Qiagen, Valencia, CA) 
according to the manufacturer’s protocol. The A domain of fnbA genes was amplified by 
PCR using previously described flanking primers [25] minus the restriction sites. Products 
resulting from amplifications were sequenced using a 3100 ABI Prism genetic analyzer 
(Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Based on sequences of 
the flanking regions, individual primer sets were designed for each strain (sequences 
available upon request) and these were used to amplify and sequence the remaining 
part of each A domain. Overlapping sequences were merged for each strain and aligned 
with publicly available reference sequences of all FnBPA isotypes, which have been 
described previously [25]. The complete sequences of all strains are available upon 
request. Primer design and alignments were performed using Primer-BLAST® (available 
at http://www.ncbi.nlm.nih.gov) and MegAlign software (DNAStar Inc., Madison, USA), 
respectively.
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expression of recombinant fnbPa isotype proteins
pQE30 constructs expressing His-tagged N2N3 A domains of isotypes I to VII were kindly 
provided by T. Foster [25]. Each construct was verified by sequencing using pQE30-
specific primers (sequence available upon request). Constructs were transformed into 
E. coli Topp 10, expressed by induction with Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) and purified under denaturing conditions with Ni-NTA agarose (Qiagen, Valencia, 
CA) according to instructions of the manufacturer’s ‘the QIAexpressionist™’ handbook. 
Resulting proteins were quality controlled by SDS-PAGE and dialysed against PBS for 24 
hours at 4 0C.
measurement of antibodies
IgG levels against all recombinant N2N3 A domains of FnBPA isotypes in the serum 
samples of bacteremia patients were measured using a bead-based flow cytometry 
technique (xMAP®; Luminex Corporation, Austin, TX, USA), as previously described [26]. 
Briefly, recombinant proteins constituting the N2N3 A domains of FnbpA isotypes 
were covalently coupled to carboxylated xMAP® beads, which were activated with 
N-hydroxysulfosuccinimide (sulfo-NHS) and 1-ethyl-3-(3-dimethylaminopropyl) car-
bodiimide (EDC) according to a previously optimized protocol [48]. Protein-coated 
beads were then incubated with human serum which was diluted 1:100 in PBS. After 
repeated washing with PBS, bound antibodies were quantified using a 1:200 dilution 
of secondary phycoerythrin (PE)-labeled goat anti-human IgG antibodies. All measure-
ments were performed in duplicate and the median fluorescence intensities (MFIs), a 
semi-quantitative measure of antibody levels, were averaged. Eighty-nine out of 1827 
duplicate measurements (0,05%) had coefficients of variation larger than 25% and were 
excluded from further analysis. All measurements were corrected for non-specific back-
ground signal by subtracting the MFIs of control beads not coupled to any protein. The 
course of IgG levels over time were assessed graphically and initial-to-peak increases 
in IgG levels were calculated for all isotypes in each patient. A more than 4-fold initial-
to-peak increase in IgG following within two weeks after the onset of bacteremia was 
considered proof of a significant immune response.
Luminex-based fnbPa-fibrinogen binding assay
Recombinant FnBPA isotypes and the non-fibrinogen binding surface proteins SdrE and 
IsdA were coupled to xMAP® beads as described above. Human fibrinogen (Calbiochem, 
Merck, Darmstadt, Germany) was labeled with phycoerythrin (PE) using the Lightning-
Link R-PE conjugation kit (Innova Biosciences, Cambridge, UK) according to the 
manufacturers protocol, starting with 15mg fibrinogen per 10 ml of 50mM MES buffer. 
Protein-coated xMAP® beads were incubated with varying concentrations of PE-labeled 
fibrinogen and, after washing with PBS-1% BSA, median fluorescence intensities (MFIs) 
164
Chapter 6
were determined as a measure of bound fibrinogen using the same bead-based flow 
cytometry technique as described above. To study the effect of potentially interfering 
antibodies, total IgG was purified from serum of 5 different bacteremia patients and from 
pooled serum obtained from healthy volunteers (Polyclonal Human IgG, PHG) using a 
HiTrap ProteinG HP 1 ml column (GE Healthcare, Fairfield, Connecticut, USA) according 
to the manufacturer’s protocol. Purified IgG was dialysed against PBS for 24 hours at 4 0C 
and resulting antibody concentrations were 4,7 mg/ml for PHG and a median of 5,1 mg/
ml (IQR 4,4-8,8 mg/ml) for patient sera. Bead-bound isotypes were pre-incubated with a 
dilution range of the purified IgG, washed with PBS-1% BSA, and then incubated with a 
standard concentration of 1 μg PE-labeled fibrinogen per reaction.
For the alternative Luminex-based binding assay, fibrinogen was coupled to beads 
and recombinant proteins of FnBPA isotype II and III were PE-labeled as described above. 
Free FnBPA isotypes were pre-incubated with purified IgG and then incubated with the 
fibrinogen-coated beads according to the protocol described above. All binding assays 
were repeated separately twice and figures present the mean of these measurements.
eLisa-based fnbPa-fibrinogen binding assay
An enzyme-linked immunosorbent assay (ELISA) was performed to further confirm 
FnBPA-fibrinogen binding as previously described [49]. In brief, 96-well immulon 4HBX 
microtiter plates (Thermo Scientific, Waltham, Massachusetts, USA) were coated over-
night at 4 °C and gentle rotation with 0.5 μg per well of FnBPA isotypes, diluted in PBS. 
After blocking the wells with 2% BSA in PBS, plates were washed once with TBS and 
coated isotypes were pre-incubated with a concentration range of purified IgG, diluted 
in TBS, for 1 hour at room temperature. Subsequently, after 3 additional wash steps with 
TBS + 0,1% Tween, plates were incubated for another hour with a fixed concentration 
of 40 nM fibrinogen (diluted in TBS). After another 3 wash steps, the bound fibrinogen 
was detected through incubation with horseradish peroxidase (HRP)-conjugated anti-
fibrinogen antibodies (1:10.000 dilution) (Thermo Scientific) for 1 hour and quantified 
after adding the substrate o-phenylenediamine dihydrochloride (OPD) (Sigma-Aldrich). 
The resulting absorbance at OD 450 nm was measured in an ELISA microplate reader 
(Thermomax).
In the case of the ClfA competition assay, 40 nM fibrinogen was pre-incubated for 1 
hour with a twofold concentration range of recombinant ClfA (40 to 0,625 µM), and then 
incubated with FnBPA isotype-coated plates as described above.
statistical analysis
Fold-increases in antibody levels were calculated as the ratio of the peak antibody level 
divided by the initial antibody level (as measured in the first serum sample). One-way 
ANOVA with the duplicate measurements of bound PE-labeled fibrinogen (or FnBPA 
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isotypes) as dependent variables and the IgG dilutions as factor were used to determine 
the significance of any differences in bound protein between different IgG dilutions. 
P-values ≤ 0.05 were considered statistically significant. IBM® SPSS® Statistics version 21 
(IBM corporation, Armonk, NY, USA) was used for statistical analysis. Graphics were made 
using Graphpad Prism version 5 (Graphpad Inc. La Jolla, CA, USA).
acknowLedGements
We would like to acknowledge Dimitris Rizopoulos of the department of Biostatistics 
at the Erasmus Medical Center for his helpful insights into the statistical analysis of our 
data.
166
Chapter 6
suPPLementaL data
      



















 


 




 


    








 








  


 




 


 
figure s1. Validation of fibrinogen binding by FnBPA isotypes.
a: increasing concentrations of PE-labeled fibrinogen bind to all FnBPA isotypes but not to the control pro-
teins (IsdA, SdrE and ClfB) in a dose-dependent and saturable manner. b: adding increasing concentrations 
of unlabeled fibrinogen to a fixed amount of 1,5 μg of PE-labeled fibrinogen shows competition for the 
binding to all FnBPA isotypes. Data points represent the mean of two separate measurements.
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figure s2. Specific and dose-dependent binding of human IgG to FnBPA isotypes I to V.
a: Beads coated with recombinant FnBPA isotypes I to V were incubated in a Luminex setup with a dilution 
range of total IgG purified from human pooled serum (PHG) or patients (p14 to p19: for each FnBPA isotype, 
serum was chosen from a patient that was infected with a strain carrying that isotype). b: FnBPA isotypes 
coated onto wells (0.5 µg/well) were incubated in an alternative ELISA setup with a dilution range of the 
same IgG, purified from PHG or patients. A plateau in antibody binding at higher concentrations can be 
observed, indicating that only FnBPA-specific IgG within the polyclonal antibodies bind.
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table s1. Initial- to peak fold-increases in specific IgG levels for FnBPA isotypes in bacteremia patients.
Patient Isotype 
infecting 
strain
Fold-increase in IgG specific for isotype1
Isotype I Isotype II Isotype III Isotype IV Isotype V Isotype VI Isotype VII
1 II 1,7 1,4 1,4 1,6 1,6 1,4 1,5
2 III 2,8 2,7 3,7 2,7 1,0 1,0 1,0
3 I 1,5 3,8 1,4 1,4 1,5 1,5 1,3
4 II 7,3 23,1 3,8 1,9 2,3 2,1 2,0
5 II 1,1 1,0 1,0 1,1 1,0 1,0 1,0
6 I 1,7 2,4 2,3 2,7 2,9 2,9 3,1
7 III 1,8 1,6 1,7 1,5 1,6 1,7 1,6
8 IV 1,0 1,1 1,1 1,0 1,0 1,1 1,1
9 III 2,0 1,7 1,3 2,2 1,9 1,7 2,6
10 IV 1,0 1,1 1,0 2,9 1,4 1,4 2,9
11 II 2,0 2,7 2,2 3,1 3,3 2,1 2,0
12 I 1,4 1,0 1,1 1,0 1,2 1,1 1,4
13 IV 2,8 1,2 1,1 2,5 1,1 2,2 1,5
14 II 1,0 1,0 1,1 1,1 1,0 1,0 1,4
15 V 1,0 2,7 1,2 2,4 20,6 2,2 3,7
16 IV 1,0 1,0 1,2 1,0 1,0 1,0 1,0
17 III 7,6 4,3 9,3 10,8 7,1 3,6 1,6
18 III 1,5 2,1 1,7 1,5 2,0 2,0 2,6
19 I 1,2 1,5 1,1 1,5 1,3 1,7 1,5
20 I 2,5 1,4 4,5 2,6 2,2 1,8 3,0
21 IV 1,0 1,2 1,3 1,0 1,3 1,0 1,2
22 IV 1,0 1,0 1,2 1,0 1,6 1,0 1,0
1 A fold-increase of 1,0 means that the IgG level did not change during the course of infection, compared 
to that of initial measurement at the onset of bacteremia; whereas a fold-increase of e.g. 23.1 fold means 
that the peak IgG level in that patient after onset of infection was 23.1 times higher compared to the initial 
measurement. The FnBPA isotype of the infecting S. aureus strain, as determined with sequencing, is indi-
cated in the second column. Significant initial-to-peak increases in IgG of more than four-fold are indicated 
in italic bold.
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summary
Staphylococcus aureus is an infamous bacterial pathogen which can produce a wide 
array of virulence factors, enabling it to cause many different infections with significant 
morbidity and mortality in humans. The ability of S. aureus to form biofilm and its ris-
ing resistance against antibiotics further complicate treatment of many infections [1, 
2]. Therefore, alternative treatment strategies, such as vaccination, are receiving great 
scientific and clinical interest. However, despite the many different virulence factors that 
have been targeted by vaccines and their promising effects in animal models, so far 
all clinical trials failed to demonstrate any favourable effect in humans [3]. Thus, there 
remains a need for more insights into the presence of S. aureus virulence factors and 
their ability to induce an antibody response during infection in humans.
The general aim of this thesis was twofold; to provide further insights into the pres-
ence of a wide range of well-characterized virulence factors of S. aureus during growth 
in in vitro and ex vivo infection models, mimicking the in vivo situation during different 
infection in humans, and to further characterize the human antibody response during 
these different infections. The high-throughput, bead-based Luminex assay was used 
together with confirmation by additional techniques such as RT-PCR and mass-spec-
trometry throughout this thesis to achieve these aims. Data concerning in vitro presence 
of -and in vivo antibody responses against S. aureus virulence factors are compared and, 
together, can help in identifying potential targets for novel vaccination strategies as 
discussed below. 
main findings
Using a Luminex assay, chapter 2 expanded on previous data [4-6] by further character-
izing the human antibody response against an expanded set of 56 S. aureus virulence 
factors in 21 patients suffering from bacteraemia. In general, prospective measurement 
of patient IgG levels following infection further confirmed the large inter-individual 
heterogeneity found in antibody responses. Specific IgG levels against 15 proteins 
increased at some time point after the onset of bacteremia in 95 to 100% of patients, 
of which the highest initial-to-peak fold-increase was observed for the putative ABC 
membrane transporter SACOL0688. Compared to 30 age-matched, healthy controls, IgG 
levels against 27 proteins, including those mentioned above, were significantly higher 
in bacteremia patients (Table 1). These results suggest that these specific proteins are 
present and induce a significant antibody response in vivo. To gain further insight into 
protein expression during growth in human blood, gene expression in human blood ex 
vivo was determined using micro-array with two genetically different strains isolated 
from different bacteremia patients. Out of the 56 virulence factors mentioned above, 
mRNA expression levels of SA0688, IsaA, EsxA and SCIN genes were consistently high in 
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both isolates during growth in blood. However, compared to the transcriptomes at the 
start of incubation, only 86 out of the 3626 tested genes were consistently upregulated 
in both strains, of which the gamma-hemolysin A and B precursors were the only known 
virulence factors. In addition, expression of all known virulence factors did not differ 
during growth in blood or artificial BHI broth, suggesting that their expression is not 
specifically associated with blood-stream infections.
In contrast to the acute infection caused by bacteremia, little was known about the 
human antibody response during a more chronic, biofilm-associated infection such 
as osteomyelitis. This issue was addressed in chapter 3, wherein IgG levels against 50 
S. aureus virulence factors were prospectively measured in 10 patients suffering from 
osteomyelitis. Again, pronounced inter-individual heterogeneity in IgG levels was 
found. IgG levels against 14 proteins were significantly higher in osteomyelitis patients 
compared to 20 age-matched healthy controls (Table 1). Interestingly, none of these IgG 
levels differed significantly compared to those in the 20 bacteremia patients described 
above. When S. aureus strains isolated from the bone of 9 patients were allowed to form 
biofilms on polystyrene (PS), 14 different proteins could be detected during biofilm 
formation by the majority of strains using a competitive Luminex assay (CLA) (Table 1). 
Twelve of these proteins were also detected in the majority of strains during biofilm 
formation ex vivo on human bone. Comparison between in vitro protein detection and 
the in vivo antibody responses revealed that eight proteins were both detectable in the 
majority of biofilms in vitro and induced an antibody response in vivo. However, 4 other 
proteins induced an antibody response in vivo but were detected in only a minority of 
biofilms in vitro while, vice versa, 7 proteins were detected in most biofilms in vitro but 
not associated with a significant antibody response in vivo (Table 1).
The presence of 52 S. aureus virulence factors was further established in chapter 4 
during biofilm growth of 5 (methicillin resistant) strains on PS and an ex vivo model for 
human skin, the Leiden Epidermal Model (LEM) [7]. Six functionally diverse proteins were 
consistently detected in biofilms of all strains on both surfaces (Table 1). At the same 
time, in contrast to the largely similar protein detection in biofilms on PS and human 
bone as described in chapter 3, eight other proteins were detectable in biofilms of most 
strains on LEMS but not on PS. These proteins mostly comprised diverse immune modu-
lators and toxins, including the well-characterized alpha toxin. The reverse was true for 
fibronectin binding protein B, which was detectable on PS but not on LEM. Interestingly, 
further experiments showed that, although alpha toxin could not be detected at the 
protein level in biofilms on PS, mRNA and a GFP-construct for this toxin were detectable 
in biofilms on PS, suggesting that the hla gene is expressed but not translated and/or 
that the protein is rapidly degraded. Lastly, another noteworthy observation was the 
variable ability of all strains to form biofilms on both surfaces, with two strains (including 
177
Summary and discussion
7
table 1. Summary of Luminex results from chapters 2, 3, 4 and 5 for the most frequently present viru-
lence factors in studied S. aureus strains.
Protein1 Function Presence in vitro/ ex vivo  
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Alpha toxin toxin   + + +   ND + - -
CHIPS immmune modulator + +     - - - +
ClfA surface protein   + +     + - - -
ClfB surface protein   + + +   + - - +
FlipR Immune modulator + +     + + - -
FnbpA surface protein   + +     - - - +
Glucosaminidase housekeeping   + + +   + + + +
HlgB toxin       +   + + + +
IsaA housekeeping + + + +   + - + +
IsdA surface protein   + + +   + + + +
IsdH surface protein   +       + - - -
Lipase housekeeping/ toxin +       + - - -
LukD toxin           + + + +
LytM housekeeping           - - + +
Nuclease housekeeping/ toxin + + +   + - + -
SACOL0688 housekeeping + + + +   + + + +
SCIN immmune modulator + + +     + + - -
SdrE surface protein     +     - + - +
SSL1 immmune modulator         + - - -
SSL3 immmune modulator         - + - +
SSL5 immmune modulator         + + + -
SSL9 immmune modulator         + - + -
1only proteins are shown for which genes were consistently present in more than half of all strains in each 
study, 2only proteins with significantly increased mRNA expression, detected with micro-array in 2 strains 
at 0, 30, 60 and 90 minutes growth in blood, are indicated with ‘+’, 3only proteins that were detectable with 
CLA in the majority of 9 strains are indicated with ‘+’, 4only proteins that were detectable with CLA in all 
5 strains are indicated with ‘+’, 5significantly increased IgG levels in 22 patients compared to 30 controls, 
6significantly increased IgG levels in 10 patients compared to 20 controls, 7significantly increased IgG levels 
in 182 patients compared to 53 controls, 8 An association with clinical outcome is defined as the presence 
of either a significant estimated effect of IgG levels on lung function (FEV1%) or a significant Odds ratio for 
experiencing an exacerbation in 182 patients, ND: not determined
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the extensively used laboratory strain NCTC 8325-4) being able to form biofilms on PS 
but not on LEM.
The human antibody response against 44 S. aureus virulence factors was further 
characterized in Cystic Fibrosis (CF) patients suffering from chronic pulmonary infection 
caused by S. aureus in chapter 5. IgG levels against 15 proteins, being mostly the same 
proteins that were also found to induce an antibody response in chapters 2 and 3, were 
significantly higher in 182 patients compared to 53 healthy nasal carriers of S. aureus 
(Table 1). These results thus further suggests the presence of a particular set of S. aureus 
virulence factors during infection in vivo. Importantly, this study also demonstrated a 
significant association between specific IgG levels and several clinical parameters, as 
was recently already described for IgG levels against alpha toxin and several leucocidin 
components in CF patients [8]. IgG levels against 18 proteins were significantly and 
inversely associated with lung function (FEV 1% predicted) and IgG levels against 8 
more proteins were significantly associated with the risk (Odds ratio, OR) to experience 
a pulmonary exacerbation (OR < 1 and > 1 for 3 and 5 proteins, respectively) (Table 1). 
Finally, IgG levels against respectively 22, 14 and 16 proteins were significantly associ-
ated with serum IL-6 levels in CF patients, S. aureus nasal carrier status and presence of 
small colony variants in airway cultures of patients.
The human antibody response against one specific virulence factor, Fibronectin Bind-
ing Protein A (FnbpA), is characterized in more detail in the final chapter 6. Furthermore, 
in addition to the more descriptive data of previous chapters, a first attempt is made 
to explore the functionality of anti-FnbpA antibodies. In line with previous data [9] a 
marked sequence diversity is found in the fibrinogen-binding A domain of the fnbpa 
gene amongst 22 strains isolated from the same bacteraemia patients as described in 
chapter 2. Despite this diversity, IgG from all 22 patients detectably bound the 4 most 
common FnbpA isotypes and a significant antibody response against the isotype of 
the infecting strain was observed in only 2 patients, of which one case involved the 
rare isotype V. These results suggest, in contrast to the limited cross-reactivity observed 
for monoclonal anti-FnbpA antibodies in animal models [9], the presence of either 
cross-reactivity of polyclonal human IgG or the presence of different antibodies due 
to previous exposure to the most common isotypes. Finally, using a novel, Luminex-
based FnbpA-fibrinogen binding assay, this study shows that pre-incubation of diverse 
FnbpA isotypes with human IgG from neither patients nor healthy controls can interfere 
with the binding of FnbpA to human fibrinogen. These results are confirmed with two 
independent Luminex- and one ELISA-based assays and are in line with earlier data 
describing the binding between FnbpA and fibronectin [10, 11]. Although the exact mo-
lecular explanation is still unclear, these results might suggest that human antibodies 
induced by FnbpA in vivo normally bind non-functional binding sites of the protein. This 
could implicate that novel vaccine approaches that involve (the induction of ) antibodies 
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directed against functional epitopes of FnBPA that are not normally targeted by the im-
mune system might more successfully confer protection against infection, as discussed 
later in this chapter.
main conclusions
1. A specific set of functionally diverse virulence factors of S. aureus, which are sum-
marized in Table 1, are ubiquitously present during bacterial growth in different 
infection models in vitro/ ex vivo, and induce significant antibody responses during 
different infections in vivo (bacteremia, osteomyelitis and chronic pulmonary infec-
tion in CF patients). This is established for multiple collections of genetically different 
S. aureus strains.
2. Discrepancies exist for other virulence factors between in vitro protein detection and 
the in vivo detected antibody response, suggesting that interpretation of both data 
combined is most informative in determining the role of a virulence factor during 
pathogenesis and its potential use as a vaccine target.
3. Both healthy controls without any clinically apparent infection and patients at the 
start of an infection possess readily detectable, often significant IgG levels against S. 
aureus virulence factors.
4. There exists extensive inter-individual heterogeneity in the titers of IgG antibodies 
directed against virulence factors of S. aureus.
5. In CF patients suffering from chronic pulmonary infection with S. aureus, the height 
of IgG levels against diverse virulence factors of S. aureus is significantly associated 
with clinical parameters such as lung function and risk of experiencing an exacerba-
tion.
6. Although some virulence factors are ubiquitously detectable during biofilm forma-
tion in vitro, many other virulence factors are more variably detectable amongst ge-
netically different strains, even when corresponding genes are ubiquitously present.
7. Several factors can influence the detection of specific virulence factors during biofilm 
formation in vitro, including the used environment (polystyrene, bone or artificial 
skin) and the time of measurement.
8. Although some virulence factors, such as alpha toxin, might be expressed at the 
transcriptomic level during biofilm formation, this does not always lead to detec-
tion at the proteomic level. This can be explained by rapid degradation of either 
transcripts and/or the protein.
9. By far most of the S. aureus virulence factors that were specifically upregulated dur-
ing bacterial growth in human blood ex vivo have an unknown function. Compared 
to bacterial growth in artificial broth, no known virulence factor could be identified 
that are specifically expressed in blood. 
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11. Human antibodies against many S. aureus virulence factors can be absorbed by bio-
films, suggesting that these virulence factors are immunologically accessible within 
a biofilm environment.
12. Despite the ubiquitous presence of human IgG against the A domain of FnBPA, only 
a minority of patients mount a significant antibody response against this virulence 
factor after the onset of bacteremia, indicating lack of expression and/ or immune 
evasion by FnBPA during this infection.
13. Although human antibodies can bind to the genetically variable A domain of FnbpA, 
these antibodies are unable to block binding between FnbpA and its substrate 
fibrinogen.
discussion
strengths and limitations of Luminex assay
Most results described in this thesis have been obtained using a Luminex based setup, 
which continues to be validated for immunological and molecular assays in both re-
search and diagnostic settings [12-14]. An advantage of this multiplex format is its abil-
ity for rapid, high-throughput screening of multiple targets simultaneously using small 
sample volumes. In addition, the Luminex assay has a wider dynamic (up to mean fluo-
rescence intensity [MFI] of 1 x 104 arbitrary units) and extended linear range compared 
to ELISA [15, 16]. Finally, the covalent coupling of proteins to Luminex beads allows for 
the production of a single batch of protein-coupled beads that can be used throughout 
an entire study for several months, minimizing intra-assay variation.
However, analogous to ELISA, there are also some general limitations in regard to 
the Luminex assay. First and foremost, the sensitivity of these assays depends on the 
number, availability and quality of the recombinant proteins that are coupled to beads 
or surfaces, respectively. Only antibodies against coupled proteins (or protein domains) 
will be detected and, although polyclonal human IgG bound diverse FnbpA isotypes in 
our assay (chapter 6), we cannot completely rule out that sequence diversity of pro-
teins might influence assay sensitivity. Furthermore, just as for ELISA the exact amount 
of coupled protein remains unknown due to an unknown coupling efficacy. Finally, 
when determining whether a protein is present or immunogenic during infection, some 
results should be interpreted cautiously due to immunological cross-reactivity. This was 
observed in our Luminex assay between gamma-hemolysin and the leucocidin S and F 
components (chapter 2).
The above mentioned limitations also apply to the Competitive Luminex Assay. In ad-
dition, results that are obtained with the CLA can be somewhat difficult to interpret for 
non-experts, hampering accessibility of the data. Finally, in general the (semi-) quantita-
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tive measurement of protein presence and antibody responses described in this thesis 
only provides descriptive data and does not allow any conclusions about the function or 
importance of detected proteins and antibodies. Thus, altogether, the Luminex assays 
used in this thesis should be considered as robust screening tools for the presence of 
antibodies and (indirectly) proteins, yet they do not provide precise, quantitative nor 
mechanistic data.
Given these limitations, future use of the Luminex assays should mainly be limited 
to studies that wish to preliminary screen large number of bacterial strains or serum 
samples for the presence of proteins or antibodies, respectively. The latter could involve 
further characterization of antibody responses or, as briefly discussed below, T-cell 
responses against specific virulence factors. In addition, virulence factors that are identi-
fied as potential vaccine targets should be subject to more mechanistic and functional 
studies, for instance involving transcriptomic approaches to further unravel bacterial 
regulatory systems or functional antibody binding and neutralization assays, as partly 
described in chapter 6.
implications for vaccine development
In the context of vaccination, it seems reasonable to assume that the target for an effec-
tive vaccine should at least be present at some time in the majority of clinical strains dur-
ing colonization or infection. Following this logic, several virulence factors of S. aureus 
could be potential vaccine targets according to data presented in this thesis. Several of 
the virulence factors that are summarized in Table 1, such as SA0688, IsdA and IsaA, ap-
pear to be ubiquitously present in genetically diverse strains under different conditions 
in vitro and induce a significant antibody response in patients in vivo, which implies their 
presence during infection. These virulence factors have indeed been successfully used 
as vaccine targets in animal models of diverse S. aureus infections [17-19]. Yet it appears 
that merely the presence of virulence factors, although it might be a prerequisite, is not 
enough for an effective vaccine in humans, nor is the successful evaluation of a vaccine 
target in animal models. This is for example demonstrated by the results obtained with 
a vaccine targeting the highly conserved iron surface determinant B (IsdB), which is 
closely related to the IsdA described in this thesis. Although IsdB induced protection 
against S. aureus infection in animal models and was immunogenic in human patients, 
a large phase II clinical study failed to show any reduction in the rate of postoperative 
S. aureus infection compared to the placebo, and was actually associated with higher 
mortality in the vaccinated patients who developed S. aureus infections [20].
The failure so far to develop a clinically effective vaccine against S. aureus in humans 
has raised questions about its feasibility [for recent reviews see [3, 21-24]. Besides the 
discouraging history, there are several other issues that complicate this matter. Firstly, it 
is currently unclear how important the humoral branch of the human immune response 
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actually is for controlling infections with S. aureus. As shown by data in chapters 2, 3, 5 
and 6 and previous studies [4, 5], antibodies against many virulence factors of S. aureus 
are readily detectable in both healthy controls and patients at the start of a clinically 
apparent infection, yet these antibodies do not prevent colonization or infection. Fur-
thermore, based on the results presented in chapter 6, it appears that at least some 
human antibodies are unable to interfere with the actual function of S. aureus virulence 
factors. As already described in chapter 1, it is now increasingly recognized that the 
cellular rather than humoral immunity, particularly the actions of T helper 17 cells, play 
a central part in the host defence [3, 25].
A second issue complicating vaccine development is the extensive diversity in the 
presence and sequences of many genes encoding virulence factors amongst genetically 
different S. aureus strains [26-29]. This means that S. aureus strains with a genetically 
different variant or complete absence of the virulence factor, being targeted by a vac-
cine, will be unaffected. This scenario becomes even more likely in the light of variable 
expression levels amongst S. aureus strains, as has been established for e.g. alpha toxin 
[30]. In addition, in case of alpha toxin, S. aureus can also alter protein expression post-
translationally (chapter 5).
A third issue complicating vaccine development involves the extensive immune eva-
sion abilities of S. aureus [31, 32]. As described in chapter 1, many virulence factors 
secreted by S. aureus can inhibit or divert both innate and adaptive immune responses 
of the host. Furthermore, S. aureus can also retreat into either extra- or intracellular per-
sistence [33, 34] and into biofilms [1], which can further dampen the effect of a vaccine-
induced antibody response. These immune evasive capabilities of S. aureus might reflect 
its long co-evolution as part of the normal human flora, which contrasts to other, more 
transiently present species such as Streptococcus pneumoniae and Haemophilus influen-
zae. This might partially explain why vaccination against the latter bacterial species but 
not against S. aureus are effective [3].
Based on the above mentioned discussion, it can be concluded that the presence 
and immunogenicity, established for several virulence factors in this thesis, on its own 
will likely be insufficient to warrant an effective vaccine in humans. Nevertheless, these 
virulence factors might still be potential targets in the development of novel vaccina-
tion approaches. In contrast to the so far unsuccessfully evaluated monovalent vaccines, 
such as the IsdB based vaccine, current awareness is rising that a multivalent vaccine is 
likely to have a higher chance of success [23, 35]. Although whole cell vaccines with in-
activated S. aureus appear to only moderately induce an antibody response with limited 
clinical effect in both veterinary and human medicine [36], these vaccines are based 
on poorly characterized cocktails of bacterial proteins. In contrast, multivalent vaccines 
consisting of novel recombinant forms of well-characterized virulence factors of S. au-
reus might just induce novel, functional antibodies that are protective against infection. 
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Whereas naturally occurring antibodies might not functionally interfere with S. aureus 
virulence factors (chapter 6) or protect against infection, this might be achieved by 
antibodies raised against specific protein epitopes that are not normally targeted by the 
immune system. This rationale is supported by previous work demonstrating that serum 
from unvaccinated human subjects was unable to block binding between Clumping fac-
tor A (ClfA) and fibrinogen, while antibodies elicited by a recombinant ClfA-containing 
vaccine could block this binding [37]. Moreover, the level of functional antibody titres, 
able to block ClfA-fibrinogen binding in vitro, could directly be correlated to protection 
against S. aureus infection in an animal model in vivo [38].
In addition to the above mentioned, well-characterized virulence factors of S. aureus, 
it should be noted that other virulence factors might also prove to be interesting vac-
cine targets. These could be currently less-characterized proteins, such as cytosol-based 
proteins involved in bacterial metabolism. Antibody responses against these proteins 
are comparably rare and weak [39], yet vaccine-induced antibodies might interfere 
with bacterial viability. Another group of novel, potential vaccine targets might include 
specific biofilm-associated virulence factors [40]. This rationale is generally supported 
by results from chapters 3 and 4, which demonstrate specific antibody binding by 
biofilms, suggesting that antibodies can bind and therefore target biofilm-associated 
virulence factors. Indeed, previous work demonstrated that a pentavalent vaccine, 
combining virulence factors that are mainly associated with either planktonic growth 
or biofilm formation, effectively cleared infection in a murine tibial osteomyelitis model 
[41].
Another study from the same group also showed that infection in a rabbit osteo-
myelitis model was significantly better cleared when vaccination was combined with 
antibiotic treatment, compared to either vaccination or antibiotic treatment alone [17]. 
These results suggest the potential use of combining existing and novel treatment op-
tions, such as vaccination and currently used antibiotics, to augment each other.
Finally, it should be noted that both this thesis and most research efforts so far have 
focussed on characterizing antibody responses, yet specific T cell responses against S. 
aureus are only now beginning to be defined [for recent review see [25]. In light of the 
earlier mentioned, increasingly recognized importance of T-cell mediated immunity 
against S. aureus, the key to an effective vaccine might actually involve induction of spe-
cific T-cell mediated immunity, rather than humoral immunity. Interestingly, all patients 
who were vaccinated with the failed IsdB-based vaccine and subsequently died from 
post-operative S. aureus infection, were shown to have undetectable IL-2 and mostly 
undetectable IL-17 levels at the time of vaccination and during the course of infection 
[42]. Based on these findings it can be speculated that the quality of pre-existing T-cell 
mediated immunity is important for protection against S. aureus infection. Further re-
search is needed to firstly determine whether vaccination can influence T-cell mediated 
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immunity, and secondly whether this can favourably alter the course of infection with 
S. aureus.
When considering novel vaccination approaches, one final question remains as to 
which (patient) populations might best benefit. Based on the earlier discussed issues 
complicating vaccine development, it seems unlikely that a universal vaccine that can 
prevent all S. aureus infections will ever be achieved [21]. However, temporal reduction 
of the risk and/ or severity of infection are more realistic and also valuable endpoints. 
This could for example involve the active or passive immunization of patients prior to 
elective surgery to reduce post-operative wound infections, or immunization of patients 
suffering from chronic infection to reduce morbidity and treatment duration. In addi-
tion, although patients suffering from acute infection might not directly benefit from 
active immunization, severity of especially toxin-mediated infections might be limited 
by passive immunization, e.g. by infusing antibodies against alpha toxin [43, 44] and 
Toxic Shock Syndrome Toxin [45]. As discussed earlier all these approaches might be 
synergistically combined with currently used antibiotic treatments.
In conclusion, several virulence factors of S. aureus that are ubiquitously present in 
vitro and induce a significant antibody response in vivo are identified in this thesis, and 
although these observations alone will likely not warrant an effective vaccine in humans, 
these virulence factors might be useful targets in novel vaccination approaches which 
are currently being explored. Ever since its first description by Alex Ogston in 1881, the 
question remains whether effective immunization against S. aureus is possible.
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Staphylococcus aureus is een grampositieve bacterie welke een breed scala aan infec-
tieziekten in de mens kan veroorzaken, variërend van krentenbaard tot een levensbe-
dreigende bloedvergiftiging (bacteriemie). Bij de totstandkoming van deze infecties 
spelen verschillende bacteriële virulentie factoren, zoals toxines en adhesie eiwitten, 
een belangrijke rol. Daarnaast is S. aureus in staat om biofilms te vormen, een clustering 
van bacteriën omgeven door een laag slijm en eiwitten, waarin zij verminderd gevoelig 
zijn voor antibiotica en de afweer respons van de gastheer. Tenslotte wordt de behande-
ling van bovenstaande infecties toenemend bemoeilijkt door de wereldwijde opkomst 
van antibioticaresistentie en het tegelijkertijd ontbreken van alternatieve behandelmo-
gelijkheden, zoals vaccinatie. Maar hoewel er dringend behoefte is aan een effectief 
vaccin tegen S. aureus, ontbreken nog veel van de hiervoor benodigde inzichten in 
de pathogenese van S. aureus en de menselijke antilichaam respons tegen S. aureus. 
Daarom had het onderzoek beschreven in dit proefschrift tot doel om verder inzicht in 
deze onderwerpen te verkrijgen, wat uiteindelijk kan bijdragen aan de ontwikkeling van 
nieuwe vaccinatie mogelijkheden.
In hoofdstuk 2 wordt de humane antilichaam respons tegen 56 virulentie factoren 
van S. aureus in 21 patiënten met een bacteriemie beschreven. Hierbij wordt gebruik ge-
maakt van een eerder ontwikkelde flowcytometrie (Luminex) techniek die antilichamen 
tegen meerdere bacteriële eiwitten tegelijk kan meten. Het blijkt dat IgG antilichamen 
tegen 15 virulentie factoren in sera van een meerderheid van de patiënten stijgen, en dat 
deze titers gemiddeld significant hoger zijn vergeleken met die van gezonde controles. 
De meest prominente antilichaam respons is gericht tegen een nog relatief onbekend 
celmembraan-gebonden transporteiwit van S. aureus (SACOL0688) welke eerder geas-
socieerd is met biofilm vorming. Dit eiwit blijkt samen met diverse andere virulentie 
factoren ook continu tot expressie te komen in twee klinische isolaten tijdens in vitro 
incubatie in humaan bloed. Verdere vergelijking van eiwitexpressie tussen incubatie 
in bloed en een kunstmatig groeimedium toont aan dat expressie voor geen enkele 
virulentiefactor conditie specifiek is.
De humane antilichaam respons tegen een set van 50 virulentie factoren van S. aureus 
wordt verder bestudeerd in hoofdstuk 3, deze keer in 10 patiënten met een infectie 
van het bot (osteomyelitis). Het blijkt dat IgG antilichaam titers tegen 15 virulentie 
factoren, grotendeels dezelfde als beschreven in hoofdstuk 2, significant verhoogd zijn 
in patiënten vergeleken met gezonde controles. Aangezien osteomyelitis geassocieerd 
is met biofilm vorming wordt de expressie van alle virulentiefactoren vervolgens in vitro 
gemeten tijdens biofilm vorming op zowel polystyreen als humaan bot door 10 S. aureus 
isolaten, inclusief 9 isolaten uit geïnfecteerd bot van bovenstaande patiënten. Hierbij 
wordt een nieuw ontwikkelde, op de Luminex gebaseerde techniek gebruikt, waarbij 
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met behulp van antilichamen indirect bacteriële eiwitten worden gedetecteerd. Acht 
van de 15 boven genoemde virulentiefactoren, inclusief SACOL0688, worden door alle 
10 isolaten consistent in biofilms tot expressie gebracht. Tegelijkertijd blijkt dat er voor 
andere virulentiefactoren discrepanties zijn tussen de gemeten antilichaam respons in 
vivo en eiwitexpressie in vitro. Het waarnemen van een verhoogde antilichaam produc-
tie in vivo gaat dus niet altijd gepaard met detecteerbare eiwitexpressie in vitro en vice 
versa.
Met behulp van dezelfde techniek als in hoofdstuk 3 wordt in hoofdstuk 4 de in vitro 
expressie van 52 virulentiefactoren verder onderzocht in biofilms van 5 (methicilline 
resistente) stammen op polystyreen en een menselijk huidmodel. Voor diverse viru-
lentiefactoren zoals reeds beschreven in hoofdstuk 2 en 3 wordt opnieuw consistente 
expressie in alle stammen waargenomen. Tegelijkertijd blijkt er voor enkele virulentie-
factoren ook verschil te zijn tussen de expressie op respectievelijk polystyreen en het 
huidmodel. Alpha toxine blijkt bijvoorbeeld alleen detecteerbaar te zijn in biofilms op 
het huidmodel, hoewel transcriptie van het hla gen op beide oppervlaktes aantoonbaar 
is. Deze resultaten wijzen op de complexiteit van translatie en post-translationele modi-
ficatie van bacteriële eiwitten, welke S. areus in reactie op verschillende omstandighe-
den lijkt aan te passen.
In hoofdstuk 5 wordt een link gelegd tussen de antilichaam respons tegen 44 vi-
rulentiefactoren van S. aureus en diverse klinische parameters in jonge patiënten met 
taaislijmziekte (Cystic Fibrosis, CF). Vergeleken met een groep van 53 gezonde controles 
blijken IgG titers tegen 15 virulentiefactoren, hoofdzakelijk dezelfde zoals reeds beschre-
ven in hoofdstuk 2 en 3, significant verhoogd in CF patiënten waarbij de luchtwegen 
persisterend gekoloniseerd zijn met S. aureus. Verder blijkt dat de hoogte van IgG titers 
tegen diverse virulentiefactoren significant geassocieerd is met de longfunctie van 
patiënten en/of kans op het krijgen van een exacerbatie van luchtwegklachten.
In hoofdstuk 6 wordt de humane antilichaam respons tegen het eiwitdomein van één 
specifieke virulentiefactor van S. aureus, het Fibronectine Bindend Proteïne A (FnBPA), 
zowel kwantitatief als kwalitatief gekarakteriseerd. Er blijkt aanzienlijke variatie in de 
sequentie van dit gen te zijn tussen de 22 klinische stammen geïsoleerd uit de 22 bacte-
riemie patiënten beschreven in hoofdstuk 2. Ondanks deze genetische variatie blijkt dat 
alle patiënten IgG antilichamen bezitten die de 4 meest voorkomende varianten kunnen 
binden. Echter, slechts in 3 van de 22 patiënten wordt een stijging van IgG antilichamen 
waargenomen tijdens het doormaken van een bacteriemie. Dit suggereert dat, hoewel 
alle patiënten al vóór infectie zijn blootgesteld aan het FnBPA eiwit, dit eiwit tijdens een 
bacteriemie óf niet tot expressie komt óf afgeschermd wordt van de menselijke antili-
chaamrespons. Met behulp van een nieuwe, op Luminex gebaseerde techniek wordt 
verder aangetoond dat antilichamen uit zowel patiënten als gezonde vrijwilligers niet in 
staat zijn om de binding tussen het FnBPA eiwit en diens ligand fibrinogeen te verstoren.
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Op basis van alle resultaten uit hoofdstukken 2 – 5 blijkt dat een specifieke set van vi-
rulentiefactoren van S. aureus consistent tot expressie komt en leidt tot een antilichaam 
respons in de mens, zoals SACOL0688 (samengevat in Tabel 1 in hoofdstuk 7). Echter, 
alleen het aantonen van eiwitexpressie en een antilichaam respons is onvoldoende 
bewijs voor de geschiktheid van deze virulentiefactoren voor inclusie in een effectief 
vaccin. Ook duiden de discrepante resultaten tussen in vitro eiwitexpressie en in vivo 
antilichaam responsen uit hoofdstuk 3 erop dat interpretatie van verschillende data 
nodig is om hierover te kunnen oordelen. Tenslotte is het voor de ontwikkeling van een 
effectief vaccin nodig om meer inzicht te krijgen in de functie van specifieke antilicha-
men, welke in het geval van FnBPA bijvoorbeeld de binding van dit eiwit aan fibrino-
geen niet kunnen blokkeren (hoofdstuk 6). Tezamen kunnen deze nieuwe inzichten in 
eiwitexpressie, antilichaam respons én functie uiteindelijk leiden tot de ontwikkeling 
van nieuwe, effectievere vaccinatie strategieën. Hierbij valt bijvoorbeeld te denken aan 
vaccinatie met een recombinant eiwit dat wel functioneel blokkerende antilichamen 
induceert, of vaccinatie met biofilm-gerelateerde virulentiefactoren ter bestrijding van 
biofilm-gerelateerde infecties met S. aureus.
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Laten we eerlijk zijn: de meeste lezers van een proefschrift zullen (in ieder geval als 
eerste) het dankwoord lezen. Dit is het meest persoonlijke en leukste onderdeel van een 
boekje, hoewel inderdaad lastig om daadwerkelijk te schrijven. Hoe kan ik kort maar 
krachtig recht doen aan alle gebeurtenissen en de daarbij betrokken personen in de 
afgelopen zeven jaar?
Zeven jaar geleden begon ik, zonder jaren aan klinische ervaring, aan dit onderzoek en 
(2 jaar later) aan mijn opleiding. Zeven jaar van aanvankelijk soms frustraties, maar ook 
van volharding en uiteindelijk een prachtige persoonlijke ontwikkeling. Dat was niet 
mogelijk geweest zonder de steun en het vertrouwen van vele anderen, die ik hierbij 
graag wil bedanken. Als dit boekje -en het voltooien van mijn opleiding- laten zien dat 
dergelijk vertrouwen zich uitbetaald, dan is dat voor mij het grootste compliment.
Beste Prof.dr. Verbrugh, ik heb altijd getwijfeld of het correct is om u aan te spreken met 
‘beste Henri’. Hoe het ook zij, dank dat u mij de mogelijkheid voor dit onderzoek en de 
opleiding heeft gegeven. Daarnaast heeft uw kritische blik zeker bijgedragen aan het 
verbeteren van diverse hoofdstukken uit dit proefschrift.
Beste Willem, Dr. van Wamel, jij bent vanaf het begin nauw betrokken geweest bij mijn 
onderzoek en verdere ontwikkeling op de afdeling. Soms hadden we pittige discussies, 
maar altijd met ‘open vizier’ en uiteindelijk een beter experiment, presentatie of manu-
script als resultaat. Dank voor je vertrouwen en steun, zeker ook in aanloop naar -en 
tijdens mijn opleidingsjaren. 
Beste Alex, Prof.dr.dr. van Belkum, al verliet je kort na ons kennismakingsgesprek de 
afdeling en hebben we daarna weinig samengewerkt, ook jou wil ik bedanken voor het 
geven van de mogelijkheid tot dit promotieonderzoek, alsmede je kritische blik op mijn 
eerste manuscript en het plaatsnemen in de grote promotiecommissie.
Prof.dr Kahl, Barbara, vielen dank für die angenehme Zusammenarbeit. I felt most 
welcome during our two visits to Germany. Thank you for being part of the reading 
commission.
Prof.dr. Verbon en Prof.dr. van Strijp, dank voor het plaats nemen in de leescommissie 
van mijn proefschrift.
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Dr. Ko, dear Ya-Ping, thank you for facilitating my internship in Houston and learning me 
some principles about ELISA. I feel that our collaboration has certainly improved the fi-
nal manuscript of this thesis. It would be nice to meet again for another lively discussion.
Dr. Nouwen, beste Jan, dank voor het plaats nemen in de grote commissie -en het over-
leg midden in de nacht tijdens mijn dienst!
Dr. Bos, Koen, en Marjan, dank voor alle botstukjes, de prettige samenwerking vanuit de 
Orthopedie en het daarmee mogelijk maken van één van mijn studies.
Beste Dr. Nibbering, Peter, en (inmiddels ook Dr.?) Ilse, we hebben heel wat meetings en 
werk gehad voor ons gezamenlijk onderzoek, maar met resultaat. En de bezoeken aan 
mijn voormalig Leids opleidingscentrum hadden ook persoonlijke, nostalgische waarde. 
Dank voor de prettige samenwerking.
Beste Marion en Marja, dank dat ik dagelijks de Luminex op de Immunologie kon gebrui-
ken, inclusief het incidenteel troubleshooten. Dit proefschrift was zonder de Luminex 
niet tot stand gekomen.
Nicole, Susan, Mehri, Hélène en (in den beginne) Corné, dank voor het vele meedenken 
en werken aan mijn onderzoek. Zonder jullie inzet waren mijn publicaties (en die van 
vele anderen!) niet mogelijk geweest.
(Oud) collega-promovendi binnen de S. aureus onderzoeksgroep; Jasper, Silvie en Bibi, 
ik vond het prettig om met jullie te samen te werken en de dagelijkse promotiebeslom-
meringen te delen. Mooi om al jullie diverse vervolgcarrières in binnen- en buitenland 
te zien!
Sybren, fijn dat je me terzijde wil staan tijdens de verdediging. Ik heb je leren kennen 
als een goede gesprekspartner voor belangrijke discussies (met onderwerpen variërend 
van geopolitieke issues tot the Marvel Cinematic Universe).
Rofyan, I will never forget your hospitality in Makassar. Nor the bus ride to Toraja. Terima 
kasih.
Beste (oud) research collega’s, de L-vleugel is niet meer, maar de mooie herinneringen 
blijven. De roze map met CD’s van Wendy Ka, de reistips van Suzanne, de paar uit de 
hand gelopen vrijdagmiddag borrels….dank voor de leuke researchjaren. Overigens is 
een liedje zingen op mijn promotieborrel niet verplicht.
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Collega-arts assistenten, tijdens onze opleiding zijn we continu verspreid over vele 
stageplekken, maar bij elkaar zijn (waren) we (jullie) een prettige, diverse groep om in 
te werken. Dank voor het continu delen van alle kennis en ervaringen. Voor je het weet 
is de opleiding voorbij!
Beste opleidingsgroep; alle arts-microbiologen, infectiologen, (moleculair) biologen 
en andere senior specialisten waarmee ik in de afgelopen jaren in het Erasmus MC en 
Maasstad heb samengewerkt; mede dankzij jullie ben ik gekomen waar ik nu ben. Dank 
hiervoor.
Dr. Vonk, Alieke, jou wil ik in het bijzonder bedanken voor je inzet en support als opleider. 
Zoals je mij leerde is het goed om complimenten te geven. Bij dezen.
Oud-volleybal vrienden, dank voor alle biertjes, all-you-can-eat festijnen en foute filma-
vonden. Wie wordt nou niet enthousiast van de Cornetto trilogie, Django unchained of 
Sharknado?
Arthur, dank dat je me terzijde wilt staan tijdens mijn verdediging.
Anke, dank voor alle etentjes en je continue interesse in mijn opleiding en onderzoek. 
Hopelijk kunnen we in de toekomst nog met regelmaat langskomen in Schoonhoven.
Ma, Jeannette, zonder jou was ik er niet geweest. Zo’n 30 jaar aan opleiding is heel wat, 
maar was het anders gelopen dan had je me evengoed gesteund. Ik kom nog altijd 
graag langs voor een bloemkool, ditjes & datjes en -eigenlijk het meest belangrijk- het 
soms even relativeren van de zaken met jouw nuchtere, ervaren blik daarop. Dat is 
onvervangbaar.
Lieve Mirjam, van lab maatje werd jij mijn levensmaatje. Of we nou een verre reis of 
wandeling door het park maken, jij maakt het bijzonder. Dank je wel. Ik ga niet eindigen 
met de cliché dat we nu eindelijk meer tijd hebben om samen te gaan genieten van het 
leven -dat doen we al en, gezien onze gelijkwaardige carrières en arbeidsethos, ook 
de komende decennia is er ongetwijfeld genoeg werk te doen. Op naar nog veel meer 
mooie momenten samen!

